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1. Abstract
Suppressor of Cytokine Signaling 1 (SOCS1) is a negative feedback inhibitor of cytoplasmic
Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signaling path-
ways. In 2008, it has been shown that SOCS1 contains a nuclear localization sequence (NLS)
resulting in translocation of the protein into the cell nucleus. The exact function of SOCS1 in
the cell nucleus remains largely unknown. To study the role of SOCS1 in the cell nucleus in
vivo, a transgenic mouse model was established using a bacterial artificial chromosome (BAC)
containing a mutated Socs1 locus with non-nuclear Socs1∆NLS, GFP and firefly Luciferase,
termed MGL. C57BL/6 mice expressing only non-nuclear Socs1∆NLS were bred by back-crossing
Socs1MGLtg mice on a SOCS1 deficient background and named Socs1-/-MGLtg mice. Non-
nuclear Socs1∆NLS was shown to rescue those mice from the early lethal phenotype observed in
Socs1-/- mice. Interferon gamma (IFNγ) signaling was analyzed by Western Blot, flow cytom-
etry, quantitative real-time PCR and whole-genome expression analysis. Socs1-/-MGLtg mice
showed functional regulation of canonical IFNγ signaling – a function classically attributed to
cytoplasmic SOCS1. Only a small subset of non-canonical, IFNγ dependent genes was dif-
ferentially regulated. In contrast, Socs1-/-MGLtg mice showed altered cell cycle regulation as
well as sustained NFκB signaling - two functions suggested to be dependent on SOCS1 in the
cell nucleus. Socs1-/-MGLtg mice spontaneously developed a Th2 prone low-grade inflamma-
tion in the lung including elevated serum IgE levels and low-grade airway eosinophilia. Influx
of eosinophils could be enhanced both in an experimental asthma model using ovalbumin and
upon IL-13 instillation. Bone-marrow transplantation experiments indicated an important role
for radiation-resistant cells in the development of the allergic phenotype in Socs1-/-MGLtg mice.
Therefore, epithelial cells were investigated in more detail. Reduced epithelial cell barrier in-
tegrity was observed both in vivo by the detection of albumin in BAL and in vitro using primary
murine trachea epithelial cells (pmTECs). In summary, Socs1-/-MGLtg mice were used to study
the role of nuclear SOCS1. Nuclear SOCS1 was shown to be an important regulator of local
immunity in the lung and to exert a so-far unrecognized function in epithelial cells.
1
2. Zusammenfassung
SOCS1 (”Suppressor of Cytokine Signaling 1”) ist induzierbarer feedback Inhibitor fu¨r JAK/
STAT (Janus kinase/ signal transducer and activator of transcription) Signalwege. Es wurde
gezeigt, dass SOCS1 eine nuklea¨re Kernlokalisationssequenz (”nuclear localization sequence”,
NLS) besitzt, die dazu fu¨hrt, dass das Protein in den Zellkern transloziert. Um die Funk-
tion von SOCS1 im Zellkern in vivo zu untersuchen, wurde eine transgene Maus mit Hilfe
eines bakteriellen artifiziellen Chromosomes (BACs) generiert. Diese Maus entha¨lt neben einem
mutierten SOCS1 Lokus, in dem SOCS1 durch nicht kernga¨ngiges SOCS1∆NLS ersetzt wurde,
die Reporter eGFP und Luciferase, und wird MGLtg bezeichnet. C57BL/6 MGL transgene
Ma¨use wurden auf einen SOCS1 defizienten Hintergrund gezu¨chtet, sodass diese Tieren kein
SOCS1 im Kern exprimieren. Diese Ma¨use wurden Socs1-/-MGLtg genannt. Nicht kernga¨ngiges
SOCS1∆NLS war in der Lage den Interferonγ Signalweg zu regulieren, wie es fu¨r SOCS1 im
Zytoplasma beschrieben ist. Somit konnten Socs1-/-MGLtg Ma¨use vor dem lethalen Pha¨notyp
SOCS1 defizienter Ma¨use gerettet werden. Die funktionelle Regulation des Interferonγ Sig-
nalweges wurde anhand von phosphorylierten STAT1, klassischen Interferonγ induzierten Ziel-
genen und genom-umfassender Expressionsanalysen untersucht. Ein Teil der nicht-klassischen
Interferonγ abha¨ngigen Gene war jedoch in Socs1-/-MGLtg Ma¨usen unterschiedlich reguliert.
Socs1-/-MGLtg Ma¨use zeigten weiterhin Unterschiede im Zellzyklus sowie NFκB Signalweg,
dessen negative Regulation durch SOCS1 im Kern beschrieben ist. Daher liegt die Vermu-
tung nahe, dass Socs1-/-MGLtg Ma¨use kein funktionelles SOCS1 im Kern exprimieren und ver-
wendet werden ko¨nnen, um die in vivo Relevanz von SOCS1 im Kern zu untersuchen. Inter-
essanter Weise zeigten Socs1-/-MGLtg Ma¨use eine spontane leicht-gradige Entzu¨ndung in der
Lunge. Genauere Analysen zeigten, dass es sich um eine Th2 abha¨ngige Eosinophilie handelt.
Erho¨hte Serum IgE Werte weisen auf eine allergische Atemwegserkrankung hin. Die Eosinophilie
konnte in einem klassischen Asthma Modell durch Ovalbumin sowie durch Gabe von IL-13 -
einem klassischen Th2 Zytokin- noch versta¨rkt werden. Um herauszufinden welcher Zelltyp fu¨r
den Lungenpha¨notyp verantwortlich ist, wurde eine Knochenmarktransplantation durchgefu¨hrt.
Ergebnisse besta¨tigten eine wichtige Rolle der strahlungsresistenten Zellen wie zum Beispiel
Epithelzellen an der Entstehung der Th2 abha¨ngigen Atemwegserkrankung. Daher wurden
Epithelzellen genauer untersucht und eine erho¨hte Durchla¨ssigkeit sowohl in prima¨ren Trachea-
Epithelzellen in vitro, als erho¨hte Albumin Werte in der BAL in vivo festgestellt. Zusammen-
fassend konnten Socs1-/-MGLtg Ma¨use genutzt werden, um die bislang unterscha¨tzte Funktion
von SOCS1 im Kern zu untersuchen und dessen Rolle bei der Entstehung von Th2 bedingten
Atemwegserkrankungen wie Asthma genauer zu untersuchen.
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3.1. Cytokine receptors
Cytokines represent a diverse group of small soluble proteins that can act upon secretion in
an autocrine or paracrine fashion. Cytokine receptors are cell-surface glycoproteins that bind
specifically to cytokines and initiate signaling cascades. There are different receptor classes: type
I cytokine receptors, type II cytokine receptors, tumor necrosis factor (TNF) receptor family,
IL-1 receptors, tyrosine kinase receptors and chemokine receptors. Type I cytokine receptors
as well as type II cytokine receptors signal via the Janus kinase (JAK)/ signal transducers and
activators of transcription (STAT) signaling pathway [255, 43, 155, 110, 209]. The JAK/ STAT
pathway was originally discovered through the study of interferon induced intracellular signal
transduction. Meanwhile, a large number of cytokines, hormones and growth factors have been
found to activate JAK/ STAT signaling such as interleukins or hematopoietic growth factors.
A well known example for JAK/ STAT signaling is signal transduction upon IFNγ (see Fig.
1). Upon binding of IFNγ to its receptor, the receptor subunits (IFNγ receptor chains 1 and
2; IFNGR1 and IFNGR2) dimerize leading to autophosphorylation and activation of associated
JAKs [21]. There are four members of the JAK family: JAK1, JAK2, JAK3 and Tyk2. To
enable diversity of immune responses, activation of different combinations of JAKs by different
cytokine receptors is possible. Both receptor chains of the IFNγ receptor are associated with
JAKs [124]: IFNGR1 with JAKl and IFNGR2 with JAK2 [123]. Once in close proximity to
each other, JAKs activate each other by phosphorylation, and then phosphorylate the IFNGR1
chain on tyrosine 440 [88] to create docking sites for STAT1. Members of the STAT family of
proteins contain a SH2 domain and are therefore major substrates of JAKs [118, 156]. There are
seven mammalian STATs: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6 [42].
Upon receptor phosphorylation, STAT1 binds through its SH2 domain and gets phosphorylated
by JAKs on tyrosine 701 (pY-STAT1) [225]. Phosphorylated STAT1 proteins form homodimers
through mutual SH2-phosphotyrosine (pY) interactions and translocate into the nucleus. Rapid
accumulation of pY-STATs in the nucleus in turn activate transcription of certain target genes
by binding to specific IFNγ-activated sequences (GAS) in the promoter region. Type I interferon
signaling additionally leads to an activation of interferon-stimulated response elements (ISREs).
Besides tyrosine phosphorylation of STAT1 leading to its activation, serine phosphorylation of
STATs occurs leading to increased activity and specificity [48, 147]. In contrast to tyrosine
phosphorylation, it is not substantial for signaling.
There is emerging evidence of non-canonical JAK/ STAT activity. Stat1-/- mice infected with
Sendai virus, MCMV, or DENV developed some level of resistance against these pathogens,
showing that STAT1-independent responses to IFNs exist [76, 245, 80]. STAT-independent
pathways include the PI3K/AKT pathway or the mitogen activated protein kinase (MAPK)
pathway [131]. It has been shown that IFNAR1, TYK2 and unphosphorylated STAT1 translo-
cate into the nucleus as well [3, 152]. Non-canonical JAK/ STAT activity can be achieved by
tyrosine kinase-independent action of JAKs, transcriptional complexes other than ISGF3 and
GAF, and pathways building on U-STATs that are not phosphorylated on tyrosine [48]. Mice
with a kinase-dead TYK2 showed a rescue in natural killer cell maturation and tumor killing
as compared to TYK2-/- mice [221], arguing for a tyrosine kinase-independent action. Similar
data was shown for JAK2. JAK2 kinase-dead mutants revealed a kinase-independent scaffolding
function of JAK2 for the IFNγ receptor complex [137]. In addition, classical interferon signaling
leads not only to accumulation of pY-STAT1 in the cell nucleus, but also unphosphorylated
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Figure 1.: JAK/ STAT signaling pathway.
Upon binding of IFNγ (orange triangle) to its re-
ceptor (dark blue), receptor subunits IFNGR1 and
IFNGR2 dimerize leading to autophosphorylation
and activation of associated JAKs. This creates
docking sites for cytoplasmic STAT1 proteins that
get phosphorylated. Phosphorylated STAT1s dimer-
ize and translocate into the nucleus to activate
gene transcription by binding to IFNγ-activated se-
quences in promoter regions for their target genes.
One target is SOCS1 that negatively regulates the
signaling pathway in the cytosol. Figure adapted
from Samuel, 2001 [234].
STAT1 (U-STAT1) [182, 30]. pY-STATs and U-STATs shuttle via different pathways into the
nucleus where they lead to activation of a distinct set of genes. U-STAT1 dependent genes such
as IFI24, IFI44, OAS or BST2 are induced upon stimulation with IFNβ or IFNγ especially
at low doses and expression of those genes increased even after 48 to 72 h unlike pY-STAT1
dependent genes that are usually early-induced [220]. Besides classical interferon signaling via
STAT1, there has been evidence of STAT1-independent pathways [80, 226, 182].
There are three types of IFNγ induced genes:
1st genes dependent on pY-STAT1 activation such as IRF1, IP-10, MIG or SOCS1. Those
genes need binding of pY-STAT1 dimers to GAS elements.
2nd genes that can be induced in both a pY-STAT1 dependent and independent manner such
as MCP1, GGR1 or SOCS2 and SOCS3
3rd genes that are induced independently of pY-STAT1 such as IL-1β, c-myc or c-jun [226, 80]
To ensure for effective pathogen clearance on the one hand and to avoid excessive immune
signaling and autoimmunity on the other hand, duration and intensity of the signaling need
to be tightly regulated. Regulation can occur at various levels: abundance of ligand for the
receptor, expression or stability of the receptor or expression or stability of internal components
of the signaling cascade [132, 87, 246]. There are different kinds of negative regulators: SOCS
(Suppressor of Cytokine Signaling) proteins [257, 194, 62], PIAS (protein inhibitors of activated
STATs), CD45 and PTPs (protein tyrosine phosphatases) [249]. SOCS proteins negatively regu-
late JAK/ STAT signaling by acting as negative feedback inhibitors upon interferon stimulation,
whereas negative regulators such as PIAS terminate STAT action by promoting degradation of
receptors and pathway components.
4
3. Introduction
3.2. Suppressor of Cytokine Signaling (SOCS) proteins
3.2.1. Structure and Regulation of SOCS1 proteins
Structure of SOCS1 proteins
The Suppressor of Cytokine Signaling (SOCS) family is important for negative feedback in-
hibition of Janus kinases (JAK) and signal transducer and activator of transcription (STAT)
signaling. SOCS proteins get induced upon type I and II cytokine receptor signaling and in
turn regulate the signaling as inducible negative feedback inhibitors. The family contains eight
members, namely SOCS1 – 7 and CIS. All SOCS family members share key structural elements
(see Fig. 2) such as the central cytokine-inducible Src-homology 2 (SH2) domain, which together
with the extended SH2 subdomain (ESS) allows binding to phosphorylated tyrosine [290]. Nega-
tive regulation of cytokine signaling by SOCS proteins can be performed by either direct binding
to receptors or JAKs [290] or by competing with STATs for binding sites [224]. Therefore, the
SH2 domain is substantial and determines substrate specificity. SOCS2 binds to phosphorylated
tyrosine on cytokine receptors, whereas SOCS3 preferably binds to gp130-like receptors and
SOCS1 to interferon receptors and JAKs. In addition, all SOCS proteins contain the common
C-terminal SOCS-box, a 40 amino acid long motive giving the family its name [5, 87, 115]. The
SOCS-box interacts with Elongin B, C and other proteins to build a E3-ubiquitin ligase leading
to degradation of associated proteins via the proteasome. The N-terminal region of SOCS pro-
teins is of varying length and amino acid composition. The two closely related proteins SOCS1
and SOCS3 additionally contain a kinase inhibitory region (KIR) through which they can act
as a pseudosubstrate for Janus kinases [81]. SOCS1 is the only SOCS family member known to
contain a bipartite NLS located between the SH2 domain and the SOCS-box.
Figure 2.: Structure of SOCS proteins.
Schematic structure of SOCS family members. All SOCS family members contain a central cytokine-
inducible Src-homology 2 (SH2) domain (yellow) together with an extended SH2 subdomain (ESS, green),
an amino-terminal (N-term) domain of variable length and divergent sequence, and a carboxy-terminal
40-amino-acid long SOCS-box (blue). SOCS1 and SOCS3 additionally contain a kinase-inhibitory region
(KIR, orange). SOCS1 is the only family member containing a nuclear localization sequence (NLS, red)
located between the SH2 domain and the SOCS-box. Not to scale. Figure adapted from Alexander, 2002
[5].
Regulation of SOCS1 proteins
Upon activation of JAK/ STAT signaling, transcriptional and translational induction of SOCS
proteins follows. SOCS proteins in turn inhibit ongoing receptor activation in a negative feedback
loop. There are STAT1, 3 and 6 binding site through ISRE and GAS elements in the SOCS1
5’ flanking region [194, 233, 237]. Although constant expression of SOCS1 is rather low and is
sometimes difficult to detect, it can be strongly and rapidly induced [257, 194, 62]. Moreover,
there is data indicating that certain SOCS proteins are unstable [295, 136] and that their half-
life is influenced by binding of Elongins B and C to their SOCS box [295, 136]. By interacting
with the SOCS box, the Elongin B/C complex increases expression of SOCS1 by inhibiting its
degradation [136]. SOCS1 can be regulated by translational repression [89, 237]. Structure-
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function analyses indicated that this effect is mediated by the 5’ untranslated region (UTR)
and that it relates to the presence of two upstream AUGs in this region [89]. This translational
repression is responsible for low endogenous concentration of SOCS in resting cells. Further
studies revealed that translation of SOCS1 is cap-dependent and modulated by eIF4E-binding
proteins [89].
3.2.2. Inhibition of JAK/ STAT signaling pathway by SOCS1
SOCS1 has first been described in 1997 as a negative feedback inhibitor of cytoplasmic JAK/
STAT signaling (see Fig. 1) [62, 194, 257]. Firstly, by the means of the ESS and the KIR
domains, SOCS1 can directly bind to JAK2 and inhibit its catalytic activity. [290]. Therefore,
the SH2 domain of SOCS1 binds to Y1009 within the activated domain in JAK2 and the KIR
acts as a pseudosubstrate. Secondly, SOCS1 has been shown to bind to interferon receptor
domains occupying binding sites for STATs [68, 224]. Finally, due to the SOCS box, SOCS1
acts as an ubiquitin E3 ligase that targets JAK cytokine receptor complexes for proteasomal
degradation [281, 295]. In particular, the SOCS-box interacts with Elongins B and C leading
to recruitment of an E3-ubiquitin ligase complex consisting of Elongin B/C, Cullin-2 /Cullin-5,
SOCS1 and the ring-finger protein Rbx1 or Rbx2 [138, 135]. In presence of an E1 activating
enzyme and an E2 conjugating enzyme, this E3-ubiquitin ligase complex transfers polyubiquitin
chains on the substrate that is bound to SOCS1 leading to its proteasomal degradation.
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Figure 3.: Negative feedback inhibition of the JAK/ STAT signaling pathway by SOCS1.
Activation of the receptor (dark blue) by binding of a ligand (orange triangle) leads to phosphorylation
of the associated Janus kinases (JAKs) and phosphorylation of STATs. Phosphorylated STATs dimerize
and translocate into the nucleus to activate gene transcription. One target is SOCS1 (red) that negatively
regulates the signaling pathway in the cytosol. Inhibition of JAK/ STAT signaling is achieved by (1)
competing with STAT binding sites, (2) direct binding to JAK or by (3) degradation of JAK cytokine
receptor complexes via the proteasome. Figure adapted from Shuai and Liu, 2003 [246].
3.2.3. Additional functions of SOCS1
Besides negative regulation of JAK/ STAT signaling, SOCS1 has been shown to act as a crosstalk
inhibitor for TLR signaling pathways [41, 40, 258, 196]. Macrophages lacking SOCS1 are hy-
persensitive to LPS as shown by increased production of pro-inflammatory cytokines [139, 196].
In addition, LPS-induced NO synthesis, TNFα production and both IκB and p38 phosphoryla-
tion were elevated in SOCS1 deficient macrophages [139]. Indirect paracrine inhibition of TLR
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signaling was shown by IFNβ leading to the activation of secondary genes [11]. In addition to
indirect regulation of TLR signaling, SOCS1 contributes to direct regulation of the pathway by
interacting with components of the TLR signaling pathway [171, 196]. It has been shown that af-
ter TLR2 and TLR4 stimulation, the MyD88 adapter like (MAL) protein interacts with SOCS1
leading to its phosphorylation, polyubiquitination and subsequent degradation [171]. SOCS1
has also been shown to be involved in maturation and differentiation of DCs. Immature DCs
show constitutive activation of STAT6. During maturation, STAT6 signal diminishes leading
to a strong induction of SOCS1 together with SOCS2, SOCS3 and CIS accompanied with the
predominant use of STAT1 signals in mature DCs [129].
In 2008, a nuclear localization sequence (NLS) was identified for SOCS1, resulting in translo-
cation of the protein into the cell nucleus [12, 143]. SOCS1 directly interacts with the tumor
suppressor p53 in the cell nucleus leading to activation of p53 via phosphorylation of serine
15 by forming a ternary complex with ATR or ATM [169]. Activation of the p53 pathway by
SOCS1 can establish an anti-proliferative program in cells exposed to sustained or aberrant cy-
tokine stimulation. p53 activation results in G1 arrest and apoptosis by synthesis of inhibitors
of cyclin-dependent kinases, such as p21/WAF1 [1, 242]. Therefore, an anti-proliferative role
for SOCS1 is suggested [134, 169]. Moreover, SOCS1 induces proteasomal degradation of NFκB
[168, 230, 232]. NFκB proteins function as dimeric transcription factors and consist of the
subunits NFκB1 (p105/p50), NFκB2 (p100/p52), c-Rel, RelA (p65) or RelB. In the canonical
pathway, NFκB proteins are bound and inhibited by IκB inhibitors. Activation of the IKK
complex (IKKα, IKKβ, and NEMO) phosphorylated IκB proteins leading to their ubiquitina-
tion and proteasomal degradation and the release of NFκB complexes. Active NFκB complexes
translocate into the nucleus where they induce expression of pro-inflammatory cytokines such as
IL-1, IL-6, IL-8, or TNFα. In particular, SOCS1 interacts with the NFκB subunit p65 in the cell
nucleus, thereby limiting induction of a subset of NFκB dependent genes [260]. Interaction with
p65 has been shown for SOCS1, but no additional SOCS family member. The N-terminal part
of the SH2 domain contributes to p65 binding, whereas the SOCS box mediates E3 ubiquitin
ligase activity. Therefore, a mutant lacking the SOCS-box is ineffective in p65 ubiquitination
[260]. SOCS1 is also involved in degradation of tyrosine phosphorylated ASK1 in response to
growth factors. In SOCS1 deficient mice, ASK1 expression and activity are upregulated, result-
ing in enhanced TNF-induced activation of JNK, expression of pro-inflammatory molecules and
apoptotic responses [106]. SOCS1 additionally interacts with HPV (human papilloma virus) E7
protein and induces ubiquitination and degradation of E7 [134].
3.2.4. SOCS1 in T cell differentiation
CD4+ T cells are activated by foreign antigens presented on APC’s via MHC class II and induced
depending on the surrounding cytokine milieu into different Th cell subtypes. IL-12 and IFNγ
lead to activation of the transcription factor Tbet via STAT4 and differentiation of na¨ıve CD4+
T cell into Th1 cells [261]. Those cells are produced against intracellular viral and bacterial
pathogens. In contrast, Th2 cells play a major role in protection against large extracellular
pathogens and during allergic responses. Th2 cells are characterized by the expression of Gata3
via STAT6 in an IL-4 and IL-10 dominant milieu [8]. Another Th cell subset is the Th17 cell
that is important for mucosal immunity and autoimmune disorders. TGFβ and IL-6 favour
the differentiation of Th17 cells that are expressing Rorc via STAT3 [288]. Regulatory T cells
(Tregs) maintain immune homeostasis. Those cells are induced in a TGFβ and IL-10 dominant
milieu and are characterized by the expression of Foxp3 [298]. Overexpression of SOCS1 in T cells
results in disturbed thymocyte development with an increasing number of CD4+ thymocytes and
spontaneous activation of lymphocytes in the periphery [72]. Altered thymic T cell development
and aberrant T cell activation has been shown for SOCS1 deficient mice [173, 272]. T cells from
SOCS1 deficient mice proliferate spontaneously in the presence of IL-2 without the need for a
T cell receptor signal [173]. This data suggest that SOCS1 can regulate T cell differentiation.
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Indeed, SOCS1 is differentially expressed both in Th1 and Th2 cells. The lack of SOCS1 leads
to elevated IFNγ or IL-4 levels in response to classical Th1 or Th2 model organisms (Listeria
monocytogenes or Nippostrongylus brasiliensis) [72], respectively. Differentiation into Th1 or
Th2 phenotype is accompanied by preferential expression of distinct SOCS mRNA transcripts
and proteins. SOCS1 expression is 5-fold higher in Th1 as compared to Th2 cells. In contrast,
Th2 cells contain 23-fold higher levels of SOCS3 [61]. There is conflicting data regarding which
cell fate SOCS1 drives differentiation towards. On the one hand, SOCS1 blocks Th1 development
via inhibition of IFNγ signaling favouring Th2 differentiation [264, 54]. Tanaka et al. showed in
2008 that most SOCS1 deficient na¨ıve CD4+ T cells differentiate into Th1 cells, even under Th2
or Th17 skewing conditions [264]. In line with this, SOCS1-deficient mice develop autoimmune
inflammatory diseases with age [274] and are sensitive to dextran sulfate sodium induced colitis
[117], but resistant to experimental autoimmune encephalomyelitis, a typical Th17 type disease
[264]. Th1 skewing in SOCS1 deficient animals is achieved by high levels of IFNγ [264].
On the other hand, SOCS1 negatively regulates Th2-dependent pathways by inhibition of
pSTAT6 [73]. Administration of IL-13 induces SOCS1 expression at the inflammatory site that
in turn suppresses IL-13–dependent STAT6 activation. Thereby, Eotaxin expression can be
downregulated leading to reduced airway inflammation [73]. In addition, serum IgE levels and
infiltrating eosinophils are considerably increased in the lungs of OVA-treated Socs1-/-IFNγ-/-
mice as compared to IFNγ-/- mice [153]. Those mice show increased expression of the Th2
cytokines, IL-4, IL-5 and IL-13 in CD4+ cells of the lung [153]. In line with this, Socs1 gene ex-
pression is significantly lower in the airways of severe asthmatics compared with mild/moderate
asthmatics, and inversely correlates with airway eosinophilia [57, 73]. Data suggest that the
absence of SOCS1 leads to Th2 bias. In addition, SOCS1 is necessary for Th17 differentiation
[58]. Th17 suppression by SOCS1 deficiency is probably due to the excessive IFNγ signaling
[61]. SOCS1 also plays an important role in the regulation of Tregs. Higher numbers of Tregs
are observed in the thymus and spleen of T cell-specific SOCS1 deficient mice [161], probably
due to increased IL-2 levels. It has been shown that SOCS1 deletion in Tregs induces the devel-
opment of spontaneous dermatitis, splenomegaly, and lymphadenopathy, suggesting a defective
Treg function in these mice [160].
3.2.5. Physiological Relevance of SOCS1
SOCS1 proteins are ubiquitously expressed, however with predominant expression in the lung,
spleen [194], thymus [257] and liver [173]. SOCS1 has been shown to have an essential role in
immune regulation. SOCS1 deficient mice develop a fatal neonatal disease that results in death
by three weeks of age due to unlimited IFNγ signaling leading to multiorgan inflammation [173,
256, 193] (see Table 1). Those mice are characterized by neonatal death, fatty liver degeneration,
hematopoietic infiltrations in various organs as well as accelerated apoptosis and aberrant T cell
activation [173, 256, 193]. This phenotype is highly dependent on IFNγ hypersensitivity as
Socs1-/-IFNγ-/- mice show reduced pathology, however, these mice develop polycystic kidneys
as well as chronic inflammation [181, 6]. Deletion of the SOCS box of SOCS1 delays the onset
of the disease [296], but still leads to increased responsiveness to IFNγ and the development of
chronic inflammatory lesions. Marine et al. characterized the phenotype of the Socs1-/- mice
further, showing perturbed thymic T cell development and activation in Socs1 deficient mice
[173]. T cell-specific Socs1-/- mice do not develop the lethal multiorgan inflammation, but rather
specific lymphoid deficiencies through defective T cell development and proliferation [72, 272].
In addition, Socs1-/- mice can be rescued by back-crossing to either STAT4-/- or STAT6-/-
mice [64, 193], supporting the important role for SOCS1 in T cells. Consistent with this,
Socs1-/- mice that additionally lack Rag2 (recombination activating gene, a key gene in lymphoid
maturation), survive the early lethal phenotype of Socs1-/- mice and exhibit normal levels of
IFNγ. However, Socs1-/-Rag2-/- mice show increased CD8+ T cell differentiation, splenomegaly,
and lymphadenopathy [173, 264]. They show accumulation of DCs in the thymus and spleen,
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Table 1.: Effects of SOCS1 manipulation in mice.
Mouse model Phenotype Described by
Socs1-/- Neonatal death, Lymphopenia, Fatty liver degeneration [257, 194, 173]
Socs1-/-IFNγ-/- Polycystic kidneys, Inflammatory lesions [296]
Socs1-/-Rag2-/- Increased CD8+ differentiation, Splenomegaly [173, 264]
Socs1SOCS-box del Increased responsiveness to IFNγ, Inflammatory lesions [296]
Socs1-/-CD28-/- Aberrant expansion of CD8+ DCs, Autoimmunity [274, 100]
Socs1-/-TCRα-/- Aberrant expansion of CD8+ DCs, Autoimmunity [274]
Socs1-/-TCRtg Inflammatory lesions, Aberrant T cell activation [37]
which are hyperresponsive to both IFNγ and IL-4. Socs1-/-TCRα-/- or Socs1-/-CD28-/- mice
are rescued from early lethality of Socs1-/- mice as well [274, 100]. However, the CD8+ DC
subset is increased, resulting in enhanced secretion of IFNγ and IL-12p40 [274]. Therefore,
those mice show DC mediated systemic autoimmunity at an old age [100, 274]. Socs1-/-TCRtg
mice (expressing a transgenic TCR detecting only exogenous antigen) have an increased lifespan
as compared to Socs1-/- mice [37]. However, TCR transgenic SOCS1 deficient mice still die as
young adults with inflammatory infiltrations and aberrant T cell activation [37], suggesting both
antigen-dependent and -independent mechanisms to be responsible for the inflammatory disease
in SOCS1 deficient mice.
SOCS1 expression has been linked to several diseases. The anti-proliferative role of SOCS1 is
circumvented by aberrant methylation resulting in silencing of SOCS1 transcription in hepato-
cellular cancers [293]. In a murine arthritis model, the extent of joint destruction and synovial
inflammation is exacerbated in Socs1-/- mice [60]. In addition, SOCS1 expression has been shown
to correlate inversely with the severity of disease in idiopathic pulmonary fibrosis patients [197].
However, SOCS1 does not always confer protection against immune diseases. Thus, transgenic
mice expressing high levels of SOCS1 in lymphocytes spontaneously develop colitis [126]. In ad-
dition, SOCS1 plays a role in allergic diseases including psoriasis and allergic contact dermatitis
[67], where it is highly expressed in keratinocytes. SOCS1 was also shown to protect β-cells from
cytotoxic T cells in a murine type 1 diabetes model [15]. Furthermore, increased expression of
SOCS1 was observed in livers of obese insulin-resistant mice [276]. Furthermore, SOCS1 plays an
important role in the pathogenesis of asthma which has been shown both in a mouse model using
SOCS1-/-IFNγ-/- mice [153] and in asthmatic patients [101, 79, 57]. There is a significant as-
sociation between an SOCS1 promoter polymorphism (-1478CA >del) and adult asthma [101].
Severe asthmatic patients with persistent airway eosinophilia have reduced airway epithelial
SOCS1 expression [57]. Data shows the involvement of SOCS1 in many inflammatory diseases
and therefore SOCS1 is a potential target for drug development. SOCS mimetics are peptides
corresponding to functional domains of SOCS1 coupled to protein translocation domains that
facilitate cell entry. Peptides resembling the KIR region are potent therapeutics in experimental
allergic encephalomyelitis mouse model of multiple sclerosis [190] and show promising results in
a psoriasis model [148] and diabetes-associated cardiovascular diseases [227].
3.3. Immunerecognition in the lung
Immune reactions in primary ”sterile” organs such as spleen or blood differ from immune re-
actions in organs where commensal microbes are found such as the the respiratory tract or the
gastrointestinal tract. The respiratory tract displays a large surface of the body that is crucial
for gas exchange. It is in constant contact with the outside environment. Whereas the pharyn-
geal mucosa is colonized by microbes, the lower respiratory tract is considered to be colonized
by only few usually nonpathogenic microbes [102]. Pathogenic microbes that migrate into the
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respiratory tract represent a serious threat that requires immediate immune responses. On the
other hand, constant immune responses against nonpathogenic microbes need to be prevented
to avoid chronic infections and autoimmunity. Therefore, tolerance mechanisms are necessary to
assure tissue homeostasis and host protection. Alveolar and airway epithelial cells serve distinct
roles in the innate defense of the lungs and therefore differ in their cellular composition. The
alveolar epithelium consists of two main populations: alveolar type I and type II epithelial cells.
The predominant cell by number is the alveolar type I epithelial cell, covering 95% of the ep-
ithelial cell [259]. Alveolar type II epithelial cells express chemokines and cytokines, synthesize
and secrete pulmonary surfactants and participate in the innate immune response of the lung
[175]. Gas exchange is mediated by the close apposition of type I and type II epithelial cells to
the endothelial cells of pulmonary capillaries, creating an extensive surface area. In contrast,
the airways (trachea, bronchi and bronchioles) show of a pseudostratified epithelium consisting
of mainly ciliated cells and a small number of secretory cells including serous, club, neuroen-
docrine and goblet cells. In the airways of mouse and other rodents, secretory cells are more
abundant [285]. Airway epithelial cells (AECs) prevent colonization by inhaled bacteria in four
ways [174, 50]:
• AECs built a physical barrier between the outside environment and immune cells through
cell-cell contacts.
• AECs physically remove pathogens by ciliary clearance.
• AECs produce a broad-spectrum of antimicrobials (such as defensins, LL-37, lysozyme or
secretory leukocyte proteinase inhibitor) and secrete them in the mucus [14, 240].
• AECs recruit phagocytic cells and orchestrate inflammatory responses.
To recognize pathogenic microorganisms, airway epithelial cells are equipped with pattern
recognition receptors (PRRs) such as TLRs (Toll-like receptors), RLRs (RIG-I (retinoic acid
inducible gene I)-like receptors) and NLRs (NOD (nucleotide-binding oligomerization domain)-
like receptors) [178, 189, 217, 241, 9, 86, 206, 149, 275]. TLRs are classically found either on
the cell surface (TLR1, 2, 4, 5, 6, 10) or in the endosome (TLR3, 7, 8, 9, 11, 13) [2, 109,
176]. They recognize a variety of PAMPs such as peptidoglycan or lipoproteins (recognized
by TLR1, 2, 6) [262], double-stranded RNA or the mimetic pI:C (recognized by TLR3) [7],
LPS (lipopolysaccharide, recognized by TLR4) [218], flagellin (recognized by TLR5) [4], single-
stranded RNA (recognized by TLR7, 8) [94, 170] or unmethylated CpG-rich DNA (recognized
by TLR9) [33]. Signaling through TLRs induces a signaling cascade leading to production
of pro-inflammatory molecules and recruitment of phagocytic cells and APCs to the site of
pathogen invasion. To induce tolerance and prevent from constant activation, morphology and
differentiation of epithelial cells is critical. Primary airway epithelial cells cultured under air-
liquid interface (ALI) differentiate into ciliated cells that are more resistant to virus infection and
show weaker inflammatory responses [159] as compared to undifferentiated cells. Importantly,
multiple receptors have a polarized distribution in epithelial cells such as the IFNα/β receptor
(IFNAR) that is exclusively expressed on the basolateral surface [32]. Another example is
basolateral localization of TLR2 and 6 or intracellular localization of TLR4 that prevents the
interaction between PAMPs located in the airway lumen and their respective receptors unless
the integrity of the epithelial barrier is compromised [127, 95]. Endogenous low expression of
receptors and upregulation only upon stimulation is another important mechanism to prevent
from constant signaling. It has been shown that TLR3 expression can be induced by the influenza
A virus and by dsRNA in alveolar and bronchial epithelial cells [95]. In addition, mucins
are exclusively expressed on the apical surfaces of differentiated epithelial cells and negatively
regulate TLR signaling [277]. Another important mechanism to induce tolerance by epithelial
cells is the secretion of prostaglandins. Prostaglandin E2 (PGE2) for example as a key regulator
of DC functions, alters MHC class II surface expression and cytokine production [278, 279].
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3.4. Scientific question
Since its discovery as a classical feedback inhibitor for JAK/ STAT signaling, there has been
emerging evidence that there are additional functions for SOCS1 except for regulation of JAK/
STAT signaling. In 2008, a nuclear localization sequence (NLS) has been identified for SOCS1,
resulting in translocation of the protein into the cell nucleus [12, 143]. To date, some functions
for nuclear SOCS1 have been described, however, the physiological relevance has not been ad-
dressed so far. To study the function of SOCS1 in the cell nucleus in more detail in an in vivo
system, a transgenic mouse model was established using a bacterial artificial chromosome (BAC)
containing a mutated Socs1 locus with non-nuclear Socs1∆NLS, GFP and firefly Luciferase,
termed MGL. MGL transgenic mice should be characterized to ensure for successful integra-
tion and regulation of the BAC. Afterwards, mice expressing only non-nuclear Socs1 (thereafter
referred to as Socs1-/-MGLtg mice) were analyzed for disease symptoms. Socs1-/-MGLtg mice
were rescued from early-lethal phenotype as compared to mice deficient for SOCS1. Since this
phenotype is known to be highly dependent on IFNγ, IFNγ signaling should be analyzed in
Socs1-/-MGLtg mice. Unlike IFNγ signaling that is known to be regulated by SOCS1 in the
cytoplasm, NFκB signaling is described as a classical function for SOCS1 in the cell nucleus
and should therefore be used to answer the question whether Socs1-/-MGLtg mice lack nuclear
SOCS1. Socs1-/-MGLtg mice should be further characterized with respect to their pathophys-
iology, focusing on lung pathology. The aim of this study is to establish a mouse model that
allows investigating the physiological relevance of nuclear SOCS1.
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4.1. Materials
4.1.1. Devices
Instrument Company
AutoMACS Miltenyi Biotec, Bergisch-Gladbach
Bioanalyzer Agilent Technologies GmbH, Berlin
Blotting chambers Biometra, Jena
Centrifuges Heraeus Instruments, Hanau (Multi 3 SR)
Sigma 2K15/ B. Braun, Melsungen (Multi 3 SR+)
Counting chamber Neubauer 0.00025mm2/0.1 mm/ Brand GmbH, Schwerin
Cytospin Cytospin 4/A. Dervos – G. Dimitrakopoulos and Co S. A., Athen,
Greece
COULTER Ac-T Hematology Analyzer, Beckmann Coulter, Brea, CA, USA
ELISA reader Sunrise/ Tecan, Crailsheim
FACS FACSCanto/ Becton Dickinson, Heidelberg
Gel Documentation Peqlab, Erlangen
Heating blocks AccuBlock, digital dry bath/ Eppendorf, Hamburg
Incubators BBD6220i/ Heraeus Instruments, Hanau
Luminometer LUMIstar OPTIMA system, BMG LABTECH, Offenburg
Magnetic stirrer Ikamag Reo stirrer/ Roth, Karlsruhe
Micro-CT SKYSCAN
1276
Burker, Billerica, MA, USA
Microscope Leica DM-LS/ Leica GmbH, Wetzlar
Leica DMI 6000B, Leica Microsystems GmbH, Wetzlar
PCR-Thermocycler Primus 96 advanced/ Peqlab Biotechnology GmBH, Erlangen
Primus 25 advanced
pH-Meter Seven Easy/ Mettler-Toledo, Giessen
Photometer NanoDrop ND-1000/ Peqlab Biotechnology GmBH, Erlangen
Power supply Power Pac HC/ BioRad, Mu¨nchen
Consort E835/ Sigma-Aldrich, Steinheim
Real time PCR cycler StepOne Real-time PCR/ Applied Biosystems, Foster City, USA
Scales Sartorius Basic Feinwaage Sartorius TE 2101
Shaker Heidolph 1010/ Hilab, Karlsruhe
Sterile bench Hera Safe KS 12/ Heraeus Instruments, Hanau
TER system Millicell electrical resistance system (ERS), Millipore, Darmstadt
Vortexer Heidolph Reax 2000/ Hilab, Karlsruhe
Tissueruptor Quiagen, Hilden
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4.1.2. Software
Software Description
Bio-Capt For visualizing gels, Vilber Lourmat GmbH
FACSDiva BD Bioscience, San Diego
FCS Express Demo version 5, DeNOVO Software, Glendale, CA, USA
GraphPad Prism Version 6.05, GraphPad Software, Inc. San Diego, USA
ImageJ 1.46r developed at the National Institutes of Health, USA
Inkscape 0.92.0 r15299, licensed GPLv2
LAS AF 2.6.0.7266, Leica Microsystems, Solms
LeicaLS Lite Leica Microsystems, Solms
Magellan V For protein determination and ELISA, Tecan, Gro¨dig, Austria
NanoDrop 3.0.1, Nanodrop Technologies, Rockland, USA
OPTIMA For Luciferase assay, BMG Labtech, Allmendgru¨n
Tierbase Version 4D v14 SQL Release 8, University Heidelberg
4.1.3. Consumables
Consumable Company
Blotting membrane Immobilon-P Transfer/ MilliporeBillerica, USA
Blotting paper Whatman GB003/ Whatman GmbH, Dassel
Eppendorf tubes 0.5 ml, 1.5 ml or 2 ml, Eppendorf AG, Hamburg
Cell culture bottles Cellstar, Greiner Bio-One GmbH, Frickenhausen
Cell culture plates 6-/12-/24-/96-well or 10 cm plates, Cellstar, Greiner Bio-One
GmbH, Frickenhausen
Culture plates for 1. glass bottom dish (35 mm) ibidi GmbH, Martinsried
microscopy 2. µ-Slide 8 well glass bottom (175 µm) ibidi GmbH, Martinsried
Cell scraper Greiner Bio-One GmbH, Frickenhausen
ELISA plates 96 well, Greiner Bio-One GmbH, Frickenhausen
Luminometer plates LUMI TRAC 200, USA Sceintific, Ocala, FL, USA
Needles 22G, 27G or 29G, BD Biosciences, Heidelberg
Pipette tips 0.1-100 µl, 1-200 µl or 100-1000 µl, Corning, New York, USA
qRT-PCR plates MicroAmp, Fast 96-well reaction plate (0.1 ml)/ AppliedBiosys-
tems, UK
Syringes 2 ml or 10 ml, BD Discardit/ BD Biosciences, Heidelberg
1 ml, Braun, Melsungen
Transwell plate 12 mm insert, 0.4 µm polyester membrane insert (#CLS3470-
48EA) Corning Costar, Sigma, MO, USA
Tubes Cellstar Tubes (50 ml, 15 ml), Greiner Bio-One, Frickenhausen
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4.1.4. Chemicals and Reagents
Chemical/ Reagent Company
Acetic acid (100%) Riedel-de Hae¨n AG, Seelze
Acrylamid, stock solution Carl Roth GmbH, Karlsruhe
Agarose Eurobio, Courtaboeuf, France
Ampicillin (Sodium salt) Sigma-Aldrich, Taufkirchen
Alcian Blue Solution Sigma-Aldrich, Taufkirchen
Aluminum hydroxide Thermo, Rockford, IL, USA
Aprotinin Sigma-Aldrich, Taufkirchen
APS (Ammonium persulphate) Sigma-Aldrich, Taufkirchen
Aqua dest Braun, Melsungen
Arginine Carl Roth GmbH, Karlsruhe
Bacto-Agar BD, Biosciences, Heidelberg
BamH1 (10 U/µl, #ER0051) ThermoFisher Scientific, Waltham, MA, USA
Bromphenol blue Sigma-Aldrich, Taufkirchen
BSA (Bovine serum albumin) Carl Roth GmbH, Karlsruhe
anti-CD3/CD28-coated beads ThermoFisher Scientific, Waltham, MA, USA
CFSE Sigma Aldrich, Taufkrichen
Collagen-IV, human placenta #C7521 Sigma, MO, USA
Cycloheximide Merck Millipore, Massachusetts, US
DiffQuick stain Medion Diagnostics, Duedingen, Switzerland
DMEM (Dulbecco’s Modified Eagle
Medium)
Biochrom AG, Berlin
DMSO (Dimethylsulfoxide) Sigma-Aldrich, Taufkirchen
DMEM:Ham’s F12 1:1 Mix GibcoTM/Invitrogen, Karlsruhe
DMSO (Dimethyl sulfoxide) SERVA Electrophoresis GmbH, Heidelberg
DNase I #11284932001 Roche, Mannheim
DTT (Dithiothreitol) Sigma-Aldrich, Taufkirchen
ECL-Reagent PerkinElmer, Rodgau
EcoRI (10 U/µl, #ER0271) ThermoFisher Scientific, Waltham, MA, USA
EDTA AppliChem GmbH, Darmstadt
EGTA Carl Roth GmbH, Karlsruhe
Ethanol Sigma Aldrich, Taufkirchen
Eukitt mounting medium Sigma-Aldrich, Taufkirchen
FCS (Fetal calf serum) 1 Biowest, Nuaille´, Frankreich
2 GibcoTM/Invitrogen, Karlsruhe
Fe(NO3)3 (Ferric nitrate) Sigma-Aldrich, Taufkirchen
FITC–dextran Sigma-Aldrich, Taufkirchen
Giemsa staining solution Merck, Darmstadt
Glutamaic acid Carl Roth GmbH, Karlsruhe
HCl (Hydrochloric acid) Merck, Darmstadt
Heparin solution StemCell Technologies, Ko¨ln
Hoechst 34580 (Trihydrochloride salt) Sigma Aldrich, Taufkirchen
Insulin, recombinant #12585014 ThermoFisher Scientific, Waltham, MA, USA
Imidazole Merck, Darmstadt
IPTG #R1171 ThermoFisher Scientific, Waltham, MA, USA
Jet Prime Transfection Reagent Polyplus-transfection SA, Illkirch, France
Kanamycine AppliChem GmbH, Darmstadt
Latex beads #L1030, Sigma Aldrich, Taufkirchen
LB Broth AppliChem GmbH, Darmstadt
Leupeptin (-hydrochloride) Sigma-Aldrich, Taufkirchen
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Chemical/ Reagent Company
Liberase #5401119001 Roche, Mannheim
Lysozyme Sigma-Aldrich, Taufkirchen
May-Gru¨nwald staining solution Merck, Darmstadt
β-Mercaptoethanol Sigma-Aldrich, Taufkirchen
NaCl (Sodiumchloride) AppliChem GmbH, Darmstadt
NaH2PO4 (Sodiumdihydrogenphosphate) AppliChem GmbH, Darmstadt
Na3PO4 (Sodiumphosphate) Merck, Darmstadt
Na2S2O5 (Sodiummetabisulfite) Sigma-Aldrich, Taufkirchen
Na3VO4 (Sodium orthovanadate) Sigma Aldrich, Taufkirchen
Ovalbumin (EndoGrade) Hyglos GmbH, Regensburg
PFA (Paraformaldehyde) Merck, Darmstadt
PBS (1x) with or without Ca2+/Mg2+ PAA Laboratories, Pasching, Austria
Penicillin/Streptomyin (100x) Sigma-Aldrich, Taufkirchen
Pepstatin A Sigma-Aldrich, Taufkirchen
PeqFect Peqlab, Erlangen
Periodic acid 10%, Sigma-Aldrich, Taufkirchen
Phusion Taq Polymerase (2000 U/ml,
#M0530S)
New England Biolabs (NEB), Ipswich, MA,
USA
Propidium iodide # 25535-16-4 Sigma-Aldrich, Taufkirchen
Pronase E #P5147 Sigma, MO, USA
Protease inhibitors Roche, Mannheim
Proteinase K #03115836001 Roche, Mannheim
Red blood cell lysis buffer eBioscience, CA, USA
Roticlear Carl Roth GmbH, Karslruhe
Rotiquant Carl Roth GmbH, Karslruhe
RPMI 1640 Medium (1x) Biochrome AG, Berlin
Saponin Carl Roth GmbH, Karslruhe
Schiff’s Reagent Sigma-Aldrich, Taufkirchen
SDS (Sodiumdodecylsulphate) AppliChem GmbH, Darmstadt
SYBR Green PCR Master Mix Fast Applied Biosystems, Foster City, USA
T4 Ligase (ExpressLink #A13726) Invitrogen, Karlsruhe
Taq DNA Polymerase (5 U/µl, #EP0402) ThermoFisher Scientific, Vilnius, Lithuania
TEMED (Tetramethylethylendiamin) Sigma-Aldrich, Taufkirchen
Thrombin Sigma-Aldrich, Taufkirchen
Tris Base AppliChem GmbH, Darmstadt
Triton X-100 Merck, Darmstadt
Trypan blue Sigma-Aldrich, Taufkirchen
Trypsin/EDTA (10x) PAA Laboratories, Pasching, Austria
Tween 20 Sigma-Aldrich, Taufkirchen
Ultroser G #15950–017 Pall Corporation, Dreieich, Germany
Urea Sigma Aldrich, Taufkirchen
XhoI (10 U/µl, #ER0691) ThermoFisher Scientific, Waltham, MA, USA
Xylene Sigma-Aldrich, Taufkirchen
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4.1.5. Kits
Kit Company
OptEIA Mouse IL-6 ELISA #555240, BD Biosciences, Heidelberg
OptEIA Mouse TNFα ELISA #560478, BD Biosciences, Heidelberg
OptEIA Mouse IL-12p40 ELISA #555165, BD Biosciences, Heidelberg
Mouse IL-33 ELISA #DY3626-05, R&D systems, Minneapolis, MN, USA
Albumin ELISA #108791, abcam, Cambridge, UK
TransAM Kit #43296, Active Motif, Carlsbad, CA, USA
IL-4, IL-5 and IL-13 CBA Flex
Set
#558298, 55832, 558349, BD Biosciences, Franklin Lakes,
NJ, USA
Monoclonal anti-IgE clone R35-72, BD Biosciences, Heidelberg
Anti-IgE conjugated with HRP clone 23G3, Southern Biotech, Birmingham, AL, USA
High Capacity cDNA Reverse
Transcription
Applied Biosystems, Life Technologies, Darmstadt
HotStartTaq DNA Polymerase Qiagen, Hilden
IHC Detection Mouse and Rabbit Specific HRP/DAB (ABC) Detection,
#ab64264, abcam, Cambridge, UK
PeqGold DNase I Digest Kit Peqlab Biotechnology GmBH, Erlangen
PeqGold Total RNA Kit Peqlab Biotechnology GmBH, Erlangen
RNeasy Total RNA Kit Quiagen, Hilden
CD4+ negative selection Kit #130-104-454, Miltenyi Biotec, Bergisch Gladbach
CD11c+ positive selection Kit #130-052-001, Miltenyi Biotec, Bergisch Gladbach
4.1.6. Buffers
Buffer Ingredients
PBS 80 mM disodiumhydrogenphosphate, 20 mM sodium di-
hydrogenphosphate 1.4 M sodium chloride, pH 7.4
Penicillin/Streptomycin, 100x 10,000 U/ml penicillin G, 10 mg/ml streptomycin, 0.9%
(w/v) NaCl
Trypan blue solution 2 mg/ml trypan blue in 1x PBS
Trypsin solution 0.05% trypsin, 0.02% EDTA in 1x PBS
Buffer for agarose gels
TAE buffer 2M Tris-Base, 1M conc. acetic acid, 0.05 M EDTA, pH
8.0
Buffers for ELISA
Coating buffer 0.1 M Na2CO3, pH 9.5
Wash buffer 0.05% Tween 20 in PBS (v/v)
Blockbuffer PBS/10% FCS (v/v)
Buffers for Westen Blot
Lamelli buffer, 4x 200 mM Tris-HCl, 0.4% (w/v) bromophenolblue, 40%
(w/v) glycerol, 8% (w/v) SDS, 400 mM (v/v) β-
mercaptoethanol, pH 8.8
Separating gel buffer 1.5 M Tris-HCl, 0.4% (w/v) SDS, pH 8.8
Stacking gel buffer 1 M Tris-HCl, 0.8% (w/v) SDS, pH 6.8
SDS Page running buffer 25 mM TRIS-OH, 192 mM Glycin, 10% (v/v) Methanol,
pH 8.3
Semidry blotting buffer 25 mM Tris-OH, 192 mM Glycin, 10% (v/v) Methanol,
pH 8.3
Blocking buffer 5% BSA solution in 1x TBS, 0.05% (v/v) Tween-20
Wash buffer (TBST) 1x TBS, 0.05% (v/v) Tween-20
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Buffer Ingredients
10x TBS 100 mM Tris-HCl, pH 8.0; 1.5 M NaCl
Buffers for IHC
EDTA buffer 1 mM EDTA, pH 8.0
Citrate buffer 10 mM Citric Acid, 0.05% Tween-20, pH 6.0
Wash buffer 1x PBS, 0.05% (v/v) Tween-20
Buffer for FACS
FACS buffer 1x PBS, 2% (v/v) FCS
Buffers for Luciferase Assay
Luciferase lysis buffer 1% (v/v) Triton X-100, 25 mM Glycyl-Glycine (pH 7.8),
15 mM MgSO4, 4 mM EGTA and 1 mM DTT
Luciferase assay buffer 100 mM K3PO4, 100 mM MgSO4, 200 mM EGTA, H2O,
pH 7.8, before use: 2 mM ATP, 1 MM DTT, 25 mM
GlyGly (D-luciferine)
Buffers for protein expres-
sion
Lysis buffer 50 mM NaH2PO4, 300 mM NaCl, 50 mM Imidazole, 0.5%
Triton X-100, before use: 2 mg/ml lysozyme
Wash buffer 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1% Triton X-100
Dialysis buffer 20 mM Na3PO4, 20 mM NaCl, 50 mM arginine, 50 mM
glutamate, 2 mM DTT, 1 mM EDTA, pH 6.5
Extraction buffer 50 mM Tris-HCl, pH 7.5, 8 M urea, 1 mM DTT, before
use: add Proteinase inhibitors
Buffers for H&E staining
Haematoxylin solution 50 g/l aluminium ammonium sulphate, 5 g/l haema-
toxylin (CI 75290), 1% ethanol, 1 g/l sodium iodate, 2%
acetic acid, 30% glycerol
Acid alcohol 0.3% HCl, 70% ethanol
Scott’s tap water substitute 2 g/l sodium hydrogen carbonate, 20 g/l magnesium sul-
phate
Eosin solution 1% eosin (CI 45380), 1% phloxine (CI 45405), 95% alco-
hol and 4% acetic acid
4.1.7. Media
Media Description
DMEM Culture Medium 10% (v/v) heat-inactivated FCS, penicillin G (100 IU/ml),
streptomycin sulfate (100 µg/ml), Biochrom, Berlin
DMEM for differentiation of
BMMs
10% (v/v) heat-inactivated FCS, penicillin G (100 IU/ml),
streptomycin sulfate (100 µg/ml); 30% of M-CSF containing
supernatant, Biochrom, Berlin
DMEM / Ham’s F12 culture
medium
DMEM/ Ham’s F12 1:1 medium mix, 5% (v/v) heatinacti-
vated FCS, penicillin G (100 IU/ml), streptomycin sulfate
(100 µg/ml), 120 IU/l human insulin, Biochrom, Berlin
RPMI Culture Medium 10% (v/v) heat-inactivated FCS, penicillin G (100 IU/ml),
streptomycin sulfate (100 µg/ml), Biochrom, Berlin
UltroserG Medium DMEM/Ham’s F12 1:1 medium mix, penicillin G (100
IU/ml), streptomycin sulfate (100 µg/ml) and 2% UltroserG
serum complement, Biochrom, Berlin
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4.1.8. Markers and Stains
Marker Company
6x Loading Dye Thermo Fisher Scientific, Waltham, USA
GeneRuler DNA Ladder Mix Fermentas, St.Leon-Rot
PageRule Plus Protein ladder Fermentas, St.Leon-Rot
peqGREEN DNA/RNA Dye Peqlab, Erlangen
CellMask Membrane Stain ThermoFisher Scientific, Waltham, MA, USA
Hoechst final concentration 1µg/ml, Sigma Aldrich, Taufkirchen
4.1.9. Antibodies
Antigen Dilution Company
SOCS1 (Hybridoma super-
natant)
1:20 newly generated by immunizing mice against the
peptide RRITRASALLDA, Abmart, Shanghai
SOCS1 (Charles River) 1:50-
2000
Newly generated polyclonal antibody against
recombinant murine SOCS1, Charles River,
Chatillon-sur-Chalaronne, Ecully, France
SOCS1 (CST) 1:50-
2000
#3950, Cell Signaling Biotechnology, Frankfurt
SOCS1 (Abcam) 1:50-
2000
#ab-9870, Abcam, Cambridge, UK
SOCS1 (SC) 1:50-
2000
#sc-9021, Santa Cruz Biotechnology, Heidelberg
β-Actin 1:4000 #4970, Cell Signaling Biotechnology, Frankfurt
IκBα 1:1000 #9242, Cell Signaling Biotechnology, Frankfurt
pSTAT1 (Tyr701) 1:1000 #9167, Cell Signaling Biotechnology, Frankfurt
STAT1 1:1000 #9172, Cell Signaling Biotechnology, Frankfurt
Histon3 (H3) 1:1000 #9715, Cell Signaling Biotechnology, Frankfurt
E-Cadherin 1:1000 #3195, Cell Signaling Biotechnology, Frankfurt
Occludin 1:1000 #168986, Abcam, Cambridge, UK
Anti-Rabbit IgG HRP-linked 1:4000 #7074, Cell Signaling Biotechnology, Frankfurt
Anti-Mouse IgG HRP-linked 1:4000 #7076, Cell Signaling Biotechnology, Frankfurt
AlexaFluor 647 Anti-STAT1
(pY701)
1:50 #612597, BD Biosciences, Heidelberg
PE Anti-Mouse CD11c 1:50 #553802, BD Biosciences, Heidelberg
FITC Anti-Mouse CD4 1:100 #561828, BD Biosciences, Heidelberg
FITC Anti-Mouse CD3 1:50 #559975, BD Biosciences, Heidelberg
APC anti-Mouse CD45.2 1:200 #558702, BD Biosciences, Heidelberg
FITC Anti-Mouse CD45.1 1:200 #561871, BD Biosciences, Heidelberg
PE Anti-Mouse F4/80 1:50 #56541, BD Biosciences, Heidelberg
APC-Cy7 Anti-Mouse CD11b 1:50 #557657, BD Biosciences, Heidelberg
FITC Anti-Mouse MHCII 1:50 #553623, BD Biosciences, Heidelberg
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4.1.10. Stimuli
Stimuli Description
Poly(I:C), pIC Invivogen, Toulouse, France
S-LPS from Salmonella minnesota, smooth-LPS, Ulrich Seydel,
Forschungszentrum Borstel
CpG phosphorothioate-modified CpG-oligonucleotide 1668 from TIB
Molbiol, Berlin
IFNγ #315-05, Peprotech, Hamburg
IL-13 #210-13, Peprotech, Hamburg
OVA Ovalbumin grade VI #A2512; Sigma-Aldrich, Deisenhofen
Ovalbumin grade V #A5503; Sigma-Aldrich, Deisenhofen
IL-2 #402-ML-020, R&D Systems, Minneapolis, MN, USA
IL-4 #214-14, Peprotech, Hamburg, Germany
anti-IFNγ #517903, BioLegend, San Diego, CA, USA
anti-IL-12 #505203, BioLegend, San Diego, CA, USA
T-cell stimulation containing PMA and ionomycin, #00-4970, eBioscience, CA, USA
Dynabeads R© Mouse T-Activator CD3/CD28 for T-Cell Expansion and Activa-
tionm #11456D, ThermoFisher Scientific, Waltham, MA, USA
4.1.11. Anesthetic solution
Anesthetic Description
Xylazine and Ketamine 1.2 ml ketamine (10%), 8 ml NaCl, 0.8 ml xylazine (2%), 100 µl/
10 g bodyweight i.p.
Isofluorane 4% isofluorane, 500 ml/min O2, inhaled for max. 45 sec.
Pentobarbital Narcoren 16 g / 100 ml solution, 25 µl / 10 g bodyweight i.p.
4.1.12. Vectors and plasmids
Vector Description
eGFP-C1 Enhanced GFP. CMV promotor and cloning sites for BamHI and
XhoI. Kanamycine resistance.
eGFP-mSocs1 Murine Socs1 cloned into eGFP-C1 backbone via BamHI and XhoI
generating a fusionprotein. Kanamycine resistance.
eGFP-mSocs1∆NLS Murine Socs1∆NLS cloned into eGFP-C1 backbone via BamHI
and XhoI. In Socs1∆NLS, the NLS is replaced by the sequence
GCT GGT ACT GAG CCG ACC TCT CTC CTC CAA CGT
GGC CAC CCT from Socs3. Kanamycine resistance.
pGex-mSocs1 Vector for protein expression with a tac promoter that is induced
by IPTG. Murine Socs1 cloned into pGex using BamHI and EcoRI.
Generates GST-tagged protein. Thrombin protease sites for cleav-
age of the GST taq. Ampicillin resistance.
PA-GFP-C1 photoactivatable GFP, pPAGFP-C1 was a gift from Jennifer
Lippincott-Schwartz (Addgene plasmid #11910) [213]. CMV pro-
motor and cloning sites for BamHI and XhoI. Kanamycine resis-
tance.
PA-GFP-mSocs1 Murine Socs1 cloned into PA-GFP-C1 backbone via BamHI and
XhoI. Kanamycine resistance.
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4.1.13. Primers
Target Forward sequence 5’-3’ Reverse sequence 5’-3’
Socs1∆NLS CAC CTT CTT GGT GCG CG GAG GAG AGA GGT CGG CTC AGT AC
Socs1 CAC CTT CTT GGT GCG CG CCC CCA ACA TGC GGC GCG
Socs1WT FAM-ATGTTGGGGGCCCCGCTGCG-
BHQ2
Actb CCC TGT GCT TGG CTT CAC CGA ACA GTG TGG GTG ACC CCG TTC
GFP CAA CAG CCA CGT CTA TAT CAT ATG TTG TGG CGG ATC TTG AAG
Luciferase TAA ACG GCC ACA AGT TCA GC TTC ATG TGG TCG GGG TAG C
TNFα AAA ATT CGA GTG ACA AGC CTG TAG CCC TTG AAG AGA ACC TGG GAG TAG
IL-6 CCG GAG AGG AGA CTT CAC AG TTC TGC AAG TGC ATC ATC GT
IL-12p40 AAG AAG GAA AAT GGA ATT TGG TCC ATG TCA CTG CCC GAG AGT CAG
iNOS CAG CTG GGC TGT ACA AAC CTT CAT TGG AAG TGA AGC GTT TCG
Irf9 GCC GAG TGG TGG GTA AGA C GCA AAG GCG CTG AAC AAA GAG
Icam1 GGC ATT GTT CTC TAA TGT CTC CG TGT CGA GCT TTG GGA TGG TAC
Gdf3 ATG CAG CCT TAT CAA CGG CTT AGG CGC TTT CTC TAA TCC CAG
Sla ATG GGG AAT AGC ATG AAA TCC AC GGA GAT GGG TAG TCA GTC AGC
Sell TAC ATT GCC CAA AAG CCC TTA CAT CGT TCC ATT TCC CAG AGT C
Indo GCT TTG CTC TAC CAC ATC CAC CAG GCG CTG TAA CCT GTG T
IL-4 GGT CTC AAC CCC CAG CTA GT GCC GAT GAT CTC TCT CAA GTG AT
IL-5 CTC TGT TGA CAA GAC CTG TCT TCA GTA TGT CTA GCC CCT G
IL-13 CCT GGC TCT TGC TTG CCT T GGT CTT GTG TGA TGT TGC TCA
IL-25 ACA GGG ACT TGA ATC GGG TC TGG TAA AGT GGG ACG GAG TTG
IL-33 TCC AAC TCC AAG ATT TCC CCG CAT GCA GTA GAC ATG GCA GAA
Tslp ACG GAT GGG GCT AAC TTA CAA AGT CCT CGA TTT GCT CGA ACT
CCL26 TTC TTC GAT TTG GGT CTC CTT G GTG CAG CTC TTG TCG GTG AA
4.1.14. Primer for genotyping
Target Forward sequence 5’-3’ Reverse sequence 5’-3’ Annealing
Socs1WT GCA TCC CTC TTA ACC CGG TAC AAA TGA AGC CAG AGA CCC TCC 59 ◦C
Socs1KO CCT CCA GCT GGC CCC TCG AGT
AGG ATG
CAT TCG CCA TTC AGG CTG CGC
AAC TGT T
59 ◦C
Socs1MGL TAA ACG GCC ACA AGT TCA GC TTC ATG TGG TCG GGG TAG C 59 ◦C
β2M CAC CGG AGA ATG GGA AGC CGA A TCC ACA CAG ATG GAG CGT CCA G 59 ◦C
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4.1.15. Organisms
Mice
C57BL/6 mice were purchased from Charles River Laboratories. Breeding occurred under spe-
cific pathogen free conditions in the animal facility (IBF, Heidelberg, Germany). Breeding and
monthly control for infections were performed according to the GV-SOLAS, 1995. Transgenic
mice were generated by pronucleus injection using a BAC containing a part of chromosome #16
(10.78 – 10.80 Mb) including a mutated Socs1 locus with non-nuclear Socs1∆NLS, eGFP (codon
optimized for mouse and human) and LuciferaseCBG99 (Click Beetle Green from Pyrophorus
plagiophalam), termed MGL (RP23-360O7). The BAC (generated by Arnold Ku¨blbeck, DKFZ)
consist of the sequence for Socs1∆NLS (red indicating the exchanged NLS corresponding re-
gion), GFP (green), Luciferase and 2 A sequences in between the three coding regions (blue):
ATG GTA GCA CGC AAC CAG GTG GCA GCC GAC AAT GCG ATC TCC CCG GCA GCA GAG CCC
CGA CGG CGG TCA GAG CCC TCC TCG TCC TCG TCT TCG TCC TCG CCA GCG GCC CCC GTG
CGT CCC CGG CCC TGC CCG GCG GTC CCA GCC CCA GCC CCT GGC GAC ACT CAC TTC CGC
ACC TTC CGC TCC CAC TCC GAT TAC CGG CGC ATC ACG CGG ACC AGC GCG CTC CTG GAC
GCC TGC GGC TTC TAT TGG GGA CCC CTG AGC GTG CAC GGG GCG CAC GAG CGG CTG CGT
GCC GAG CCC GTG GGC ACC TTC TTG GTG CGC GAC AGT CGC CAA CGG AAC TGC TTC TTC
GCG CTC AGC GTG AAG ATG GCT TCG GGC CCC ACG AGC ATC CGC GTG CAC TTC CAG GCC
GGC CGC TTC CAC TTG GAC GGC AGC CGC GAG ACC TTC GAC TGC CTT TTC GAG CTG CTG
GAG CAC TAC GTG GCG GCG CC G CTG GTA CTG AGC CGA CCT CTC TCC TCC AAC GTG GCC
ACC CT G CAG GAG CTG TGT CGC CAG CGC ATC GTG GCC GCC GTG GGT CGC GAG AAC CTG
GCG CGC ATC CCT CTT AAC CCG GTA CTC CGT GAC TAC CTG AGT TCC TTC CCC TTC CAG ATC
GGT TCC GGA GCC ACG AAC TTC TCT CTT TTA AAG CAA GCA GGA GAC GTG GAA GAA AAC
CCC GGT CCC ATG GTG AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG
GTC GAG CTG GAC GGC GAC GTA AAC GGC CAC AAG TTC AGC GTG TCC GGC GAG GGC GAG
GGC GAT GCC ACC TAC GGC AAG CTG ACC CTG AAG TTC ATC TGC ACC ACC GGC AAG CTG
CCC GTG CCC TGG CCC ACC CTC GTG ACC ACC CTG ACC TAC GGC GTG CAG TGC TTC AGC
CGC TAC CCC GAC CAC ATG AAG CAG CAC GAC TTC TTC AAG TCC GCC ATG CCC GAA GGC TAC
GTC CAG GAG CGC ACC ATC TTC TTC AAG GAC GAC GGC AAC TAC AAG ACC CGC GCC GAG
GTG AAG TTC GAG GGC GAC ACC CTG GTG AAC CGC ATC GAG CTG AAG GGC ATC GAC TTC
AAG GAG GAC GGC AAC ATC CTG GGG CAC AAG CTG GAG TAC AAC TAC AAC AGC CAC AAC
GTC TAT ATC ATG GCC GAC AAG CAG AAG AAC GGC ATC AAG GTG AAC TTC AAG ATC CGC
CAC AAC ATC GAG GAC GGC AGC GTG CAG CTC GCC GAC CAC TAC CAG CAG AAC ACC CCC
ATC GGC GAC GGC CCC GTG CTG CTG CCC GAC AAC CAC TAC CTG AGC ACC CAG TCC GCC
CTG AGC AAA GAC CCC AAC GAG AAG CGC GAT CAC ATG GTC CTG CTG GAG TTC GTG ACC
GCC GCC GGG ATC ACT CTC GGC ATG GAC GAG CTG TAC AAG GGT TCC GGA GCC ACG AAC
TTC TCT CTT TTA AAG CAA GCA GGA GAC GTG GAA GAA AAC CCC GGT CCC 5’ ATG GTG AAG
CGT GAG AAA AAT GTC ATC TAT GGC CCT GAG CCT CTC CAT CCT TTG GAG GAT TTG ACT GCC
GGC GAA ATG CTG TTT CGT GCT CTC CGC AAG CAC TCT CAT TTG CCT CAA GCC TTG GTC
GAT GTG GTC GGC GAT GAA TCT TTG AGC TAC AAG GAG TTT TTT GAG GCA ACC GTC TTG
CTG GCT CAG TCC CTC CAC AAT TGT GGC TAC AAG ATG AAC GAC GTC GTT AGT ATC TGT
GCT GAA AAC AAT ACC CGT TTC TTC ATT CCA GTC ATC GCC GCA TGG TAT ATC GGT ATG ATC
GTG GCT CCA GTC AAC GAG AGC TAC ATT CCC GAC GAA CTG TGT AAA GTC ATG GGT ATC
TCT AAG CCA CAG ATT GTC TTC ACC ACT AAG AAT ATT CTG AAC AAA GTC CTG GAA GTC
CAA AGC CGC ACC AAC TTT ATT AAG CGT ATC ATC ATC TTG GAC ACT GTG GAG AAT ATT CAC
GGT TGC GAA TCT TTG CCT AAT TTC ATC TCT CGC TAT TCA GAC GGC AAC ATC GCA AAC TTT
AAA CCA CTC CAC TTC GAC CCT GTG GAA CAA GTT GCA GCC ATT CTG TGT AGC AGC GGT
ACT ACT GGA CTC CCA AAG GGA GTC ATG CAG ACC CAT CAA AAC ATT TGC GTG CGT CTG
ATC CAT GCT CTC GAT CCA CGC GTG GGC ACT CAG CTG ATT CCT GGT GTC ACC GTC TTG
GTC TAC TTG CCT TTC TTC CAT GCT TTC GGC TTT AGC ATT ACT TTG GGT TAC TTT ATG GTC
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GGT CTC CGC GTG ATT ATG TTC CGC CGT TTT GAT CAG GAG GCT TTC TTG AAA GCC ATC
CAA GAT TAT GAA GTC CGC AGT GTC ATC AAC GTG CCT AGC GTG ATC CTG TTT TTG TCT
AAG AGC CCA CTC GTG GAC AAG TAC GAC TTG TCT TCA CTG CGT GAA TTG TGT TGC GGT
GCC GCT CCA CTG GCT AAG GAG GTC GCT GAA GTG GCC GCC AAA CGC TTG AAT CTT CCA
GGG ATT CGT TGT GGC TTC GGC CTC ACC GAA TCT ACC AGC GCT AAC ATT CAC TCT CTC
GGG GAT GAG TTT AAG AGC GGC TCT TTG GGC CGT GTC ACT CCA CTC ATG GCT GCT AAG
ATC GCT GAT CGC GAA ACT GGT AAG GCT TTG GGC CCG AAC CAA GTG GGC GAG CTG TGT
ATC AAA GGC CCT ATG GTG AGC AAG GGT TAT GTC AAT AAC GTT GAA GCT ACC AAG GAG
GCC ATC GAC GAC GAC GGC TGG TTG CAT TCT GGT GAT TTT GGA TAT TAC GAC GAA GAT
GAG CAT TTT TAC GTC GTG GAT CGT TAC AAG GAG CTG ATC AAA TAC AAG GGT AGC CAG
GTT GCT CCA GCT GAG TTG GAG GAG ATT CTG TTG AAA AAT CCA TGC ATT CGC GAT GTC
GCT GTG GTC GGC ATT CCT GAT CTG GAG GCC GGC GAA CTG CCT TCT GCT TTC GTT GTC
AAG CAG CCT GGT AAA GAA ATT ACC GCC AAA GAA GTG TAT GAT TAC CTG GCT GAA CGT
GTG AGC CAT ACT AAG TAC TTG CGT GGC GGC GTG CGT TTT GTT GAC TCC ATC CCT CGT
AAC GTA ACA GGC AAA ATT ACC CGC AAG GAG CTG TTG AAA CAA TTG TTG GAG AAG GCC
GGC GGT TAG 3’
Pronucleus injection resulted in 12 transgenic founder mice, named C57Bl6-tg(Socs1-MGL)Uhg.
This work was done by Prof. Dr. Bernd Arnold and Gu¨nter Ku¨blbeck (DKFZ, Heidelberg, Ger-
many) in cooperation with Frank Zimmermann (IBF, Heidelberg) and Patrick Walker. Mice were
genotyped at an age of 2 weeks using ear material for PCR detecting either Socs1 wildtype (wt)
and Socs1 knock-out or Socs1 MGL and β2microglobulin (β2M) (Primer sequences see section
4.1.14). Breeding, sacrificing and dissection were approved and experiments properly recorded
and reported to the regional commission in Karlsruhe (Permit number: 35-9185.81/G-54/14).
Socs1+/-MGLtg mice were mated with Socs1+/- to generate Socs1-/-MGLtg and the correspond-
ing control mice. Using this breeding strategy, 17.6% of the offsprings were Socs1-/-MGLtg,
showing no gender bias (Fig. 4).
Socs1+/-
Socs1+/+
Socs1-/-
Socs1-/- MGLtg
Socs1+/- MGLtg
Socs1+/+ MGLtg
50.2% female 49.8% male
11.5%
8.6%
19.6%
28.4%
14.2%
17.6%
10.6%
6.6%
20.0%
30.4%
15.2%
17.6% 12.4%
10.6%
19.2%
26.4%
13.2%
17.6%
B
A
Socs1+/-MGLtg Socs1+/-
Socs1+/+MGLtg Socs1+/+ Socs1+/-MGLtg Socs1+/- Socs1-/-MGLtg Socs1-/-
12.5% 12.5% 25% 25% 12.5% 12.5%
Figure 4.: Breeding strategy for Socs1-/-MGLtg mice.
(A) Socs1+/-MGLtg mice were mated with Socs1+/- to generate Socs1-/-MGLtg (12.5% expected) and the
corresponding littermate controls. Percentages showing expected frequencies of the different genotypes.
(B) Percentage of offsprings according to their genotype in all offsprings (left), female offsprings (middle)
and male offsprings (right). n = 107 - 353 mice per group
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Eukaryotic cells
• BEAS2B cells: BEAS2B cells were derived from normal bronchial epithelium obtained
from autopsy of non-cancerous individuals and transformed by SV40 T-antigen.
• NIH3T3 cells: Mouse embryonic fibroblast cells come from a cell line isolated and initiated
in 1962 at the New York University School of Medicine Department of Pathology.
• Raw264.7 cells: Macrophage cell line established from an ascites of a tumour induced in a
male mouse by intraperitoneal injection of Abselon Leukaemia Virus (A-MuLV).
• BMMs: Murine bone marrow-derived macrophages, AG Dalpke (isolation protocol given
below)
• pmTEC: Primary murine tracheal epithelial cells, AG Dalpke (isolation protocol given
below)
• Hybridoma cells: Originated by Abmart (Shanghai) by immunizing mice against the pep-
tide RRITRASALLDA.
Prokaryotic cells
• DH5α: Chemically competent E.coli strain for cloning. Saftey level S1.
• BL21: E.coli strain for the expression of recombinant proteins. Saftey level S1.
4.2. Methods
4.2.1. Genotyping
DNA was extracted from mouse ear tissue using the DirectPCR Lysis reagent (peqlab) according
to the manufacturer’s protocol. The extracted DNA was used in a PCR to check for amplification
of Socs1WT, Socs1KO or Socs1 MGL. In brief, ear material was incubated in 180 µl DirectPCR
Lysis reagent with 0.3 mg/ml Proteinase K at 55 ◦C overnight. After incubation at 85 ◦C for
45 min, 3 µl of DNA was used in a PCR using Taq Polymerase (5 U/µl). The reaction mix
was composed of: 2 µl 10x buffer, 0.4 µl dNTPs, 0.2 µl primermix, 0.2 µl Taq Polymerase, 2
µl MgCl2, 0.4 µl DMSO, 11.8 µl H2O and 3 µl DNA template in 20 µl reaction volume. The
following PCR conditions were used with 35 cycles between step 2 - 4:
1. 5 min at 95 ◦C
2. 1 min at 59 ◦C
3. 1 min at 72 ◦C
4. 1 min at 95 ◦C
5. 5 min at 72 ◦C
Expected bands for Socs1WT at 360 bp and Socs1KO at 160 bp or for β2M at 350 bp and
GFP at 150 bp were controlled on a 2% agarose gel. Agarose gel was prepared in 1x TAE buffer
and peqGREEN DNA/RNA Dye was added. Amplified DNA samples were mixed with 4 µl of
6x loading dye and loaded on the 2% agarose gel that run at 100 V for 45 min. GeneRuler DNA
Ladder Mix (100-10000 bp) was used as a marker. For documentation, the gels were analyzed
under UV light and imaged.
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4.2.2. Cell culture and transfection of eukaryotic cells
RAW264.7 cells were cultured at 37 ◦C and 5% CO2 in RPMI-1640 and Beas2B or NIH3T3 cells
in DMEM, respectively. Cell culture medium was further supplemented with 10% (v/v) heat-
inactivated fetal calf serum (FCS), penicillin (50 units/ml) and streptomycin (50 µg/ml) (P/S).
Cells were split every 3 or 4 days when reaching approximately 80-90% confluence. After washing
with PBS, Beas2B or NIH3T3 cells were trypsinized in trypsin-EDTA (0.05%) solution at 37
◦C (approximately 1 min), followed by addition of corresponding culture medium to terminate
trypsinization. Raw264.7 cells were split using a cell scraper. Cells were diluted 1:10 in trypan
blue solution and viable cells counted with a Neubauer counting chamber. For transfection of
RAW264.7 cells, the transfection reagent JetPRIME was used and for transfection of Beas2 or
NIH3T3 cells, PeqFect was used and transfection was performed according to the manufacturer‘s
protocol.
4.2.3. Cell culture of primary murine tracheal epithelial cells (pmTECs)
The procedure used for isolation of murine tracheal epithelial cells was adapted from Davidson
et al. in 2000 [46]. In brief, mice were killed by CO2 inhalation. Tracheas were removed,
cut length-ways, washed in PBS and transferred to collection media (1:1 mixture of DMEM
and Ham’s F12 with 1% (v/v) penicillin-streptomycin). Tracheas were then incubated at 4
◦C overnight in dissociation media (44 mM NaHCO3, 54 mM KCl, 110 mM NaCl, 0.9 mM
NaH2PO4, 0.25 µM FeN3O9, 1 µM sodium pyruvate, pH 7.5, and supplemented with 1% (v/v)
penicillin-streptomycin, 0.1 mg/ml DNaseI and 1.4 mg/ml PronaseE). Enzymatic digestion was
stopped by adding 20% FCS to the dissociation media. Epithelial cells were dissociated by gentle
agitation followed by physical removal of the trachea skeletons. Cells were then centrifuged at
1000 x g for 10 min at RT. Cell pellets were resuspended in culture medium (1:1 mixture of
DMEM and Ham’s F12 with 1% penicillin-streptomycin, 5% FCS and 120 U/l Insulin) and
seeded in a 10 cm cell-culture dish for 2 h at 37 ◦C. The supernatant containing epithelial cells
was carefully collected and centrifuged at 1000 x g for 10 min at RT. Cell pellets from 2 tracheas
were resuspended in 200 µl culture medium and seeded in the inner well of a transwell coated
with human placenta collagen-IV. After 7 days, medium from the inner well was removed and
medium from the outer well was replaced with UltroserG medium (1:1 mixture of DMEM and
Ham’s F12 with 1% penicillin-streptomycin, 2% UltroserG serum. After 30 days of culture,
murine trachea epithelial cells were used for experiments.
4.2.4. Generation of bone-marrow derived macrophages
M-CSF derived macrophages (BMMs) were prepared as described previously [58], with minor
modifications. Briefly, mice were sacrificed by CO2 inhalation. Femurs and tibiae were removed
and bone marrow was collected by flushing with supplemented DMEM using a 27 G syringe.
After centrifugation of the cell suspension at 1300 rpm for 5 min, the pellet was resuspended
in 48 ml of the respective medium. 12 ml of the cell suspension was placed per 145 cm2 tissue
culture plate plus 6 ml M-CSF containing cell supernatant (L929, 30%). On day 3, additional
9 ml of M-CSF containing cell supernatant were added and on day 7, adherent BMMs were
harvested. For this purpose, BMM were washed with 1x PBS and detached by scraping using
a cell scraper. Cells were centrifuged (1300 rpm, 5 min) and plated. For generation of BMMs
from 2-week old mice, the same procedure was followed except using 29G syringes and 56.7 cm2
dishes. 2.5x105 or 1x106 BMMs per well were cultured in 500 µl in a 24-well plate or in 2 ml in
a 6-well plate. For cycloheximide chase, 1x106 BMMs were stimulated with IFNγ for 6 h and
chased with 100 µg/ml Cycloheximide.
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4.2.5. Preparation of single-cell suspensions from tissue
For analysis of lung homogenate, mice were sacrificed using xylazine and ketamine and lungs
were perfused through the right ventricle with PBS. Once lungs appeared white, they were
removed and sectioned. Dissected lung tissue was then incubated with 0.2 mg/ml LiberaseTM
and 0.1 mg/ml DNaseI at 37 ◦C for 1 h. Digested lung tissue was gently disrupted by passage
through a 19 G needle and afterwards through a 70 µm pore size nylon cell strainer. Red blood
cells were lysed using red blood cell lysis buffer. CD11c+ or CD4+ T cells were isolated using the
positive selection CD11c+ beads or the negative selection CD4+ T Cell Isolation Kit (Miltenyi
Biotec), respectively. Magnetically labeled cells were isolated via the autoMACS Separator and
purity was verified by FACS. For single cell suspension of splenocytes, spleens were dissected
and treated as described above without enzymatic digestion.
4.2.6. Cell culture of prokaryotic cells
Bacteria stocks were kept at -80 ◦C for long term storage. For culturing of prokaryotic cells,
veils were thawn on ice and used for transformation. Culture was done at 37 ◦C in a shaker
(liquid culture) or in an incubator (agar plates). Culture volume was dependent on the copy
number of the plasmid, the bacterial strain as well as the medium used.
4.2.7. Amplification of plasmids
To obtain sufficient amount of plasmids for transfection, plasmids were transformed into bacteria,
amplified and purified. Chemical competent E.coli (DH5α or BL21, 50 µl per plasmid) were
thawn on ice, incubated with the desired plasmid for 30 min, heat shocked for 45 sec at 42
◦C and cooled down on ice for 2 min. Thereafter, 250 µl prewarmed SOC-medium was added
and bacteria were incubated at 37 ◦C and 225 rpm for 1 h. 10% and 90% of this bacterial
suspension were streaked out on two agar plates with the corresponding antibiotic and cultured
at 37 ◦C in an incubator overnight. On the next day, one colony was picked and used for plasmid
amplification in 5 ml of LB medium with the corresponding antibiotic overnight at 37 ◦C while
shaking (ca. 250 rpm). This culture was either used for mini-prep or added to 250 ml of fresh
LB medium and incubated again overnight for a maxi-prep on the next day. For harvesting,
bacteria were centrifuged at 4.000 rpm at 4 ◦C for 20 min and further processed for plasmid
isolation or stored for short term at -20 ◦C. For plasmid isolation, the commercially available
kits from Quiagen were used according to the manufacturer’s instructions either for mini-prep
(for 5 ml of bacteria suspension) or for maxi-prep (for 250 ml of bacteria suspension). Eluted
plasmids were stored at -20 ◦C.
4.2.8. Cloning
For Cloning of a part of a plasmid into another vector, different steps are necessary. First, a
digest of the plasmid using restriction enzymes needs to take place. For cloning of SOCS1-WT
or SOCS1∆NLS out of the C1-GFP vector into an either PA-GFP or GST containing vector, 1
µg of vector or insert were used together with 2 µl Tango buffer, 2 µl BamHI, 1 µl EcoRI in a
total volume of 20 µl and incubated at 37 ◦C for 1 h. Electrophoretic separation of nucleic acids
was done to verify the PCR or restriction digest. Therefore, 1% agarose gels were prepared in
1x TAE buffer and peqGREEN DNA/RNA Dye (4 µl in 50 ml) was added. A DNA sample was
mixed with 6x loading dye and loaded on the agarose gel and separated at 100 V for 45 min.
GeneRuler DNA Ladder Mix (100-10000 bp) was used as a marker. For documentation, the gels
were analyzed under UV light and imaged. Afterwards, the corresponding bands were cut out
and DNA was isolated using the commercially available gelextraction kit from Quiagen according
to the manufacturer’s instructions. 100 ng of extracted DNA was than used in a ligation with
a ratio vector to insert of 1 to 3 (amounts needed were calculated using the Ligation calculator
form NEB (http://nebiocalculator.neb.com/ligation)). Ligation was performed by addition of
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4 µl of T4 ligase buffer and 1 µl of T4 ligase in a total volume of 20 µl. Incubation was done
at RT for 10 min. 1 - 2 µl of the ligation was used for transformation of competent E.coli
(see section Amplification of plasmids) followed by amplification of the plasmid and another
control digest using different enzymes. Successful cloning was verified by sequencing at GATC.
Using ClustalW (http://www.ebi.ac.uk/clustalw/) or Blastn (https://blast.ncbi.nlm.nih.gov/),
correct sequence was confirmed.
4.2.9. Recombinant protein expression of SOCS1
For recombinant protein expression of SOCS1 or SOCS1-GST, BL21 cells were transformed
with GST-SOCS1 containing a thrombin cleavage site. 100 ml LB containing Ampicillin (100
µg/ml) were inoculated with a single colony from a freshly streaked plate and incubated at 37
◦C with shaking at 250 rpm, overnight. The next morning, inoculation of 2 l LB containing
Ampicillin followed that was cultured with shaking at 37 ◦C to an OD600 of 0.5-1.0. At this
point, the culture was induced by the addition of 1 mM IPTG and incubated with shaking
at 37 ◦C for 6 h. Afterwards, the cells were harvested by centrifugation at 4000 rpm at 4 ◦C
for 20 min followed by lysis in 15 ml lysis buffer and freezing 5 ml Aliquots at -80 ◦C. After
thawing of 5 ml of this bacterial suspension, protease inhibitors and lysozyme was added to
a concentration of 2 mg/ml and the cells were incubated on ice for 30 min. After sonication
for 3 times for 5 sec (on ice), centrifugation followed at 13.000 rpm at 4 ◦C for 30 min. The
pellet was resuspended in 10 ml wash buffer containing 1% Triton X-10 and incubated at room
temperature for 5 min. After another centrifugation step at 13.000 rpm at 4 ◦C for 30 min, the
pellet was resuspended in 10 ml wash buffer without Triton and centrifuged once more. Since
it has been confirmed previously, that SOCS1 is only present in the insoluble fraction, inclusion
bodies were isolated. Therefore, extraction buffer and proteinase inhibitors were added to obtain
a final protein concentration in the solution of 1 mg/ml (as measured by nanodrop) followed
by incubation at RT for 60 min. Afterwards, the solution was diluted tenfold with extraction
buffer to obtain a final protein concentration of 0.1 mg/ml, centrifuged at 13.000 rpm at 4 ◦C
for 5 min and the supernatant was dialyzed overnight against a 100 fold volume of refolding
buffer. On the next morning dialysis followed against PBS for 10 h at 4 ◦C. The obtained
dialysate was subsequently centrifuged at 45.000 rpm at 4 ◦C for 30 min and the supernatant
was transferred into a fresh tube. If necessary, a protein concentrator was used to concentrate
the protein to obtain the concentration needed for further analysis. For removal of the GST
tag, thrombin cleavage was performed using 1 U/ml thrombin per mg protein for 16 h at 4 ◦C
in a shaker. A GST-trap column was used to get rid of cleaved GST or uncleaved GST-SOCS1
with a constant flow rate of 0.5 -1 ml per min. The column was washed with 1 ml of PBS and
the flow-through containing cleaved SOCS1 only was concentrated if necessary using a protein
concentrator. Small aliquots of the recombinant protein were snap frozen using liquid nitrogen
and stored at -80 ◦C. For analysis by Western Blot, SDS loading buffer was added to the sample.
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4.2.10. Generation of polyclonal SOCS1 antibodies
Generation of polyclonal SOCS1 antibodies was done by Charles River using the following
immunization scheme:
• day 1: 1st injection
• day 28: 2nd injection
• day 38: 1st serum sample
• day 42: 3rd injection
• day 52: 2nd serum sample
• day 56: 4th injection
• day 70: bleeding of the rabbit
For each immunization, 0.2 mg of the antigen (rec. SOCS1-GST plus complete freud adjuvant
for the 1st immunization and rec. SOCS1 plus incomplete freud adjuvant for the following
immunizations) at 1 mg/ml were injected subcutaneously. Serum samples (d38 and d52) were
tested by Western Blot resulting in detection of recombinant SOCS1. Bleeding of the rabbits on
day 70 was done by heart puncture leading to 80 ml of serum. Serum was used for affinity pu-
rification of SOCS1 antibodies using a HYDRA protein affinity column with bound recombinant
SOCS1 as an antigen resulting in 2 ml of affinity purified rabbit serum with a total antibody
yield of 0.5 mg.
4.2.11. Generation of hybridoma cell supernatant containing SOCS1 antibodies
Antigen production and quality control as well as antibody production was done by Abmart
(Shanghai). In brief, 8 Balb/c mice were immunized with 7 different peptides. Ascites was
produced and 13 ascites samples were analyzed for detection of recombinant SOCS1, murine
SOCS1 upon IFNγ stimulation or cells transfected with GFP-SOCS1. Upon decision for one
ascites successfully detecting SOCS1, fusion of a B cell to a myeloma cell and subsequent sub-
cloning of 2 - 4 rounds followed. The corresponding hybridoma cellline was both cultured for
further cultivation and monoclonal antibody production. Cell culture for further cultivation was
done in DMEM supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS), penicillin
(50 units/ml) and streptomycin (50 µg/ml) (P/S) to reach a confluence of 60% and split 2 - 3
times a week. For collection of supernatant, hybridoma cells were cultured in DMEM supple-
mented with only 1% FCS and P/S until they reach a confluence of 100% and the supernatant
was collected 24 h thereafter. Hybridoma cell supernatant was used in Western Blot in a 1:20
dilution.
4.2.12. Quantitative RT-PCR
Total RNA from 2.5x105 cells was isolated using the peqGOLD RNA Kit (peqlab) according to
the manufacturer’s protocol. RNA was eluted with 40 µl DNase/RNase-free water. Quality and
quantity of RNA was measured by 230/260 nm and 260/280 nm absorbance ratios, acquired
by the nanodrop. Afterwards, reverse transcription of 200 ng RNA into cDNA was done using
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and the following
PCR conditions: 25 ◦C for 10 min, 37 ◦C for 120 min, 85 ◦C for 5 min. 5 µl cDNA (diluted
1:10) was used as template in a quantitative real time PCR using SYBR Green FAST Mix
(Applied Biosystems) with a total reaction volume of 15 µl. PCR conditions were as follows:
initial 95◦C for 20 sec and 40 cycles of 95 ◦C for 3 sec and 60 ◦C for 30 sec. Amplification
and measurement was done in a StepOne Plus RT-PCR cycler (Applied Biosystems) in a 96-
well format. Specificity of qPCR was controlled by non-template as well as no-RT samples and
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analysis of melting curves. Each cDNA was measured in duplicates. Baseline and threshold
values were manually set to the same value per gene. Detected Ct values of the endogenously
expressed reference gene (ACTB) were subtracted from the determined Ct values and relative
expression was calculated as 2-∆CT for each target gene. qPCR for Socs1wt was performed with
TaqMan Fast Universal PCR Master Mix (Applied Biosystems) in combination with a forward
primer (P1) binding in the SH2 domain and a reverse primer (P2) binding in the SOCS Box and
a FAM-labelled probe binding in the NLS of Socs1. For the detection of Socs1∆NLS, SYBR
green dye in combination with P1 and a reverse primer (P3) within the modified NLS region
were used. For detection of total Socs1 (both Socs1 and Socs1∆NLS), the primers P1 and P2
were used. This qPCR strategy (Fig. 5) allows for specific detection of Socs1, Socs1∆NLS or
total Socs1. The amplification efficiencies for both Socs1wt (1.68) and Socs1∆NLS (1.88) were
adjusted.
Figure 5.: Structure of the bacterial artificial chromosome and qPCR scheme to detect Socs1WT,
Socs1∆NLS and total Socs1 mRNA.
(A) Schematic drawing of the bacterial artificial chromosome (BAC) consisting of a mutated SOCS1 locus
containing Socs1∆NLS, eGFP and firefly Luciferase. (B) qPCR strategy to specifically detect Socs1WT
(wildtype) using the primers P1 and P2 together with a labelled probe (?) binding within the NLS,
Socs1∆NLS using P1 and P3 (reverse primer binding in the exchanged NLS) or total Socs1 using P1 and
P2.
4.2.13. Whole-Genome Expression analysis
Total RNA from 2.5x105 BMMs was isolated as described above. The quality of total RNA was
checked by gel analysis using the total RNA Nano chip assay on an Agilent 2100 Bioanalyzer.
The laboratory work was done in the Genomics and Proteomics Core Facility at the German
Cancer Research Center, Heidelberg, Germany (DKFZ). Biotin-labeled cRNA samples for hy-
bridization on Illumina Mouse Sentrix-8 BeadChip arrays were prepared according to Illumina’s
recommended sample labeling procedure based on the modified Eberwine protocol [59]. In brief,
300 ng total RNA was used for cDNA synthesis, followed by an amplification/labeling step ac-
cording to the Illumina Total Prep RNA Amplification Kit. The cRNA was column purified
according to TotalPrep RNA Amplification Kit, and eluted in 60 µl of water and quality con-
trolled. Hybridization was performed at 58 ◦C, in GEX-HCB buffer at a concentration of 100
ng cRNA/µl, unsealed in a wet chamber for 20 h. Spike-in controls for low, medium and highly
abundant RNAs were added, as well as mismatch control and biotinylation control oligonu-
cleotides. Microarrays were washed once in High Temp Wash buffer at 55 ◦C and then twice in
E1BC buffer at room temperature for 5 minutes. After blocking for 5 min in 4 ml of 1% (wt/vol)
blocker casein in phosphate buffered saline Hammarsten grade, array signals were developed by
a 10 min incubation in 2 ml of 1 µg/ml Cy3-streptavidin solution and 1% blocking solution.
After a final wash in E1BC, the arrays were dried and scanned. Microarray scanning was done
using an iScan array scanner. Data extraction was done for all beads individually, and outliers
were removed when ¿ 2.5 MAD (median absolute deviation). All remaining data points were
used for the calculation of the mean average signal for a given probe, and standard deviation for
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each probe was calculated. Data were processed using R, including log2 transformation of the
data, significance (p≤ 0.05) and fold change (log2 ≤-1 or ≥1) filtered. Data was normalized to
remove systematic variation and background subtraction. Pathway annotation was performed
using the PANTHER (Protein Analysis through Evolutionary Relationships) classification sys-
tem and transcription factor binding sites (TFBS) among the differentially regulated genes were
analyzed using the over-representation analysis tool oPOSSUM. Microarray data is available
online at ArrayExpress (accession #E-MTAB-4938).
4.2.14. Western Blotting
1x106 BMMs or RAW264.7 cells were stimulated as indicated, subsequently washed with PBS
and lysed in Laemmli buffer. After incubation for 10 min at 98 ◦C, equal amounts of lysates
were fractionated by 10% polyacrylamide gel (SDS-PAGE) and electrotransferred to Nitrocel-
lulose membranes by a semidry blotting procedure (2.5 mA/cm2 for 1 h 15 min). Blocking of
unspecific binding was performed using 5% BSA solution in 1x TBST for at least 1 h. Mem-
branes were stained with the corresponding primary antibodies ( see table 4.1.9) or hybridoma
cell supernatant for SOCS1 detection overnight at 4 ◦C. After three 10 min washing steps in
1x TBST at room temperature, blots were incubated with secondary antibodies for 1 h at RT
(HRP-linked anti-mouse or anti-rabbit), followed by additional three 10 min washing steps in
1x TBST at room temperature. Proteins were detected using an enhanced chemiluminescence
system. Gels were imaged digitally, and contrast adjustments were applied to all parts of a
figure. Where indicated, membranes were stripped and reprobed. Densitometry was performed
using ImageJ software (National Institutes of Health).
4.2.15. Flow cytometry
For detection of GFP present in MGL positive cells, 2.5x105 BMMs were harvested in FACS
buffer by centrifugation at 1300 rpm at 4 ◦C and analyzed by FACSCanto flowcytometer gating
on GFP positive cells. For FACS staining of surface proteins, tissue was homogenized as previ-
ously described and homogenate (approx. 5x105 cells) was transferred to a FACS tube. After
washing the cells with 1 ml of PBS followed by centrifugation at 1300 rpm at 4 ◦C, cells were
stained with the corresponding antibodies in 50 µl FACS buffer for 30 min at 4 ◦C. After an
additional washing step, cells were resuspended in 200 - 500 µl of FACS buffer and analyzed
by FACSCanto flowcytometer. For analysing the purity of the MACS sorted CD11c+ or CD4+
cells, PE Anti-Mouse CD11c (1:50) or FITC Anti-Mouse CD4 (1:100) were used. For the CD45.1
and CD45.2 staining upon bone marrow transplantation, 50 µl of blood was collected from the
tail vein using a 29G syringe containing Heparin (10,000 U/ml), washed twice with ice cold PBS
and resuspended in red blood cell lysis buffer for 10 minutes on ice. After washing with FACS
buffer, the cells were labelled with APC-CD45.2 (1:200) and FITC-CD45.1 (1:200) for 40 min
on ice, washed with FACS buffer and analyzed by FACSCanto flowcytometer.
For detection of intracellular pSTAT1 by flow cytometry, 1x105 cells were stimulated for the
indicated time with IFNγ (50 ng/ml), washed with PBS and transferred into a FACS tube using
a cell scraper. After fixation with 4% PFA for 30 min at RT, cells were permeabilized with
90% ice-cold MeOH for 2 h at -20 ◦C. Cells were washed with FACS buffer and stained with
anti-pSTAT1 in 50 µl FACS buffer for 90 min RT. Stained cells were washed and resuspended
in 200 µl FACS buffer prior to measuring at the FACS Canto.
4.2.16. Immunofluorescence microscopy
NIH cells were grown on µ-slides (8- well, ibidi) and transfected with 0.5 µg GFP-Socs1 or
GFP-Socs1∆NLS using PeqFect. Where indicated, cells were stained with Hoechst (1 µg/ml)
for 2 min or with CellMaskTM Plasma Membrane Stain (1:1000) for 10 min at room temper-
ature. Coverslips were mounted and analyzed by microscopy using a Leica TCS SP5 confocal
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microscope equipped with a 488- and 561-nm laser, spectrophotometer prism, tunable detectors
and a HCX PL APO 63x/1.4 oil objective. All channels were recorded in a sequential order
to avoid emission crosstalk. A z-stack was recorded and presented as an overlay using ImageJ
(National Institutes of Health).
4.2.17. Luciferase Activity Assay
2.5x105 BMMs were lysed in Luciferase lysis buffer. After injection of Luciferase assay buffer
to each well, activities in the lysates were measured using a luminometer (LUMIstar OPTIMA
system). Luminescent units are presented per µg as determined by colorimetric Bradford assay
using the Rotiquant reagent.
4.2.18. Measuring cytokine secretion
Supernatants of the indicated cells were harvested and analyzed for cytokines by commercially
available ELISA kits for IL-6, TNFα and IL-12p40 from BD and IL-33 form R&D. The super-
natant of 2.5x105 cells (250 µl) was diluted 1:50, the supernatant of 1x105 CD11c+ cells in 200 µl
was diluted 1:10 and BAL supernatant was used undiluted prior measuring murine IL-6, TNFα
or IL12p40. In brief, 96-well high binding ELISA plates were incubated with a coating antibody
overnight at 4 ◦C. After washing of the plates for 3 times, plates were blocked using 2% FCS in
PBS for 2 h at RT. After 3 additional washing steps, the sample or standard was added to the
plate followed by incubation for 2 h at RT. After 5 washing steps, the detection antibody was
added together with the HRP-conjugate for 1 1/2 h at RT (for the IL-33 ELISA, addition of the
detection antibody was done first for 1 h, followed by 3 washing steps and subsequent addition
of the HRP conjugate for 20 min). After washing the plate 7 times, the substrate was added by
mixing solution A with B and addition to each well until the standard turned blue. The reaction
was stopped using 1 M H2SO4. Cytokines were detected by measuring the absorbance at 490
nm with a 650 nm reference in a photometer (Sunrise reader). Cytokine concentrations were
calculated according to a standard dilution of the respective recombinant cytokines (standard)
using Magellan V 5.0 software.
Upon OVA sensitization and challenge, levels of IL 4, IL-5, and IL-13 in serum were measured
using an enhanced sensitivity cytometric bead array (CBA, Flex Set Kits), according to the
manufacturer’s guidelines.
For measurement of IgE levels in serum, 96-well high binding ELISA plates were coated with
monoclonal anti-IgE antibodies overnight. Serum samples were diluted in 1% (w/v) BSA in
PBS/ 0.05% (v/v) Tween 20 and incubated overnight at 4 ◦C. Afterwards plates were incubated
with anti-IgE conjugated with HRP for 3 h at room temperature. For the colorimetric detection
TMB was used as a substrate. Absorbance was measured at 450 nm with a 650 nm reference in
ELISA reader and IgE concentrations calculated according to standard curve.
4.2.19. Evaluation of NFκB p65 activity
NFκB activity was measured in 1x106 cells of a lung homogenate by the TransAM NFκB p65 pro-
tein assay (Active Motif), an ELISA-based method designed to specifically detect and quantify
NFκB p65 subunit activation with high sensitivity and reproducibility. As a positive control
Raji nuclear extract was used that was provided with the kit. Wildtype or mutant oligonu-
cleotides were used as an internal specificity control. The assay was performed according to the
manufacturer’s protocol. In brief, 20 µl sample (1x106 cells from lung homogenate prepared
as described in section 4.2.5 or one well of murine primary epithelial cells were resuspended
in 50 µl lysis buffer) were used per well in which multiple copies of a specific double-stranded
oligonucleotide have been immobilized. Either 30 µl binding buffer or 28 µl binding buffer and 2
µl wildtype or mutant oligo were added per well and incubated for 1h RT with gentle agitation
(100 rpm). After 3 washing steps, 100 µl of the diluted antibody (p65, 1:1000) was added to
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each well and incubated for 1 h RT without agitation. The plate was washed 3 times and 100 µl
of diluted HRP conjugated antibody (1:1000) was added for 1 h at RT without agitation. After
washing the plate 4 times, 100 µl developing solution was added until the optimal blue colour
density developed and stopped using 100 µl stopping solution. The absorbance was read at 450
nm with a 650 nm reference in ELISA reader.
4.2.20. Macrophage phagocytosis assay
4x105 BMMs were incubated in 37 ◦C warm (or for the negative control in 4 ◦C cold) DMEM plus
FCS and P/S for 30 min. 10 µl of a 1:10 dilution of Latex beads (amine-modified polystyrene,
fluorescent yellow-green) were added for 1 h at 37 ◦C (or for the negative control on ice). After
incubation with the beads, cells were washed twice with FACS buffer, resuspended in 200 µl
FACS buffer and measured at the FACSCanto.
4.2.21. T cell proliferation, cell cycle analysis and differentiation
CD4+ T cells were isolated from a single cell suspension as described above (section Preparation
of single-cell suspensions from tissue). For proliferation analysis, CD4+ T cells were stained
with CFSE (5 mM) in 110 µl followed by vortexing of the cells for 5 sec. After 5 min incubation
in the dark at RT, 10 ml RPMI was added and the cells were washed twice. 1x105 cells were
seeded per well in a 96 well plate (round bottom) with RPMI plus β-Mercaptoethanol (50 µM)
and 4 µl of Dynabeads. CFSE staining was analysed on day 3.
For cell cycle analysis, 1x105 CD4+ T cells were fixed in 70% ethanol for 2 h to overnight. Cells
were centrifuged at 13.000 rpm for 5 min at 4 ◦C and washed twice with PBS. Washed cells were
stained with propidium iodide (50 µg/ml) with the addition of RNAse A (100 µg/ml) in 0.5 ml
PBS. After incubation at 37◦C for 30 min, cells were analysed by FACSCanto flowcytometer
identifying PI- positive cells.
For differentiation of T cells, 1 x 105 cells per well were plated in 96-well round-bottom plate
in 100 µl RPMI plus β-Mercaptoethanol (50 µM) and stimulated with 4 µl anti-CD3 and anti-
CD28-coated beads plus 20 ng/ml IL-2, and either medium only or a Th2 differentiation solution
consisting of 100 ng/ml IL-4, 10µg/ml anti-IFNγ and 10 µg/ml anti-IL-12. Afterwards, cells
were incubated for 3 days at 37 ◦C. On day 4, T cells were restimulated with a cell stimulation
cocktail including PMA and ionomycin for 3 h and RNA was extracted.
4.2.22. micro-CT
Micro computed tomography or micro-CT is x-ray imaging in 3D on a small scale with massively
increased resolution. 6 Socs1-/-MGLtg and 6 Socs1+/-MGLtg mice were imaged. Mice were
sacrificed using xylazine and ketamine and the lungs were infiltrated with 0.7 ml air via a tracheal
cannula and closed using a silicon strand. After 4 h (rigor mortis, no further movement during
the scan), the thorax of the mice was imaged with the SKYSCAN micro-CT at a resolution of 18
µm with 50 kV and 498 mA for 515 projections at a step angle of 0.7◦ for a total orbit of 360◦.
Total imaging time was approximately 21 min with an averaging of 5. No contrast agents were
used. Lungs were removed, fixed using formalin and paraffin embedded for correlative histology.
For scanning of paraffin embedded lungs, 9 µm with 50 kV and 498 mA and a high averaging
(10 - 20) was used. CT scans were performed at AG Mall and Scans were analyzed by Dr. Willi
Wagner (radiologist) in a blinded manner.
4.2.23. Bronchoalveolar lavage
Lungs were rinsed with 1 ml fresh, ice-cold PBS containing protease inhibitor via a tracheal
cannula, and obtained cells were counted using a Neubauer chamber. Cytospins were prepared
for each sample by centrifugation of 50 µl BAL fluid plus 150 µl of sterile PBS and subsequently
stained with May Gru¨nwald/ Giemsa. Cells were microscopically differentiated and classified
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as either macrophages, neutrophils, eosinophils or lymphocytes, using standard morphologic
criteria [200].
4.2.24. Histopathological Analysis
Organs were either fixed via a tracheal cannula under constant pressure of 20 cm H20 or left
uninflated using 4% (w/v) phosphate buffered paraformaldehyde overnight. Tissues were em-
bedded in paraffin. For analysis of lung inflammation, 2 µm sections were stained with periodic
acid–Schiff (PAS) or with hematoxylin and eosin (H&E), respectively.
H&E staining was performed in an automatic manner at the Institute of Pathology. In brief,
sections were rinsed in distilled water and stained with the haematoxylin solution for 4 min at
RT. After rinsing the sections with tap water, differentiation followed using 0.3% acid alcohol for
1-2 sec. and another washing step in tap water. Afterwards, sections were rinsed using Scott’s
tap water substitute, rinsed with tap water and stained with eosin for 2 min at RT. Dehydration
was done using xylene followed by clearing and mounting of the sections.
PAS staining was performed of the lung sections by incubation in xylene for 20 min followed
by rinsing with Ethanol of decreasing concentrations (100%, 96% and 70%) for 5 min each.
After rinsing with ddH2O, staining with Alcian blue followed for 30 min at RT. Afterwards, the
sections were rinsed with tap water for 2 min and subsequently incubated in periodic acid (0.5%
aqueous solution of periodic acid in ddH2O) for 5 min. After 3 - 4 changes in ddH2O, incubation
in Schiff’s reagent followed for 15 min. Sections were rinsed in sulfurous solution (1% HCl and
10% Sodium Metabisulfite) for 1 min and incubated in tap water for 10 min with 3 - 4 changes.
Dehydration was done using xylene followed by mounting of the sections.
4.2.25. Immunohistochemistry
For immunohistochemistry, lungs were fixed overnight in 4% (v/v) formalin and embedded in
paraffin. 2 µm lung sections were cut and stained for SOCS1 using the DAB staining method.
After deparaffination, demasking of the antigens followed using either citrate buffer or EDTA
buffer for 15–45 minutes in a steamer. Incubation with peroxidase-blocking solution and pro-
tein blocking solution was followed by incubation with the anti-SOCS1 antibody at varying
concentrations (1:10–1:2000) at 4 ◦C overnight. The commercially available antibodies from
Cell Signaling, Abcam and Santa Cruz were tested as well as hybridoma cell supernatant and
a newly generated antibody against recombinant SOCS1. On the next day, incubation with
serum corresponding to the species of the secondary antibody followed. Incubation with the
secondary antibody (goat anti-rabbit antibody or goat anti-mouse antibody) was performed for
30 min. After washing, sections were incubated with the chromogen (liquid diaminobenzidine
and peroxide buffer) until a reaction was visible. Slides were counterstained with hematoxylin
to provide nuclear and morphologic detail and mounted. Lung sections of Socs1-/- mice were
used as a negative control.
4.2.26. Measuring transepithelial resistance in primary trachea epithelial cells
Epithelial cells build up tight barriers between different compartments and are characterized by
the formation of tight junctions. Tight junctions can be measured by detecting the transep-
ithelial resistance. This was achieved by using a Ohmmeter Millicell ERS. Electrodes were
disinfected with 70% ethanol and equilibrated for 15 - 30 min in the corresponding medium in
the transwell. To measure the epithelial resistance the shorter end section was brought into the
upper compartment, whereas the longer end section was extended into the lower compartment.
A well without cells was measured as a blank. Resistance was measured twice for each transwell.
The epithelial resistance was calculated by using the following formula: Rprobe-Rblank=Rcell layer;
Rcell layer / Areatranswell (0.33cm
2) = Resistance / cm2 (Ω / cm2)
Another method to measure transepithelial resistance is via addition of FITC-Dextran. There-
fore, 1 mg/ml FITC-Dextran (4 kDa) was added to the upper chamber of the transwell and cells
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were incubated at 37 ◦C for 2 h. Afterwards, fluorescence of FITC-Dextran was detected both
in the inner and outer well by measuring the absorbance at 490 nm with a 520 nm reference in a
photometer (Sunrise reader). A positive control (no cells, maximal diffusion of FITC-Dextran)
and a negative control (no FITC-Dextran added) were included.
In addition, an albumin ELISA was performed with supernatant from BAL samples. Under
physiological conditions, no albumin is found in lavages of lungs. In case of a leaky barrier,
albumin from the blood can reach alveolar spaces and will be found in BAL samples. Albumin
competitive ELISA was performed according to the manufacturer’s guidelines. In brief, 25 µl
BAL supernatant (undiluted) or albumin standard was added per well and immediately 25 µl of
1X biotinylated albumin was added. Incubation followed for 1 h at RT. After 5 washing steps,
50 µl of 1x SP conjugate was added to each well and incubated for 30 min at RT. After 5 wash-
ing steps, 50 µl of chromogen substrate was added per well and incubated till the optimal blue
colour density developed. The reaction was stopped by the addition of 50 µl of stop solution
to each well, resulting in a yellow colour. The absorbance was read at 450 nm with a 650 nm
reference in ELISA reader and albumin concentrations calculated according to standard curve.
4.2.27. OVA sensitization and challenge
The OVA sensitization and challenge was performed at the Research Center Borstel by Dr. Lars
Lunding and Dr. Michael Wegmann. Mice were sensitized to ovalbumin (OVA) by three i.p.
injections of 10 µg OVA (OVA grade VI) adsorbed to 150 µg aluminum hydroxide on days 1, 14,
and 21. Mice were exposed three times to an OVA (OVA grade V) aerosol (1% (w/v) in PBS) on
days 26, 27, and 28 to induce acute allergic airway inflammation [162]. Sham sensitization and
challenges were carried out using sterile PBS. On day 29, mice were anesthetized with ketamine
and xylazine and sacrificed by cervical dislocation. Eight animals per group were used, if not
stated otherwise. Experiments were done at the Research Center Borstel under approval of
the animal ethics committee from the Department of State, Kiel, Germany (permit number:
V244-7224.121.3 (108-9/14)).
4.2.28. IL-13 intratracheal (i.t.) instillation
Mice were anesthetized with isofluorane for 30 sec. and allowed to hang vertically with their
mouths open, supported by a taut string placed under their canine teeth. Their tongues were
gently withdrawn with a blunt forceps to keep them from swallowing, and 20 µl of PBS with or
without 5 µg IL-13 was pipetted onto the base of the tongue. When the mice had aspirated the
pipetted solution, they were put on their site until they woke up. This intratracheal instillation
was performed on days 1,2 and 3 in KEB (IBF, Heidelberg). 5 mice per group were analyzed 24
h after the last treatment. Experiments were recorded properly under approval of the animal
ethics committee in Karlsruhe (permit number: 35-9185.81/G-35/16).
4.2.29. Bone-marrow transplantation
For bone marrow isolation of donor mice, female Socs1-/-MGLtg (or CD45.1) mice were killed by
CO2 inhalation and the hind limbs removed. Bone marrow was flushed with medium from the
medullary cavities of tibiae and femurs using a 27G needle. 1x107 marrow cells were resuspended
in 100 µl of PBS and injected i.v. in lethally irradiated (2x 400 rad γ radiation with a 4
h break) CD45.1 (or Socs1-/-MGLtg and Socs1+/+) mice with a 29G needle. Radiation was
performed in the DKFZ under the supervision of Kerstin Dell. After radiation and bone marrow
transplantation, mice were kept in ”Maushotel” (IBF, Heidelberg) for 7 weeks until they were
analyzed. Mice were weighted every day for the first two weeks and afterwards every 2 - 3 days
and their health was evaluated. Mice received antibiotic treatment (2 ml CotrimK suspension
in 250 ml drinking water corresponding to 125 µg Trimethoprim and 626 µg Sulfamethoxazol
per animal per 24 h) for the first three weeks upon irradiation. At 10 days post transplant,
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replacement of blood cells was examined by FACS staining of CD45.1 and CD45.2 using the
FACS Canto (see section flow cytometry). As recipients, 10 Socs1-/-MGLtg or CD45.1 mice as
well as 6 Socs1+/+ mice were used. Experiments were recorded properly under approval of the
animal ethics committee in Karlsruhe (permit number: 35-9185.81/G-35/16).
4.2.30. Statistics
All experiments were repeated three times unless stated otherwise. Data are shown as mean
±SD. Statistical significance of comparison between two groups was determined by two-tailed
unpaired Student’s t test (for data sets following Gaussian distribution), Wilcoxon matched pairs
test (for data sets not following Gaussian distribution) or two-way ANOVA including Bonferroni
post-test (for multiple comparisons). All statistical analyses were done using GraphPad Prism
(GraphPad 6.05, San Diego, USA) software. Differences were considered significant at p ≤0.05
(*), p ≤0.01 (**) and p ≤0.001 (***).
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5.1. SOCS1∆NLS is localized in the cytoplasm
It has been shown that SOCS1 is able to translocate into the cell nucleus due to a functional
NLS localized between the SH2 domain and the SOCS-box (amino acids 159–173) [12, 143].
Confirming these results with murine Socs1 constructs, NIH3T3 cells transiently transfected
with murine eGFP-Socs1 showed nuclear localization of the GFP-tagged protein. In contrast,
eGFP-Socs1∆NLS, in which the NLS has been replaced by the murine Socs3 sequence, was
localized more in the cytoplasm (Fig. 6A) as already described for human eGFP-SOCS1∆NLS
[12]. Cells transfected with Socs1 were also stimulated with IFNγ. Upon stimulation, enhanced
fluorescence in the cytoplasm could be observed, suggesting that SOCS1 is partly translocating
out of the nucleus to inhibit signaling in the cytoplasm (Fig. 6B). Whereas untreated cells showed
a ratio of cytoplasmic versus total fluorescence of 0.2 ± 0.07, indicating higher fluorescence in the
cell nucleus, already 1 h upon IFNγ stimulation, cells showed a ratio of 0.5 ± 0.09 suggesting
equal distribution of the fluorescently labelled SOCS1. To confirm fast shuttling of SOCS1
across the nuclear membrane, photoactivatable (PAGFP-tagged) Socs1 plasmids were used.
NIH3T3 cells were transfected with PAGFP-Socs1 and a small region of interest (ROI) outside
the nucleus was activated using UV light. Fast shuttling of SOCS1 into the nucleus already
200 ms after activation was observed (Fig. 6C). In contrast, activation of SOCS1∆NLS in the
cytoplasm did not result in fluorescence in the cell nucleus, but in the activated ROI in the
cytoplasm. Of note, unlike SOCS1 that was highly mobile in the cell nucleus, SOCS1∆NLS
remained at the activated spot in the cytoplasm for the time monitored (1 min). This indicates
that SOCS1∆NLS was localized in the cytoplasm, less mobile and did not shuttle into the cell
nucleus.
To verify that SOCS1∆NLS is still functional in the cytoplasm, inhibition of IFNγ signaling at
the receptor level was analyzed by Western Blotting. Therefore, the murine macrophage cell line
Raw264.7 was transiently transfected with eGFP, eGFP-Socs1 or eGFP-Socs1∆NLS. Tyrosine
phosphorylation of STAT1 was examined upon treatment with IFNγ 1-6 h post-stimulation.
Already 1 h after IFNγ treatment, eGFP-Socs1 or eGFP-Socs1∆NLS transfected cells showed
lower levels of phosphorylated STAT1 (55 ± 8% or 53 ± 7% relative pY-STAT1 levels as com-
pared to eGFP transfected cells 1 h after IFNγ stimulation) (Fig. 7). After 6 h of stimulation,
the signal decreased to 34 ± 10% or 32 ± 6% for cells transfected with eGFP-Socs1 or eGFP-
Socs1∆NLS, respectively. Cells expressing eGFP showed higher levels of pSTAT1 (97 ± 5%) at
6 h after IFNγ stimulation as compared to 1 h. Importantly, no differences in phosphorylated
STAT1 levels between eGFP-Socs1 and eGFP-Socs1∆NLS transfected cells were observed. Al-
though SOCS1∆NLS seemed to be less mobile, data suggests that both SOCS1 and SOCS1∆NLS
were effectively inhibiting IFNγ induced STAT1 tyrosine phosphorylation.
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Figure 6.: Cytoplasmic expression of SOCS1∆NLS.
(A) Living NIH3T3 cells were transfected with the indicated eGFP-tagged plasmid and visualized by con-
focal microscopy. Nuclei were counterstained with Hoechst and membranes were stained with CellMaskTM
dye. Scale bar 5 µm. (B) NIH3T3 cells were transfected with eGFP-Socs1 and stimulated with IFNγ
(50 ng/ml) as indicated. Scale bar 25 µm. A z-stack was recorded and the fluorescence in the cytoplasm
(black) versus the fluorescence in the nucleus (grey) was measured using ImageJ (n = 3, each time 20-50
cells, mean +SD, Two-way ANOVA including Bonferroni post test). (C) Living NIH3T3 cells were trans-
fected as described above using photoactivatable plasmids (PAGFP). Photoactivation was done using
100% UV laser intensity in a small ROI in the cytoplasm in close proximity to the cell nucleus (for PA-
GFP-Socs1 the purple circle and for PA-GFP-Socs1∆NLS the orange circle). Using confocal microscopy,
images were taken directly before photoactivation (left) and after 10 sec of photoactivation (right) and
localization of SOCS1 was analyzed.
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Figure 7.: Cytoplasmic SOCS1∆NLS is able to inhibit IFNγ signaling.
(A) Western Blot analysis of tyrosine phosphorylated STAT1. Raw264.7 cells were transfected with
eGFP, eGFP-Socs1 or eGFP-Socs1∆NLS and stimulated with IFNγ (50 ng/ml) as indicated. Protein
extracts were stained for pY-STAT1 (Tyr701), SOCS1 (using hybridoma cell supernatant as described
in Section 5.2), STAT1 and β-Actin. Quantification using ImageJ is shown in (B) (n = 3, mean +SD,
Two-way ANOVA including Bonferroni post test).
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5.2. Generation of antibodies for SOCS1 detection
Since there is no commercially available antibody specifically detecting endogenous murine
SOCS1, a new antibody has to be generated for this purpose. First, a monoclonal antibody
secreted by hybridoma cells was tested. Antigen production and quality control as well as anti-
body production were done by the company Abmart (Shanghai). Mice were immunized with the
peptide (RRITRASALLDA) and ascites was produced. Upon decision for one ascites success-
fully detecting SOCS1, fusion of B cells to myeloma cells and subsequent subcloning followed.
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Figure 8.: Generation of SOCS1 spe-
cific antibodies using hybridoma cells.
(A) Beas2B cells or NIH3T3 cells were
transfected using eGFP tagged human
SOCS1 (HSOCS1) or murine Socs1
(mSocs1), respectively. Hybridoma cell
supernatant (1:20) was used to de-
tect GFP-SOCS1 (50 kDa) in both cell
lysates. Arrow indicates SOCS1-GFP.
(B) Hybridoma cell supernatant (1:20)
was used to detect SOCS1 (21 kDa)
or SOCS1∆NLS in lysates of BMMs
stimulated with IFNγ (50 ng/ml) for
6 h. Arrows indicates either SOCS1 or
SOCS1∆NLS. (C) Unspecific staining
of lung sections by hybridoma cell su-
pernatant (1:10). Socs1-/- and isotype
controls were included as negative con-
trols. 200x magnification
The corresponding hybridoma cell supernatant was used in Western Blot in a 1:20 dilution for
detection of SOCS1 in cells transfected with either human GFP-SOCS1 or murine GFP-Socs1
(Fig. 8A) and in BMMs upon IFNγ stimulation (Fig. 8B), resulting in a band at a molecular
weight of 50 kDa for GFP tagged proteins and below 25 kDa for untagged SOCS1 (molecular
weight of 21 kDa). Although there were unspecific bands as well, one specific band for SOCS1
could be detected in mice containing only wildtype SOCS1 (Socs1+/-) at 20 kDa and one band
for SOCS1∆NLS in mice only expressing SOCS1∆NLS (Socs1-/-MGLtg) at 23 kDa. Those mice
were generated using a bacterial artificial chromosome (BAC) containing a mutated Socs1 locus
with non-nuclear Socs1∆NLS, GFP and firefly Luciferase (termed MGL) and crossed onto an
otherwise SOCS1 deficient background. This mouse model will be discussed in more detail in
section 5.3.1. The difference in the molecular weight might be due to the remaining 21 amino
acids on the C-term of Socs1∆NLS upon cleavage of the 2A sequence between Socs1∆NLS
and eGFP (see Fig. 5A). Although the hybridoma cell supernatant was specifically detecting
SOCS1 by Western Blot, detection of SOCS1 on lung sections using immunohistochemistry was
not possible due to unspecific staining of the negative control (Socs1-/- mice) (Fig. 8C). Despite
using various concentrations from 1:10 to 1:2000 and different buffers, unspecific staining of lung
sections from Socs1-/- mice was observed, arguing against the use of hybridoma cell supernatant
for immunohistochemistry.
Therefore, a polyclonal antibody was produced against recombinant SOCS1. Socs1 was cloned
into the vector pGex containing a GST tag and a thrombin cleavage site. Recombinant protein
expression was carried out in BL21 codon optimized E.coli. Recombinant Socs1-GST was ex-
pressed in inclusion bodies, protein purification of inclusion bodies was performed followed by
refolding during dialysis. Using thrombin, the GST tag was cleaved-off, resulting in recombi-
nant SOCS1 that was analyzed by Western Blot using hybridoma cell supernatant (Fig. 9A).
Immunization of rabbits was performed at Charles River by injecting GST-SOCS1 for primary
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immunization and SOCS1 (untagged) for the following 3 booster immunizations. Serum samples
were tested and antibodies were purified using recombinant SOCS1 as an antigen. The resulting
antibodies were tested for the detection of SOCS1 in cells transfected with murine GFP-Socs1
resulting in high background and unspecific bands. There was one band at a molecular weight
of 50 kDa increased in lysates of cells expressing eGFP-SOCS1 that could correspond to SOCS1
(Fig. 9B). However, as observed previously for hybridoma cell supernatant, detection of SOCS1
on lung sections by the new polyclonal antibody using immunohistochemistry was not possible
due to unspecific staining of lung sections from Socs1-/- mice (Fig. 9C). In summary, a mon-
oclonal antibody (secreted by hybridoma cells) was established detecting SOCS1 by Western
Blot, however, no antibody was found specifically detecting SOCS1 by immunohistochemistry.
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Figure 9.: Generation of antibodies
against recombinant SOCS1.
(A) Protein purification of recombi-
nant murine SOCS1. Lysates of recom-
binantly expressed murine SOCS1 (ar-
row, 21 kDa) was analyzed by West-
ern Blot using hybridoma cell super-
natant (1:20). (B) Anti-Socs1 antibody
was obtained from Charles River by
immunization of rabbits with recom-
binant murine SOCS1. This antibody
was used to detect SOCS1 in lysates of
NIH3T3 cells transfected with eGFP-
Socs1 (arrow, 50 kDa) using 1:500
dilution of the antibody. (C) Un-
specific staining of lung sections by
the anti-Socs1 antibody (1:10) from
Charles River. Socs1-/- and isotype
controls were included as negative con-
trols. 200x magnification
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5.3. Generation of mice lacking nuclear Socs1
5.3.1. Characterization of Socs1+/+MGLtg founder mice
To analyze the function of Socs1 in the cell nucleus in vivo, a transgenic mouse model was
established using a bacterial artificial chromosome (BAC). This BAC contains the sequence of
chromosome 16 between 10.78 and 10.8 Mb including a mutated Socs1 locus with non-nuclear
Socs1∆NLS, GFP and firefly Luciferase, termed MGL. After transcription, co-translational
cleavage occurs due to 2A peptide sequences between the protein coding regions. In addition to
the coding region for SOCS1, protein-coding sequences for proteins involved in spermatogenesis
(PRM1, PRM2, PRM3 and TNP2) as well as a sequence for a predicted transcript Gm1034
are contained. PRM proteins are protamines that substitute for histones in the chromatin of
sperms during spermatogenesis. TNP2 is a transition protein associated with the conversion of
nucleosomal chromatin to the compact, non-nucleosomal form during spermatogenesis. Of note,
no gender biases were detectable in MGL transgenic mice and male Socs1+/-MGLtg mice were
breeding as efficiently as Socs1+/- mice, allowing the conclusion that other genes contained in
the BAC did not influence analysis shown thereafter. 12 MGL transgenic mice were generated
by pronucleus injection and three of them (founders #53, #45 and #29) were characterized
(Fig. 10). As a BAC integrates randomly into the genome, stable expression and regulation
of the mutated Socs1 locus was analyzed in different founder lines. Therefore, offsprings of
the founders #53, #45 and #29 were analyzed according to the expression of Socs1WT and
Socs1∆NLS in BMMs after stimulation with IFNγ for 24 h. qPCR was specifically designed to
distinguish between mRNA expression of Socs1WT and Socs1∆NLS (see qPCR scheme in Fig.
5B). Indeed, mRNA expression and inducibility of Socs1WT and Socs1∆NLS were comparable.
After stimulation with IFNγ, both Socs1WT and Socs1∆NLS were induced (Fig. 10A) with
an relative expression after IFNγ stimulation of 0.02 ± 0.005 of both Socs1WT or Socs1∆NLS
for founder #53, 0.06 ± 0.004 of Socs1WT or 0.03 ± 0.003 of Socs1∆NLS for founder #45 and
0.03 ± 0.005 of Socs1WT or 0.06 ± 0.004 of Socs1∆NLS for founder #29, respectively. Due to
reporter-functions of the mutated Socs1 locus, a luciferase assay could be performed. Therefore,
BMMs were treated as above and luciferase activity was measured. BMMs treated with IFNγ for
24 h showed an increased activity at 4.3 ± 1.1x106, 3.4 ± 1.2x106 and 2.8 ± 1.3x106 luminescent
units for the founders #53, #45 and #29, respectively (Fig. 10B). In addition, GFP positive
cells were analyzed after stimulation with IFNγ by flow cytometry. There was a similar increase
in the percentage of GFP positive cells after stimulation with IFNγ for founder #53 (to 26 ±
9%), founder #45 (to 25 ± 8%) and founder #29 (to 21 ± 9%) (Fig. 10C). Taken together, all
three founders showed similar expression levels of the mutated Socs1 locus, suggesting a stable
regulation and integration and of the BAC into the genome. No indications for a founder specific
effect were identified and therefore following experiments were performed using founder #53 if
not stated otherwise.
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Figure 10.: Characterization of Socs1MGLtg founders #53, #45 and #29.
(A) BMMs of Socs1+/+MGLtg mice from each founder were stimulated with IFNγ (50 ng/ml) for 24 h and
analyzed according to mRNA expression of Socs1 wildtype (WT) and Socs1∆NLS, (B) Luciferase activity
and (C) percentage of GFP positive cells (n= 3-5, mean +SD, two-way ANOVA including Bonferroni
post-test.)
5.3.2. Using Socs1+/+MGLtg mice as reporter mice
Since eGFP and Luciferase are transcribed together with Socs1∆NLS on the BAC, Socs1+/+
MGLtg mice can be used as reporter mice. Organ specific expression of Socs1 can be measured
by luciferase activity. Therefore, various organs were homogenized and luciferase activity was
determined per mg tissue, revealing high activity in thymus and muscle (Fig. 11A). In addition
mRNA expression of Socs1WT, Socs1∆NLS, eGFP and Luciferase was measured in indicated
organs. Again, high expression of Socs1 was observed in thymus. Except for the liver and the
pancreas (where expression of eGFP and Luciferase were higher than expression of Socs1WT
and Socs1∆NLS ), expression of the BAC was in good correlation for Socs1 expression arguing
for the use of Socs1MGLtg mice as reporter mice. SOCS1 expression in the thymus has already
been reported [256, 173, 193], confirming shown data and supporting the role of Socs1+/+MGLtg
mice as reporter mice.
5.3.3. Investigation of SOCS1 expression in Socs1MGLtg mice
To analyze the function of SOCS1 in the cell nucleus, Socs1+/-MGLtg mice were crossed with
Socs1+/- mice to generate Socs1-/-MGLtg mice that are expressing SOCS1∆NLS in an otherwise
SOCS1 deficient background. To prove that Socs1-/-MGLtg mice have similar expression levels
of total Socs1 (both Socs1 and Socs1∆NLS ) as compared to Socs1+/- and Socs1+/-MGLtg
mice, BMMs were stimulated with IFNγ for 24 h and qPCR was performed to detect both,
Socs1 and Socs1∆NLS indicating similar levels of total Socs1 (Fig. 12A). Socs1+/-MGLtg mice
were used as controls as they are still expressing nuclear Socs1, but also the MGL transgene
which rules out a transgene specific effect. Socs1+/- mice are another important control, as
they only have one allele of Socs1 as compared to Socs1+/-MGLtg mice with one allele of Socs1
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Figure 11.: Socs1+/+MGLtg mice can be used as reporter mice.
(A) Luciferase activity per mg tissue was measured in indicated organs of Socs1+/+MGLtg mice. (n=
3, mean +SD, Two-way ANOVA including Bonferroni post-test) (B) mRNA expression of Socs1WT,
Socs1∆NLS, eGFP and Luciferase was measured in indicated organs normalized to the reference genes
ActB and GAPDH using the REST software (http://rest.gene-quantification.info/) and displayed in
relation to their expression in lung tissue (n= 3 except for pancreas and muscle with n = 1, mean +SD,
Pair Wise Fixed Reallocation Randomisation Test).
and additionally Socs1∆NLS. Next, similar protein levels for SOCS1 and SOCS1∆NLS were
confirmed. Fig. 12B shows SOCS1 and SOCS1∆NLS detection in lysates of BMMs stimulated
with IFNγ for 6 h. Quantification of the Western Blot suggests equal protein levels for both
SOCS1 and SOCS1∆NLS. As previously mentioned, a band at the corresponding molecular
weight for SOCS1 and a slightly higher running one for SOCS1∆NLS were detected, the latter
most likely results from the remaining 21 amino acids after cleavage of the 2A sequence.
To rule out the possibility that mutating SOCS1 alters its protein half-life, cycloheximide
chase was performed. 6 h post stimulation with IFNγ, cycloheximide was added to block nascent
protein synthesis. Already after 1 h of cycloheximide treatment, there was only 60 ± 32% and
50 ± 24% of the SOCS1 or SOCS1∆NLS protein remaining and after 4 h only 6 ± 3% and 8
± 6%, respectively (Fig. 13). As a control, IκBα is shown as a protein known to be rapidly
degraded. Importantly, no alteration of the mRNA expression levels, the protein levels or the
protein half-life could be observed when mutating SOCS1 to SOCS1∆NLS.
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Figure 12.: Similar expression of SOCS1 and SOCS1∆NLS in MGL transgenic mice.
(A) mRNA expression of total Socs1 was analyzed in isolated BMMs upon stimulation with IFNγ (50
ng/ml) for 6 h (n = 4, mean +SD, two-way ANOVA including Bonferroni post-test). (B) Detection of
SOCS1 by Western Blot in lysates of BMMs upon stimulation with IFNγ for 6 h. Arrows indicate band
for SOCS1 (in Socs1+/- mice) and SOCS1∆NLS (in Socs1-/-MGLtg mice) (C) Quantification of SOCS1
and SOCS1∆NLS protein was done by densitometry using ImageJ (n = 10-13, mean +SD, Wilcoxon
matched pairs test).
Figure 13.: Similar protein stability of SOCS1 and SOCS1∆NLS.
(A) Cycloheximide (CHX, 100 µg/ml) was added at 6 h post-stimulation with IFNγ. BMMs were lysed
at the indicated time points. (B) Following Western blotting and densitometry, SOCS1 and SOCS1∆NLS
expression was normalized to βActin in order to calculate the percentage of remaining protein relative
to its expression prior to the addition of CHX. IκBα was used as a control for effective CHX treatment
(n= 3-4, mean +SD, two-way ANOVA including Bonferroni post-test).
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5.4. Socs1-/-MGLtg mice lack SOCS1 in the cell nucleus
In order to show that Socs1-/-MGLtg mice - only expressing non-nuclear SOCS1∆NLS - indeed
lack SOCS1 in the cell nucleus, staining of endogenous SOCS1 was performed by immunohis-
tochemistry. However, no sufficiently specific antibody was found that did not stain sections
from Socs1-/- mice (including newly generated antibodies described in section 5.2). Therefore,
functional assays were used to identify the lack of functional SOCS1∆NLS in Socs1-/-MGLtg
mice. It has been reported that nuclear SOCS1 leads to degradation of the NFκB subunit p65
[260], therefore the hypothesis was tested whether Socs1-/-MGLtg mice show sustained NFκB
signaling. In addition, SOCS1 has been reported to activate p53 in the cell nucleus suggesting
an anti-proliferative role of nuclear SOCS1 [169]. For this purpose, proliferation and cell cycle
were further investigated in Socs1-/-MGLtg mice.
5.4.1. Functional impairment of NFκB inhibition in Socs1-/-MGLtg mice
In order to show that Socs1-/-MGLtg mice indeed lack SOCS1 in the cell nucleus, a functional
approach was used to verify non-nuclear expression of SOCS1∆NLS. To examine whether NFκB
signaling is altered in Socs1-/-MGLtg mice, CD11c+ cells were isolated from lungs and stimu-
lated ex vivo with TLR agonists. Stimulation of CD11c+ cells from Socs1-/-MGLtg mice with
CpG-DNA, LPS and pI:C for 24 h led to an increased protein expression of IL-12p40 (3748
±142 pg/ml after LPS and 8738 ±770 pg/ml after pI:C treatment) as compared to CD11c+
cells from Socs1+/-MGLtg mice (1333 ±467 pg/ml after LPS and 3430 ±791 pg/ml after pI:C
treatment) (Fig. 14A). The same could be shown in CD11c+ cells isolated from spleens with an
increased protein expression of IL-12p40 of 4637 ±827 pg/ml after LPS and 9157 ±460 pg/ml
after pI:C treatment as compared to CD11c+ cells from Socs1+/-MGLtg mice with 1406 ±91
pg/ml after LPS and 3547 ±253 pg/ml after pI:C treatment (Fig. 14B). Of note, Socs1-/-MGLtg
mice already showed higher (however non-significant) IL-12p40 and IL-6 protein levels without
prior stimulation, suggesting pre-activation of CD11c+ cells from Socs1-/-MGLtg mice. No dif-
ferences were observed regarding TNFα protein levels, which is in full accordance with previous
findings of Strebovsky et al. 2011 [260] showing that only a subset of NFκB dependent genes is
altered in Socs1-/-MGLtg mice. In contrast to TNFα, IL-12p40 induction which needs prolonged
binding of NFκB to its promoter [20] was sensitive to SOCS1 induced NFκB inhibition. Data
suggest sustained NFκB activation in Socs1-/-MGLtg mice. This hypothesis was confirmed by a
transcription factor activity assay for p65 (Fig. 14C,D). In this assay, the activated NFκB p65
subunit in whole-cell extracts specifically binds to a plate-bound oligonucleotide. By using an
antibody that is directed against p65, the activated NFκB subunit bound to the oligonucleotide
is detected. Using this TransAM approach, increased p65 activity was demonstrated in untreated
complete lung homogenate (Fig. 14C) and primary murine trachea epithelial cells (pmTECs)
(Fig. 14D). The results entirely phenocopy in vitro data using non-nuclear SOCS1∆NLS re-
garding NFκB activation, suggesting that Socs1-/-MGLtg mice functionally lack SOCS1 in the
cell nucleus.
5.4.2. Socs1-/-MGLtg mice have an altered cell cycle
SOCS1 expression is silenced in multiple human cancers suggesting a tumor suppressor role for
this protein [39, 165, 243, 293, 125]. The anti-proliferative function of SOCS1 is thought to
be dependent on its interaction with p53 within the cell nucleus, leading to activation of p53
by phosphorylation at serine15 [169]. Therefore, proliferation and cell cycle were analyzed in
Socs1-/-MGLtg mice. Indeed, Socs1-/-MGLtg mice showed elevated spleen weight as well an an
increased number of splenocytes as compared to Socs1+/-MGLtg mice (Fig. 15A,B), suggesting
altered proliferation or cell cycle in the spleen. Proliferation of CD4+ T cells was examined in an
in vitro assay using CFSE and analysis of the cells 3 days after stimulation with anti-CD3/CD28
coated beads to induce T cell proliferation. No difference was observed comparing proliferation
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Figure 14.: Sustained NFκB signaling in Socs1-/-MGLtg mice
CD11c+ cells were isolated from (A) lung homogenate or (B) spleen homogenate and stimulated with
CpG-DNA (1 µM), LPS (100 ng/ml), and pI:C (10 µg/ml) for 24 h. TNFα and IL-12p40 protein levels
were measured by ELISA (n = 3–5, mean +SD, two-way ANOVA including Bonferroni post-test). (C)
NFκB p65 activity was examined using the TransAM DNA binding ELISA to specifically examine p65
activity in lung homogenate (left) or pmTECs (right). Raji nuclear extract was used as a positive control
and a wildtype oligonucleotide was used as a competitor (negative control). (n = 4 for lung homogenate
and n = 3 for pmTECs, mean +SD, One-way ANOVA including Bonferroni post test).
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of CD4+ T cells isolated from the spleens of Socs1-/-MGLtg or Socs1+/-MGLtg mice. On day 3,
75 ± 14% of the cells isolated from Socs1+/-MGLtg mice were proliferating and 62 ± 19% of the
cells isolated from Socs1-/-MGLtg mice as compared to 10-20% of the cells that were incubated
without CD3/CD28 coated beads (control) (Fig. 15C). For cell cycle analysis, CD4+ T cells
were isolated from spleens and stained with propidium iodide. Cell cycle analysis revealed a
reduced percentage of CD4+ T cells from Socs1-/-MGLtg mice in G1 phase of the cell cycle.
In contrast an increased percentage of cells in the S-phase of the cell cycle was observed for
CD4+ T cells from Socs1-/-MGLtg mice as compared to CD4+ T cells from Socs1+/-MGLtg mice
(Fig. 15D), suggesting an altered cell cycle in Socs1-/-MGLtg mice. Although CD4+ T cells
from Socs1-/-MGLtg mice showed no difference regarding proliferation in the in vitro assay, data
suggests alteration of the cell cycle in Socs1-/-MGLtg mice that might arise from the lack of p53
activation due to missing functional SOCS1 in the cell nucleus.
Figure 15.: Altered cell cycle in Socs1-/-MGLtg mice.
(A) Spleen weight and (B) number of splenocytes were recorded for n = 7-10 8-week-old mice (mean
+SD, Wilcoxon matched pairs test) (C) CD4+ T cells isolated from spleens were stained with CFSE
(5 mM), stimulated with CD3/CD28 coated beads and analyzed for proliferation on day 3 using flow
cytometry. Unstimulated cells (no beads added) were used as a control (n = 4-6, mean +SD, two-way
ANOVA including Bonferroni post-test). (D) For cell cycle analysis, CD4+ T cells were isolated from
spleens and stained with propidium iodide (50 µg/ml) for 30 min. Cell cycle analysis was done using flow
cytometry identifying propidium iodide stained cells in the PE channel (right) and cells in G1, S or G2
phase were identified using the DeNOVO Software (FCS Express Demo version 5) (left) (n = 3, mean
+SD, two-way ANOVA including Bonferroni post-test)
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5.5. Socs1-/-MGLtg mice survive the early lethal phenotype as
compared to Socs1-/- mice due to functional regulation of IFNγ
signaling
No alteration in survival was observed for Socs1-/-MGLtg mice. Fig. 16A shows the survival for
Socs1-/-MGLtg mice up to 60 days unlike Socs1-/- mice that show stunted growth (Fig. 16C)
and die within 2-3 weeks due to excessive immune signaling and fatty degeneration of the liver
[173, 193, 256]. In a small cohort (n= 4) survival of Socs1-/-MGLtg mice was recorded up to 38
weeks (data not shown), showing no difference to Socs1+/-MGLtg littermates. Both female and
male Socs1-/-MGLtg mice have reduced body weight as compared to Socs1+/-MGLtg littermates
(Fig. 16B) with a mean of 18 ± 2.5 g and 23.5 ± 1.5 g as compared to the controls with a mean
of 22 ± 1.7 g and 27 ± 1.8 g for female and male 8-week-old mice, respectively. However the
observed reduction in body-weight of Socs1-/-MGLtg mice was not as severe as in Socs1-/- mice
(Fig. 16C).
Figure 16.: Socs1-/- MGLtg mice survive the early lethal phenotype of Socs1-/- mice.
(A) After mating Socs1+/- to Socs1+/-MGLtg mice, survival of offsprings was recorded to the age of
60 days (n = 28–92 mice per genotype). (B) Mouse body weight analysis (n = 10–15 8-week-old mice
per gender and genotype, mean +SD, Wilcoxon matched pairs test). (C) Image showing 2-week-old
Socs1+/-MGLtg, Socs1-/-MGLtg and Socs1-/- mice (left to right).
5.5.1. Functional regulation of IFNγ signaling in Socs1-/-MGLtg mice
Socs1-/-MGLtg mice are surviving the early lethal phenotype as compared to Socs1-/- mice.
As it is known that Socs1-/- can be rescued by the administration of anti-IFNγ antibodies
in the neonatal period or by using Socs1-/- IFNγ-/- mice [6, 23], the hypothesis was raised
that canonical IFNγ signaling is not altered in Socs1-/-MGLtg mice. To prove this hypothesis,
tyrosine phosphorylation of STAT1 was examined in BMMs upon treatment with IFNγ for 1 to
6 h. IFNγ signaling was prolonged in mice completely lacking SOCS1 as shown by the sustained
levels of pY-STAT1 in Socs1-/- mice (60 ± 20% pY-STAT1). In contrast, there was a decline
in pY-STAT1 levels for both Socs1+/-MGLtg mice (to 18 ± 7%) and Socs1-/-MGLtg mice (to
25 ± 20%) already 4 h after IFNγ stimulation (Fig. 17A,B). To confirm this result, pY-STAT1
levels were analyzed using flow cytometry. Whereas the maximal number of pY-STAT1 positive
BMMs upon IFNγ treatment (22.2 - 29.1%) was reached for Socs1+/+, Socs1+/-, Socs1+/-MGLtg
and Socs1-/-MGLtg mice after 20 min, this number was steadily increasing for Socs1-/- mice to
60.9 ± 15% upon 1 h of stimulation (Fig. 17B). Again, no differences could be found regarding
tyrosine phosphorylation of STAT1 comparing Socs1-/-MGLtg and Socs1+/-MGLtg mice. Of
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note, no gene dosage effects were detected, since levels of pY-STAT1 were comparable between
Socs1+/+ and Socs1+/- mice. Looking at expression levels of canonical IFNγ target genes, both
iNOS and Irf9 were induced upon stimulation with IFNγ. There was no difference between
Socs1+/-MGLtg and Socs1-/-MGLtg mice regarding the expression of iNOS (relative expression
after 4 h of IFNγ of 0.014 ± 0.01) or Irf9 (relative expression after 4 h of IFNγ of 0.24 ± 0.4
for Socs1+/-MGLtg and 0.2 ± 0.2 for Socs1-/-MGLtg mice). For Icam-1, minor differences were
observed at 6 h after stimulation with a relative expression of 0.15 ± 0.1 for Socs1+/-MGLtg
and 0.67 ± 1.1 for Socs1-/-MGLtg mice (Fig. 17C).
Figure 17.: IFNγ signaling is unaltered in Socs1-/-MGLtg mice.
(A) Western blot analysis of tyrosine phosphorylated STAT1 (Tyr701). STAT1 and β-Actin were
used as loading controls. Protein extracts were prepared from BMMs of Socs1-/-, Socs1+/-MGLtg and
Socs1-/-MGLtg mice that were treated with IFNγ (50 ng/ml) as indicated. Quantification using ImageJ
is shown in (B) (n = 4, +SD, two-way ANOVA including Bonferroni post-test). (C) Tyrosine phospho-
rylated STAT1 (Tyr701) was examined using flow cytometry. BMMs were stimulated with IFNγ for the
indicated time and pY-STAT1 levels were examined using AlexaFluor 647 Anti-STAT1 (pY701). (n = 3,
mean +SD, two-way ANOVA including Bonferroni post-test) (D) mRNA expression of interferon target
genes iNOS, Irf9, and Icam-1 are shown normalized to Actin (ActB) expression in BMMs treated with
IFNγ (50 ng/ml) for 1–6 h (n = 4). Mean +SD is presented for each group and significance was assessed
using two-way ANOVA including Bonferroni post-test.
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5.5.2. Differential regulation of a subset on non-canonical IFNγ dependent genes
in Socs1-/-MGLtg mice
To confirm the hypothesis that canonical IFNγ signaling is not altered in Socs1-/-MGLtg mice,
whole-genome expression analysis was performed. Therefore, BMMs were stimulated with IFNγ
for 24 h, RNA was extracted and subjected to whole-genome expression analysis. Analysis was
done using R looking at the significantly (p≤ 0.05) and differentially (log2 change ≤-1 or ≥1)
regulated genes. As a result, 1097 genes were differentially regulated between untreated and
IFNγ stimulated cells, but only 86 genes were differentially regulated between Socs1-/-MGLtg
and Socs1+/-MGLtg mice upon stimulation with IFNγ for 24 h (Fig. 18A-C). Principal compo-
nent analysis showed that the controls (unstimulated) cluster together. Upon stimulation with
IFNγ, clusters for Socs1-/-MGLtg and Socs1+/-MGLtg mice were separate suggesting differential
gene regulation (Fig. 18A). According to the heat-map, most differentially regulated genes were
induced rather than repressed in Socs1-/-MGLtg mice. In Fig. 18D, the top 10 differentially reg-
ulated induced and repressed genes were displayed including the genes induced in Socs1-/-MGLtg
mice such as Indoleamine 2,3-Dioxygenase 1 (Indo, 11.47 fold) and SelectinL (Sell, 6.69 fold)
as well as the genes repressed in Socs1-/-MGLtg mice such as Src-Like-Adaptor (Sla, 0.29 fold)
and Growth Differentiation Factor 3 (Gdf3, 0.26 fold). Those genes were confirmed by qPCR to
be differentially regulated in Socs1-/-MGLtg mice (Fig. 18E). As canonical IFNγ target genes
were not differentially regulated in Socs1-/-MGLtg mice, the hypothesis was raised that IFNγ
signaling is not altered. To confirm this hypothesis, pathway annotation was performed using
the 86 differentially regulated genes (Table 3). Instead of IFNγ signaling pathway, a significant
number of differentially regulated genes was annotated to TLR and TNF signaling pathways.
For the TLR signaling pathway, 3 genes addressed to the signaling pathway are induced (CD40,
Cxcl10, Jun) and 5 are repressed (Ccl3, Ccl4, Ccl5, Tlr7, Tlr8 ) in Socs1-/-MGLtg mice. For the
TNF signaling pathway, 5 genes addressed to the signaling pathway were induced (Socs3, Fas,
Tnfaip3, Cxcl10, Jun), whereas only 1 was repressed (Ccl5 ) in Socs1-/-MGLtg mice, arguing
for a general induction of the pathway. Next, transcription factor binding sites (TFBS) were
analyzed (Table 2). As a result, the transcription factors CTCF, IRF2 and NFκB were overrep-
resented among the differentially regulated genes with 21, 8 and 56 genes, respectively. STAT1
as classical transcription factor for IFNγ signaling was not overrepresented among the differ-
entially regulated genes. The hypothesis that Socs1∆NLS is still able to regulate cytoplasmic
signaling pathways and that canonical IFNγ signaling is not altered in Socs1-/-MGLtg mice could
be confirmed, since there were no differences regarding STAT1 phosphorylation or the expression
of canonical IFNγ target genes iNOS or Irf9. In addition, whole genome expression analysis
revealed only a small subset of genes to be differentially regulated in Socs1-/-MGLtg mice, but no
canonical IFNγ target genes, suggesting that Socs1∆NLS was still able to regulate cytoplasmic
signaling pathways and that canonical IFNγ signaling was not altered in Socs1-/-MGLtg mice.
Table 2.: oPOSSUM analysis of overrepresented transcription factor binding sites.
Differentially expressed genes in Socs1-/-MGLtg mice upon IFNγ stimulation showing a log2-fold change
(≤-1 or ≥1) and p≤ 0.05 were uploaded to identify overrepresented transcription factor binding sites
among those genes. BG = background
TFBS Input/ BG class family z-score Fischer score
CTCF 21/86 Zinc coordinating ββα zinc finger 14.88 5.01
IRF2 8/86 Winged Helix-Turn-helix IRF 14.343 4.42
NFκB 56/86 Ig fold Rel 12.24 2.28
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Figure 18.: Differential gene regulation of a subset of IFNγ dependent genes in Socs1-/- MGLtg mice.
BMMs were stimulated with IFNγ (50 ng/ml) for 24 h, RNA was extracted and subjected to whole-genome
expression analysis (n = 4) (A) Principal component analysis (PCA). The two principal components and
their fraction of the overall variability of the data (%) are shown on the x-axis and the y-axis. Clusters
of experiments are circled (95% confidence interval ellipse) and annotated as ctrl for untreated samples
and +IFNγ for IFNγ-stimulated samples. (B) Volcano plot showing the genes that were differentially
expressed between BMMs of Socs1+/-MGLtg and Socs1-/-MGLtg mice. Only significant values (p≤ 0.05)
were considered showing a log2 fold change ≤-1 (red points) or ≥1 (blue points). (C) Heat map visualizing
hierarchical clustering analysis based on the expression levels of genes that are differentially expressed
between BMMs of Socs1+/-MGLtg and Socs1-/-MGLtg mice. Red indicates higher expression and blue
indicates lower expression of the corresponding gene in Socs1-/-MGLtg mice. (D) 10 most prominently
up- and downregulated genes according to their fold change. (E) Quantitative RT-PCR was performed
using RNA from BMMs stimulated with IFNγ (n = 3, mean +SD, Student’s t-test).
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Table 3.: Pathway annotation using the protein analysis through evolutionary relationships (PANTHER)
classification system.
Differentially expressed genes in Socs1-/-MGLtg mice upon IFNγ stimulation showing a log2-fold change
(≤-1 or ≥1) and p≤ 0.05 were analyzed to classify and identify gene functions. BG = background
Pathway ID Input/ BG Induced genes Repressed genes p-value
TLR signaling pathway 8/101 CD40 Ccl3 0.00129
Cxcl10 Ccl4
Jun Ccl5
Tlr7
Tlr8
TNF signaling pathway 6/109 Socs3, Ccl5 0.056
Fas
Tnfaip3
Cxcl10
Jun
5.5.3. Functional differentiation of bone-marrow derived macrophages (BMMs) of
Socs1-/-MGLtg mice
To control that BMMs used in this study were functionally differentiated, expression of classical
macrophage markers on the surface was examined using flow cytometry. Therefore, BMMs
from Socs1-/-MGLtg and Socs1+/-MGLtg mice were stimulated with IFNγ or LPS and stained
for macrophage markers such as F4/80, CD86, CD11b and MHC class II. In summary, all
tested surface proteins were expressed by the majority of the BMMs and in a similar ratio in
Socs1-/-MGLtg mice as compared to the controls (Fig. 19A-D). Stimulation of BMMs using
IFNγ or LPS led to induction of SOCS1 as shown by increased percentage of GFP+ cells due
to expression of the BAC (30.6 ± 0.4% and 30.0 ± 0.3% in Socs1+/-MGLtg and Socs1-/-MGLtg
mice) (Fig. 19E). In addition, macrophage capacity of phagocytosis was examined. Therefore,
fluorescently labelled Latex beads were added to BMMs for 1 h at 37◦C and uptake was measured
using flow cytometry. After 1 h, 63.9 ± 3.7% of BMMs from Socs1+/-MGLtg mice and 68.4 ± 1%
of the BMMs from Socs1-/-MGLtg mice took up Latex beads, suggesting functional differentiation
of BMMs of both Socs1+/-MGLtg and Socs1-/-MGLtg mice.
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Figure 19.: Socs1-/-MGLtg mice show normal macrophage function.
BMMs were differentiated and stimulated with IFNγ (50 ng/ml) for 24 h. Expression of (A) F4/80,
(B) CD86, (C) CD11b and (D) MHC class II was analyzed by flow cytometry using corresponding
antibodies. (E) Phagocytosis was determined by uptake of Latex-beads (amine-modified polystyrene
beads, fluorescent yellow-green) by BMMs within 1 h at 37◦C (n = 2, mean +SD, two-way ANOVA
including Bonferroni post-test). (F) BMMs were treated as before. Expression of the BAC was visualized
by detection of GFP positive cells using flow cytometry.
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5.6. Phenotypical characterization of Socs1-/-MGLtg mice
Since the cytoplasmic function of SOCS1∆NLS seemed to be still functional in Socs1-/-MGLtg
mice, it remained to be clarified whether those mice show deficiencies due to the lack of SOCS1
in the cell nucleus except for the slightly reduced body weight (Fig. 16B). Therefore, blood
parameters such as white blood cell count, red blood cell count, number of granulocytes, mono-
cytes, lymphocytes, platelets and the amount of hemoglobin were analyzed in whole blood using
the Coulter Ac-T Hematology Analyzer. As a result, an increase in the number of monocytes
(0.8 ± 0.2 x103 cells/µl in Socs1+/-MGLtg versus 1.6 ± 0.3 x103 cells/µl in Socs1-/-MGLtg mice)
and a reduction in the number of platelets (1.2 ± 0.4 x106 cells/µl in Socs1+/-MGLtg versus 0.8
± 0.3 x106 cells/µl in Socs1-/-MGLtg mice) was observed.
Figure 20.: Analysis of blood parameters in Socs1-/-MGLtg mice.
Numbers of (A) white blood cells (WBC), (B) red blood cells (RBC), (C) granulo-
cytes, (D) monocytes, (E) lymphocytes, (F) platelets and (G) amount of hemoglobin was
analysed from whole blood samples using the Coulter Ac-T Hematology Analyzer (n =
4-13, mean +SD, Wilcoxon matched pairs test). Grey areas indicate the physiologi-
cal range (95%) according to Mouse Hematology of the C57BL/6 mouse (Charles River,
www.criver.com/files/pdfs/rms/c57bl6/rm rm r c57bl6 mouse clinical pathology data.aspx).
In addition, histopathological analysis was performed by cutting 3 µm sections of various
organs, H&E staining and evaluation by an independent pathologist in a blinded manner. This
analysis revealed low-grade inflammation in lung and liver a significant number of Socs1-/-MGLtg
mice (Table 4). However, low-grade inflammation in the liver could not be reproduced for the
founders #29 or #45 and serum transaminase levels (ALT or AST) were in the physiological
range (Fig. 21), arguing against a liver-specific phenotype in Socs1-/-MGLtg mice. Yet, 45% of
Socs1-/-MGLtg mice showed infiltrations in lung tissue in all three founders. Therefore, the lung
phenotype in Socs1-/-MGLtg mice was investigated in more detail.
53
5. Results
Table 4.: Histological analysis revealing infiltrates in lungs of Socs1-/-MGLtg mice.
Organs were cut at 3 µm, H&E stained and histopathologically evaluated. n= 24 Socs1-/-MGLtg and 12
Socs1+/-MGLtg mice of the founder #53. ? Fisher’s exact test
Infiltrates in Socs1-/-MGLtg (%) Socs1+/-MGLtg (%) p-value ? risk-factor
Lung 45 8 0.03 5.5
Liver 54 16 0.04 3.3
Esophagus 33 8 n.s. 4
Small intestine 29 0 n.s. 3
Heart 29 0 n.s. 2
Stomach 25 8 n.s. /
Spleen 16 8 n.s. /
Skin 12 0 n.s. /
Kidney 8 0 n.s. /
Muscle 4 0 n.s. /
Brain 4 0 n.s. /
Colon 4 0 n.s. /
Pancreas 0 0 n.s. /
Parotis 0 0 n.s. /
Figure 21.: Physiological ALT
and AST levels in serum of
Socs1-/-MGLtg mice.
Serum transaminase levels were de-
termined at an age of 8-12 weeks in
n = 10-12 mice (mean +SD, two-way
ANOVA including Bonferroni post-
test). Grey areas indicate the physi-
ological range.
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5.6.1. Socs1-/-MGLtg mice spontaneously develop low-grade inflammation in the
lung
Socs1-/-MGLtg mice showed infiltrates in the lungs of 45% of the analyzed mice (Fig. 22A) in
all three founders. In addition, PAS staining was performed revealing a higher number of PAS
positive cells in the lung of Socs1-/-MGLtg mice (Fig. 22B). To investigate the occurrence of
the inflammatory aggregates observed in H&E stainings in more detail, lungs of 6 - 12 week-
old Socs1-/-MGLtg mice and littermate controls were examined by micro-CT. Since previous
histological analysis was performed by cutting the lung only once, irrespective which lung lobe,
it was expected that micro-CT analysis gives a better overview about the frequency and location
of inflammatory aggregates in Socs1-/-MGLtg mice. Optimal parameters for micro-CT scans were
established first. For detection of infiltrates in inflated lungs, whole body scans were performed
post mortem with 18 µm resolution (Fig. 22C). Afterwards, lungs were fixed using formalin
and single lobes were embedded in paraffin. For detection of infiltrates in paraffin embedded
lung lobes, a 9 µm scan with high averaging showed best results. Direct correlation of the CT
scans from whole bodies with the scans from paraffin embedded lungs and correlative H&E
stainigs was done (Fig. 22E-D). Widespread, diffuse infiltrates were found in 5 out of 6 mice,
in left lobes, right upper lobes and right cardiac lobes of Socs1-/-MGLtg mice (see Table 5 and
Fig. 22D). In addition, data revealed circular, local infiltrates mostly associated with smaller
bronchi in 5 out of 6 Socs1-/-MGLtg mice (see Table 5, Fig. 22E). Importantly, infiltrates were
distributed equally in the lung lobes and did not show a prevalence with regards to an individual
lung lobe. Correlative histology confirmed the presence of infiltrates in the identified lung lobes.
In littermate controls, only one infiltrate was observed in the right lower lobe, that could not be
found in correlative H&E stainings. Data suggests, that more than the previously identified 45%
of Socs1-/-MGLtg mice show low-grade inflammation as depicted by the presence of infiltrating
immune cells.
Figure 22.: Socs1-/-MGLtg mice develop low-grade inflammation in the lung.
(A) H&E-stained airway cross sections. Arrow highlighting infiltrating cells. Scale bar, 100 µm. (B)
Periodic acid–Schiff (PAS) stained airway cross sections. Arrow highlights PAS positive cells. Scale bar,
200 µm. (C) Axial view of a micro-CT scan from an inflated Socs1-/-MGLtg lung post mortem showing
infiltrating cells. (left) Overview. Scale bar, 2.5 mm. (right) Zoom. Arrow indicating infiltrating cells.
Scale bar, 2.5 mm (D) H&E staining showing a diffuse, inflammatory aggregate identified by micro-CT
in the right upper lobe of a Socs1-/-MGLtg. Arrow highlighting infiltrating cells. Scale bar, 100 µm. (E)
H&E staining showing a circular, local inflammatory aggregate identified by micro-CT in the right upper
lobe of a Socs1-/-MGLtg. Arrow highlighting infiltrating cells. Scale bar, 100 µm.
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Table 5.: Evaluation of lung infiltrations by micro-CT.
18 µm micro-CT scans from 6 Socs1-/-MGLtg and 6 Socs1+/-MGLtg mice were evaluated for circular,
local infiltrations and diffuse infiltrations in individual lung lobes by a radiologist in a blinded manner.
LL = left lobe, RUL = right upper lobe, RML = right middle lobe, RLL = right lower lobe, RCL =
right cardiac lobe and total = total lung.
LL RUL RML RLL RCL total
Socs1+/-MGLtg - - - - - - diffuse aggregate
Socs1-/-MGLtg 1/6 2/6 0/6 0/6 3/6 5/6
Socs1+/-MGLtg - - - 1/6 - 1/6 circular, local aggregate
Socs1-/-MGLtg 3/6 2/6 2/6 3/6 2/6 5/6
5.6.2. Lack of nuclear SOCS1 leads to airway eosinophilia and a Th2-prone disease
To identify which cells were infiltrating the lung, BAL was performed. BAL cells were dif-
ferentiated using May-Gru¨nwald/ Giemsa staining, indicating elevated, however non-significant
eosinophil influx in BAL (2.5 ± 2.4 x103 cells/ml BAL in Socs1-/-MGLtg mice as compared to
0 or 0.2 ± 0.1 x103 cells/ml BAL in Socs1+/- or Socs1+/-MGLtg mice) and to a minor extent
elevated lymphocyte counts in BAL (2.5 ± 2.3 x103 cells/ml BAL in Socs1-/-MGLtg mice as
compared to 0.35 ± 0.6 or 1.2 ± 0.4 x103 cells/ml BAL in Socs1+/- or Socs1+/-MGLtg mice)
(Fig. 23A). In contrast, no differences in macrophage and neutrophil counts were observed.
Socs1-/- MGLtg mice showed 19.4 fold increased serum IgE levels (Fig. 23B), suggesting an
allergic disease. Increased IgE and eosinophil influx suggest allergic predisposition and hint
towards Th2 bias.
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Figure 23.: Socs1-/-MGLtg mice deveopl allergic low-grade airway eosinophilia.
(A) Total numbers of macrophage, neutrophil, eosinophil and lymphocyte subpopulations in BAL are
represented (n = 5, mean +SEM, two-way ANOVA including Bonferroni post-test). (B) IgE concentration
in serum (n = 9, mean +SD, Wilcoxon matched pairs test).
Since SOCS1 has been shown to be important for T helper cell differentiation [194, 257, 51],
it was analyzed whether Socs1-/-MGLtg mice have a T helper cell bias. Therefore, CD4+ T cells
were isolated from lung homogenates and transcription factors for T helper cell subsets were
analyzed by qPCR. Socs1-/-MGLtg mice showed a 4.2 fold increase of Gata3+ cells (indicating
a higher number of Th2 cells) and a 1.2 fold, however non-significant, reduction in Rorc+ cells
(indicating a lower number of Th17 cells) (Fig. 24A). Using an in vitro differentiation assay,
na¨ıve CD4+ T cells from Socs1-/-MGLtg mice tend to express more Gata3 as compared to CD4+
T cells from Socs1+/-MGLtg mice, even under neutral conditions (T0, RPMI only) (Figure 24B).
However, this difference was not significant. Increased mRNA expression of IL-4, IL-5, and IL-
13 in complete lung homogenates of Socs1-/-MGLtg mice compared to Socs1+/-MGLtg mice
56
5. Results
confirmed this Th2 bias (Figure 24C). Notably, one population of Socs1-/-MGLtg mice was
found with a strong expression of Gata3 and Th2 type cytokines in lung homogenates, and the
second population showing a weaker Th2 bias, consistent with the fact that infiltrates were not
observed in all Socs1-/-MGLtg mice.
Figure 24.: Socs1-/-MGLtg mice show a Th2 bias.
(A) Expression levels of Foxp3, Gata3, Tbet, and Rorc in sorted CD4+ T cells from the lung of both founder
#53 and #29 (n = 7–11, mean +SD, two-way ANOVA including Bonferroni post-test). (B) Purified na¨ıve
CD4+ T cells were differentiated under T0 conditions (RPMI only) or under Th2 conditions (100 ng/ml
IL-4, 10 µg/ml anti-IFNγ, and 10 µg/ml anti-IL-12p40) for 3 days and restimulated using PMA and
ionomycin. Expression of Gata3 was examined by qPCR (n = 4, mean +SD, two-way ANOVA including
Bonferroni post-test). (C) Expression levels of IL-4, IL-5, and IL-13 in total lung homogenates of both
founder #53 and #29 (n = 7–11, mean +SD, Wilcoxon matched pairs test).
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5.7. Physiological relevance of lung phenotype in Socs1-/-MGLtg
mice
To analyze if the observed Th2 bias in Socs1-/-MGLtg mice is of physiological relevance, mice
were challenged in a classical Th2 model using ovalbumin. In addition, Socs1-/-MGLtg mice
were treated with IL-13 i.t. to provoke a Th2 response.
5.7.1. Increased airway eosinophilia in Socs1-/-MGLtg mice in an OVA
experimental asthma model
To analyze if the observed Th2 bias in Socs1-/-MGLtg mice is of physiological relevance, mice
were challenged in a classical Th2 model using ovalbumin. Socs1-/-MGLtg mice were subjected
to a well-established protocol for the induction of experimental asthma [162, 239]. Upon OVA
sensitization on days 1, 14 and 21, OVA aerosol challenge was performed on days 26, 27 and 28
and mice were analyzed on day 29 (Fig. 25A). Only minor induction upon OVA challenge and no
difference with regards to nuclear SOCS1 was detectable in airway hyperresponsiveness (AHR)
upon metacholine provocation (Fig. 25B). However, Socs1-/-MGLtg mice showed increased air-
way eosinophilia (21.5 ± 14 x104 cells/ml in BAL) as compared to Socs1+/-MGLtg control mice
(7.3 ± 6 x104 cells/ml in BAL) (Fig. 25C). In contrast, macrophages and neutrophils in BAL
were comparable between Socs1-/-MGLtg and Socs1+/-MGLtg mice.
In addition, IL-4 IL-5 and IL-13 levels were measured in BAL of Socs1-/-MGLtg mice upon
OVA sensitization and challenge as compared to Socs1+/-MGLtg mice. Upon OVA challenge,
levels of all measured Th2 cytokines increased in BAL. Increased IL-4 and IL-13 levels were
detectable in BAL of Socs1-/-MGLtg mice as compared to the controls. IL-5 levels upon challenge
were induced, yet showed no difference comparing Socs1+/-MGLtg and Socs1-/-MGLtg mice (Fig.
26). As a result, increased airway eosinophilia and Th2 cytokines were detected in Socs1-/-MGLtg
in an classical Th2 model using ovalbumin.
5.7.2. Increased airway eosinophilia in Socs1-/-MGLtg mice upon IL-13 instillation
Since IL-13 has been shown to induce eosinophil recruitment to the lung, Socs1-/-MGLtg and
control mice were treated with IL-13 intratracheally (i.t.). This model was used as a second
Th2 model to trigger airway eosinophilia. Mice were treated with IL-13 i.t. on three consecutive
days and analyzed on day 4. IL-13 treated mice of all genotypes developed neutrophilia in
the lung (Fig. 27). Socs1-/-MGLtg mice additionally showed enhanced influx of lymphocytes
(116.7 ± 37 x103 cells/ml BAL in Socs1-/-MGLtg mice as compared to 5.4 ± 1.4 x103 or 10.8
± 3.9 x103 cells/ml BAL in the controls) and eosinophils (182.3 ± 79 x103 cells/ml BAL in
Socs1-/-MGLtg mice as compared to 22.5 ± 4.4 x103 or 31.2 ± 7.9 x103 cells/ml BAL in the
controls) (Fig. 27). No differences were observed for macrophages or neutrophils comparing
IL-13 treated groups. In addition, Th2 cytokines were measured in complete lung homogenate.
Socs1-/-MGLtg mice showed increased mRNA expression of IL-4, IL-5 and IL-13, which was
even more pronounced upon IL-13 treatment (Fig. 28A). H&E staining revealed increased
infiltrations upon IL-13 treatment, most pronounced in Socs1-/-MGLtg mice (Fig. 27). As a
result, both upon OVA sensitization and challenge and upon IL-13 treatment, Socs1-/-MGLtg
mice responded with enhanced airway eosinophilia and an exaggerated Th2-prone lung disease.
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Figure 25.: Socs1-/-MGLtg mice show increased airway eosinophilia in an experimental asthma model.
(A) Mice were sensitized with OVA/Alum or PBS i.p. on days 1, 14, and 21, followed by a challenge with
1% OVA aerosol or PBS on days 26, 27, and 28. Analysis was performed on day 29 (n = 6-8) (B) Lung
function was assessed in mice that were exposed to OVA or PBS. Airway mechanics were assessed after
inhalation of nebulized saline and increasing concentrations of methacholine (MCh, 0 - 100 mg/ml) (mean
+SEM, two-way ANOVA including Bonferroni post-test). (C) Total numbers macrophages, neutrophils,
eosinophils and lymphocytes in BAL are represented (mean +SEM, two-way ANOVA including Bonferroni
post-test).
Figure 26.: Socs1-/-MGLtg
mice show enhanced expres-
sion of Th2 cytokines in an
experimental asthma model.
Levels of IL-4, IL-5, and IL-
13 in BAL were measured by
ELISA (mean +SD). Data was
tested for significance using
the two-way ANOVA including
Bonferroni post-test.
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Figure 27.: Socs1-/-MGLtg mice show increased airway eosinophilia upon IL-13 instillation.
Mice were treated with IL-13 (5 µg in 20 µl PBS) intratracheally (i.t.) on day 1, 2 and 3. Analysis
was performed on day 4 (n = 5). Total numbers of macrophage, neutrophil, eosinophil and lymphocyte
subpopulations in BAL are represented (mean +SEM, two-way ANOVA including Bonferroni post-test.)
Figure 28.: Socs1-/-MGLtg mice show increased expression of Th2 cytokines upon IL-13 treatment.
Mice were treated with IL-13 (5 µg in 20 µl PBS) intratracheally (i.t.) on day 1, 2 and 3 as described
previously. Analysis was performed on day 4 (n = 5) (A) mRNA levels of IL-4, IL-5, and IL-13 in
lung homogenate were measured by qPCR (mean +SD). (B) H&E-stained airway cross sections. Arrows
highlight infiltrating cells. Scale bar, 200 µm. Data was tested for significance using the two-way ANOVA
including Bonferroni post-test.
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5.8. The role of SOCS1 in epithelial cells
To identify the cells responsible for the observed Th2 prone lung disease and airway eosinophilia
in Socs1-/-MGLtg mice, bone-marrow transplantation was performed. In addition, pmTEC
cultures were analyzed with respect to transepithelial resistance.
5.8.1. Radiation-resistant cells are responsible for the observed lung phenotype in
Socs1-/-MGLtg mice
It was shown that Socs1-/- mice can be rescued on a Rag2 deficient background (Socs1-/-Rag2-/-
mice), arguing for an important role of SOCS1 in hematopoietic cells such as T cells. To
identify the cells responsible for the observed Th2 prone lung disease and airway eosinophilia
in Socs1-/-MGLtg mice, bone-marrow transplantation was performed. Using this approach,
one can distinguish between radiation-sensitive cells (hematopoietic cells such as T cells) and
radiation-resistant cells (structural cells such as epithelial cells). To distinguish between donor
and recipient cells, bone-marrow from wildtype mice (CD45.1) was transplanted into lethally
irradiated Socs1-/-MGLtg mice (CD45.2). The latter still contain radiation-resistant cells lacking
nuclear SOCS1, but are replaced with wildtype hematopoietic cells. Vice versa, CD45.1 mice
were lethally irradiated and replaced with bone-marrow from Socs1-/-MGLtg mice. In those
mice, radiation-sensitive cells are lacking nuclear SOCS1, but the structural cells (e.g. epithelial
cells) still do contain nuclear SOCS1 (see transplantation scheme Fig. 29A). As a control, bone-
marrow from wildtype mice (CD45.1) was transplanted into lethally irradiated wildtype mice
(CD45.2). As a result 75 - 90% of the blood cells were replaced by the donor at day 7 post
transplantation (Fig. 29A). BAL was performed 6 weeks post transplantation, showing elevated
number of eosinophils only in lethally irradiated Socs1-/-MGLtg replaced by donor bone-marrow
from CD45.1 mice (44 ± 27 x103 cells/ml BAL as compared to 2.5 ± 0.7 x103 cells/ml BAL
for lethally irradiated CD45.1 mice replaced by donor bone-marrow from Socs1-/-MGLtg mice)
(Fig. 29B).
Although hematopoietic cells were replaced by wildtype donor cells in lethally irradiated
Socs1-/-MGLtg, not only cytokines produced by epithelial cells, but also Th2 cytokines were
elevated. Those mice showed a minor (non-significant) increase in mRNA expression of IL-4,
IL-5 and and a significant increase of IL-13 (3.3 fold) (Fig. 30A). Increased expression of IL-33
(2.7 fold) and Ccl26 (4.7 fold) which are known to play a role in the recruitment of eosinophils
[223] was observed (Fig. 30B). Elevated IL-6 protein levels of 15.8 ± 9.6 pg/ml were detectable in
BAL of Socs1-/-MGLtg mice as compared to 0.1 ± 0.4 pg/ml for CD45.1 mice (Fig. 30C). Data
suggest that radiation-resistant cells such as epithelial cells are responsible for the spontaneous
low-grade inflammation in the lungs of Socs1-/-MGLtg mice. In addition, small infiltrates were
found only in H&E stainings of lung sections from lethally irradiated Socs1-/-MGLtg mice (Fig.
30D) comparable to the ones characterized in Fig 22. As a conclusion, the lung phenotype
of Socs1-/-MGLtg mice including elevated Th2 cytokines, infiltrates in lung tissue and airway
eosinophilia was only observed in lethally irradiated Socs1-/-MGLtg mice replaced with wildtype
bone-marrow. In contrast, transplantation of bone marrow from Socs1-/-MGLtg mice did not
induce this phenotype. This suggests that nuclear SOCS1 plays a major role in structural cells
such as epithelial cells.
5.8.2. Disrupted epithelial integrity in Socs1-/-MGLtg mice
Since bone-marrow transplantation revealed a critical role of radiation-resistant cells such as ep-
ithelial cells in Socs1-/-MGLtg mice, airway epithelium was analyzed in more detail. Cytokines
produced by epithelial cells such as IL-25, IL-33 and Tslp were measured in complete lung tis-
sue. Those cytokines have been shown to contribute to control Th2 immunity [70, 121, 18, 141].
Interestingly, increased expression of IL-25 (12.8 fold), IL-33 (2.3 fold) and Tslp (5.7 fold)
was observed in the lung homogenate of Socs1-/-MGLtg mice (Fig. 31). To analyze the airway
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Figure 29.: The lung phenotype of Socs1-/-MGLtg mice is dependent on radiation-resistant cells.
(A) 8-10 week-old mice were lethally irradiated and transplanted with 1x107 total bone-marrow.
Socs1-/-MGLtg (CD45.2) mice were transplanted with bone-marrow from wildtype (CD45.1) mice and vice
versa (n = 10). Wildtype (CD45.2) mice were transplanted with bone-marrow from wildtype (CD45.1)
mice as a control. Flow cytometry showing the percentage of CD45.1 or CD45.2 positive cells in blood on
day 7. (B) Total numbers of macrophages, neutrophils, leukocytes and eosinophils in BAL are represented
(mean +SEM, two-way ANOVA including Bonferroni post-test).
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Figure 30.: Th2 bias of Socs1-/-MGLtg mice is dependent on radiation-resistant cells.
Levels of (A) Th2 cytokines IL-4, IL-5 and IL-13, (B) epithelial cell cytokines IL-33 and Ccl26 in
total lung homogenate (mean +SD, two-way ANOVA including Bonferroni post-test). (C) IL-6 levels
in BAL were determined by ELISA (mean +SD, two-way ANOVA including Bonferroni post-test). (D)
H&E-stained airway cross sections. Arrow highlight infiltrating cells. Scale bar, 200 µm.
Figure 31.: Socs1-/-MGLtg mice show
enhanced expression of IL-25, IL-33
and Tslp.
IL-25, IL-33, and Tslp mRNA lev-
els in total lung homogenates of both
founders #53 and #29 (n= 9-11, mean
+SD, Wilcoxon matched pairs test).
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epithelium in more detail, tracheas were isolated and primary murine trachea epithelial cells
(pmTECs) were differentiated in air-liquid interface (ALI) culture using transwells. Increased
IL-33 expression (4.3 fold as compared to Socs1+/-MGLtg mice and 3.2 fold as compared to
Socs1+/- mice) could be verified in isolated pmTECs from Socs1-/-MGLtg mice. In addition,
Ccl26 expression was examined since it is known to play a role in the recruitment of eosinophils
[223]. pmTECs from Socs1-/-MGLtg mice expressed significantly more Ccl26 (3.8 fold as com-
pared to Socs1+/-MGLtg mice and 2.2 fold as compared to Socs1+/- mice) (Fig. 32A). Expression
of IL-25 and Tslp were slightly elevated, however non-significant. Although pmTECs of control
mice built tight barriers in the transwell, decreased transepithelial electrical resistance (TER)
was observed in pmTECs from Socs1-/-MGLtg mice (357 ± 91 Ohm/cm2)) as compared to cells
from Socs1+/- (2475 ± 726 Ohm/cm2)) and Socs1+/-MGLtg mice (2302 ± 522 Ohm/cm2)) (Fig.
32B). To confirm the observation of a disrupted epithelial barrier in vitro, FITC-Dextran (4 kDa)
was added to the inner well and diffusion into the outer well was determined after 2 h of incuba-
tion at 37◦C. There was a significant reduction in the fluorescence in the inner well containing
pmTECs from Socs1-/-MGLtg mice as compared to pmTECs from Socs1+/- or Socs1+/-MGLtg
mice (Fig. 32C). Another ex vivo assay to determine disrupted barrier function is shown in Fig.
32D. Albumin was determined in BAL samples of Socs1-/-MGLtg and Socs1+/-MGLtg mice. If
the epithelial barrier is intact, albumin in the blood cannot cross the barrier. If the epithelial
barrier is disrupted, albumin can pass and is found in BAL. Indeed, Socs1-/-MGLtg mice showed
elevated levels of albumin in BAL (180 ± 40 µg/ml as compared to 90 ± 25 µg albumin /ml
BAL) (Fig. 32E), arguing for a disrupted epithelial cell barrier that could explain low-grade
inflammation observed in the lungs of Socs1-/-MGLtg mice.
To investigate the mechanism of reduced epithelial cell barrier integrity, E-Cadherin expression
and localization was analyzed. E-Cadherin is known to be a part of desmosomes and adherens
junctions and therefore plays a major role in cell barrier function, especially in epithelial cells.
Figure 33A shows staining of E-Cadherin in pmTECs of Socs1+/-MGLtg and Socs1-/-MGLtg
mice. E-Cadherin is localized mainly at the cell surface and at the border between two cells.
There was no obvious different localization of E-Cadherin with respect to the expression of
nuclear SOCS1. Staining with FlashTM Phalloidin was used to visualize F-Actin as part of
the cytoskeleton. Again, no difference was detected between the two genotypes. To confirm
E-Cadherin staining, immunohistochemistry (IHC) was performed on paraffin embedded lung
sections. Positive staining was detected only in epithelial cells (Fig. 33B). E-Cadherin was
detected mainly at the border between two neighboring epithelial cells and to a minor extend
within the cell cytoplasm. IHC confirmed no different expression or localization of E-Cadherin
with regards to expression of nuclear SOCS1. To investigate protein levels of E-Cadherin in
pmTECs of Socs1+/-MGLtg and Socs1-/-MGLtg mice, Western Blot was performed. Lysates of
three transwells were analyzed for expression of E-Cadherin and Histon3 as a loading control.
No difference in protein amounts were detectable comparing pmTECs of Socs1+/-MGLtg and
Socs1-/-MGLtg mice. Taken together, data suggest similar protein amounts and localization of
E-Cadherin in epithelial cells of Socs1-/-MGLtg mice as compared to the controls. Therefore,
the mechanism for reduced epithelial cell barrier integrity remains to be examined.
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Figure 32.: Socs1-/-MGLtg mice show reduced airway resistance.
(A) m-RNA expression of IL-25, IL-33, Tslp and Ccl26 in primary murine trachea epithelial cells
(pmTECs) (n = 4-6). (B) Resistance in the transwell was measured using the Millicell electrical re-
sistance system (n = 4-6). (C) FITC-Dextran (4 kDa) diffusion from the inner well to the outer well in
2 h at 37◦C was detected by measuring the absorbance at 490 nm (n = 3). (D) Albumin in BAL of n =
10 Socs1+/-MGLtg and Socs1-/-MGLtg mice was determined using ELISA. Data is shown as mean +SD
and significance was assessed using the two-way ANOVA including Bonferroni post-test.
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Figure 33.: Socs1-/-MGLtg mice show no difference in localization or expression of E-Cadherin.
(A) Confocal microscopy images show staining of primary murine trachea epithelial cells (pmTECs) for
Actin (using FlashTM Phalloidin, red) and E-Cadherin (green). Nuclei were visualized using Hoechst.
Scale bar, 25 µm. n = 2 (B) Immunohistochemical expression of E-Cadherin in epithelial cells was
detected using paraffin-embedded lung sections of Socs1+/-MGLtg and Socs1-/-MGLtg mice. Scale bar,
50 µm. n = 6 (C) Detection of E-Cadherin in lysates of pmTECs suggests similar protein amounts for
both Socs1+/-MGLtg and Socs1-/-MGLtg mice. Histon3 (H3) was used as loading control. n = 3
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6.1. Generation of Socs1MGLtg mice
SOCS1 is a classical negative feedback regulator of cytoplasmic JAK/ STAT signaling [62, 194,
257]. However, it has been described that SOCS1 is also localized in the cell nucleus [12, 143], yet
the function of SOCS1 in the cell nucleus in vivo remained unclear. Baetz et al. showed in 2008
that fusion of the SOCS1-NLS to CIS - a cytoplasmic SOCS family member - resulted in nuclear
localization of this protein. Vice versa, deleting the NLS of human SOCS1 or substitution of this
sequence with the respective region of SOCS3 resulted in loss of nuclear localization [12]. SOCS3
was chosen since it is the closest related family member to SOCS1 [115]. These 2 proteins share
the same principal structure but differ in localization, because SOCS1 possesses a functional
NLS. In vitro data using human SOCS1 could now be reproduced for murine SOCS1 (Fig. 6).
Although SOCS1∆NLS was localized in the cytoplasm and less mobile, it was still efficient in
inhibiting IFNγ signaling (Fig. 7). As reported previously, SOCS1 was expressed at low levels
[257, 194, 62] and relatively short-lived [248], but could be induced by IFNγ [51] (see Fig. 12 - 13).
In addition, SOCS1 can be stabilized on protein level through phosphorylation by Pim kinases
[29]. The NLS of SOCS1 (RRMLGAPLRQRRVR, amino acids 159–173) resembles a bipartite
NLS composed of two basic stretches. Lysine as a basic amino acid is important for the ubiquitin
proteasome pathway, linking ubiquitin chains onto proteins to mark them for degradation via
the proteasome [27, 83]. Therefore, the question was addressed whether exchanging the NLS
with the SOCS3 counterpart might alter protein half-life by performing a cycloheximide chase
(Fig. 13). Protein half-life was not altered upon exchanging the NLS corresponding part of
SOCS1 with SOCS3 (SOCS1∆NLS).
To study the role of nuclear SOCS1, transgenic mice were generated using a bacterial artificial
chromosome (BAC) containing a mutated Socs1 (Socs1∆NLS ) that fails to translocate in the
cell nucleus, eGFP and LuciferaseCBG99 (MGL) by pronuclear injection of fertilized oocytes.
Using BACs to create transgenic mice is still a commonly used approach [92, 120, 140, 157].
Conventional transgenes often produce unpredictable results if they are too small to recapitulate
a natural gene context. BACs, however, are large insert DNA clones capable of carrying ge-
nomic fragments ranging between 150–300 kb in size [244], which is large enough to encompass
the natural context of most mammalian genes. The large insert size of BACs typically includes
enhancers and other regulatory elements, minimizing position-effects, such as epigenetic silenc-
ing and unexpected splicing [111]. However, BAC integration site and efficiency is difficult to
determine. Another approach to generate transgenic mice could be the use of nuclease-guided
genome editing methods such as ZFN, TALEN and CrispR/Cas [74]. Endonucleases are capable
of inducing double stranded breaks at specific locations in the genome, enabling precise genome
editing with high efficiency. Due to simplicity and easy feasibility, the previously established
method of generating BAC transgenic mice was chosen.
For Socs1MGLtg mice, stable regulation and expression of the BAC was demonstrated by
similar gene regulation of Socs1wt and Socs1∆NLS (Fig. 10), arguing for successful BAC
integration. Other genes besides SOCS1 that are encoded on the BAC are PRM1, PRM2,
PRM3 and TNP2. Those genes are involved in spermatogenesis. PRM proteins are protamines
that substitute for histones in the chromatin of sperms during spermatogenesis. TNP2 is a
transition protein associated with the conversion of nucleosomal chromatin to the compact,
non-nucleosomal form during spermatogenesis. Since no gender biases were detectable in MGL
transgenic mice and male Socs1+/-MGLtg mice were breeding as efficiently as Socs1+/- mice,
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those genes apparently did not influence analysis shown thereafter. In general, the results
confirmed previously described protein and mRNA expression patterns of SOCS1, indicating
that the transgene has integrated in a region accessible for transcriptional regulation and that
using BAC transgenic mice is a valid approach to study the function of SOCS1 in the cell nucleus.
Due to low endogenous SOCS1 expression [257, 194, 62] and the lack of sufficiently specific
antibodies for SOCS1 [31, 97], detection of SOCS1 protein without prior stimulation is difficult.
Despite the generation of a monoclonal antibody secreted from hybridoma cells and a polyclonal
antibody produced against recombinant SOCS1, no antibody was found specifically detecting
endogenous SOCS1, especially in histology. However, Socs1MGLtg mice can be used as reporter
mice due to the presence of eGFP and firefly luciferase on the same BAC (Fig. 11). 2A sequences
between the coding regions of SOCS1∆NLS, eGFP and Luciferase result in co-translational
cleavage and do not result in fusion proteins. Therefore, Socs1MGLtg mice can be used as
reporter mice on cellular, but not on subcellular level. Luciferase assay suggested high SOCS1
expression in the thymus as reported previously [257]. High luciferase activity in the muscle,
however, could arise from regeneration of ATP from phosphocreatine through the creatine kinase
and did not necessarily resemble high SOCS1 expression. The discrepancy between mRNA
expression in the pancreas of Socs1wt or Socs1∆NLS one the one hand as well as Luciferase or
eGFP on the other hand could be explained by the presence of specific pancreatic ribonucleases
involved in endonucleolytic cleavage starting at 3’ end. Isolation of intact, high-quality RNA
from pancreas remains challenging [45]. Otherwise, similar mRNA levels were observed in various
organs arguing for the use of Socs1MGLtg mice as reporter mice.
6.2. Socs1-/-MGLtg mice can be used to study the function of
nuclear SOCS1
To study the function of nuclear SOCS1 in mice, Socs1MGLtg mice were backcrossed on an
SOCS1 deficient background - named Socs1-/-MGLtg - and compared to littermate Socs1+/-MGLtg
or Socs1+/- controls. Importantly, a gene dosage effect was ruled out. In contrast to Socs1-/-
mice, Socs1+/- mice lacked detectable levels of IFNγ [173] and were found to be phenotypically
normal [256]. In addition, Socs1+/- mice showed normal survival (Fig. 16) indicating that one
allele of Socs1 is sufficient for rescue of the severe knockout phenotype. In line with this, no
difference in pSTAT1 levels was observed by flowcytometry (Fig. 17), between Socs1+/+ and
Socs1+/- mice. The lung phenotype including elevated expression of Th2 cytokines and dis-
rupted barrier function of epithelial cells was only observed in Socs1-/-MGLtg mice. Neither
Socs1+/-, nor Socs1+/-MGLtg mice showed this phenotype, arguing for a localization specific
effect resulting in eosinophilic lung inflammation and against a gene dosage effect.
To prove that Socs1-/-MGLtg mice lack nuclear SOCS1, functional assays were used to inves-
tigate interaction of nuclear SOCS1 with either p53 or the NFκB subunit p65. Nuclear SOCS1
has been shown to interact with p53, leading to its phosphorylation at serine 15 and activation
by forming a ternary complex with ATR or ATM [169] (see Fig. 34A). Activation of the tumor
suppressor gene p53 results in G1 arrest and apoptosis. In G1 arrest, p53 induces the synthesis of
inhibitors of cyclin-dependent kinases, such as p21/WAF1 [1, 242]. In addition, activation of the
p53 pathway by SOCS1 can establish an anti-proliferative program in cells exposed to sustained
or aberrant cytokine stimulation, suggesting an anti-proliferative role for SOCS1 [134, 169]. This
anti-proliferative function of SOCS1 has also been shown for cervical cancer cell lines infected
with HPV and for non-small-cell lung cancer celllines [134, 243]. Therefore, SOCS1 is frequently
downregulated in human cancer [271]. Since nuclear SOCS1 leads to activation of p53 [169], the
lack of nuclear SOCS1 should result in less active p53 and a lower percentage of cells arrested
in G1. Indeed, Socs1-/-MGLtg mice showed lower percentage of splenocytes in G1 and higher
percentage in S phase of the cell cycle (Fig. 15). SOCS1 is further known to activate apoptosis
through p53 activation. Knock-down of SOCS1 in contrast leads to reduced phosphorylation
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of p53 and apoptosis of intestinal epithelial cells [39]. Although Socs1-/-MGLtg mice showed
increased spleen weight and number of splenocytes as described for Socs1-/-IFN-/- mice [37],
no altered proliferation was detectable. Na¨ıve T cells are usually considered to remain in a
dormant state unless awakened by foreign antigens expressed on activated APCs. Following
appropriate stimulation, T lymphocytes proliferate extensively. Therefore, beads coated with
anti-CD3 and anti-CD28 were used to stimulate T cells in a manner that partially mimics stim-
ulation by antigen-presenting cells. The discrepancy between proliferation and cell cycle data
might be explained by the fact that splenocytes were freshly isolated and analyzed for their cell
cycle, whereas splenocytes were cultured in vitro under the presence of anti-CD3/CD28-coated
beads for three days prior analysis of proliferation. There might be increased proliferation in
Socs1-/-MGLtg that is dependent on factors secreted from other immune cells. One could test
T cell proliferation with isolated DCs in the presence or absence of epithelial cell conditioned
medium instead of anti-CD3 and anti-CD28 coated beads. DCs of Socs1-/-MGLtg mice might
produce increased IL-2 [294] and therefore lead to increased numbers of T cells in the spleen.
Those conditions would resemble more the in vivo situation. In addition, defects in regulation
of p53 target genes such as Mdm2, Pmp22, PUMA and Gadd45a should be investigated.
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Figure 34.: Scheme summarizing the known nuclear functions of SOCS1.
(A) Nuclear SOCS1 has been shown to interact with p53, leading to its phosphorylation at serine 15
and activation by forming a ternary complex with ATM upon DNA damage [169]. Active p53 leads to
cell cycle arrest via p21/WAF1 or apoptosis (B) Activation of the IKK complex leads to ubiquitination
and degradation of IκB proteins. Released NFκB complexes shuttle into the cell nucleus to activate gene
transcription. Nuclear SOCS1 has been shown to induce proteasomal degradation of NFκB p65 in a
complex with Elongin B/C and Cullin-2 [173, 230, 260]. COMMD1 stabilizes the interaction of SOCS1
with p65 [173, 230]. Figure adapted from Ghosh and Hayden, 2008 [78].
Besides interaction between nuclear SOCS1 and p53, SOCS1 has been shown to interact
with p65 in the nucleus [173, 230, 260] leading to its proteasomal degradation (see Fig. 34B).
NFκB proteins are involved in the control of a large number of processes, such as immune and
inflammatory responses, developmental processes and apoptosis. NFκB functions as dimeric
transcription factors and consist of the subunits NFκB1 (p105/p50), NFκB2 (p100/p52), c-
Rel, RelA (p65) or RelB. NFκB proteins are usually bound and inhibited by IκB inhibitors.
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Activation of the IKK complex phosphorylates IκB proteins leading to their ubiquitination
and proteasomal degradation and the release of NFκB complexes. Active NFκB complexes
translocate into the nucleus where they induce expression of pro-inflammatory cytokines like
IL-1, IL-6, IL-8, or TNFα. Nuclear SOCS1 has been shown to induce proteasomal degradation
of NFκB [173, 230] by interaction with p65, thereby limiting induction of a subset of NFκB
dependent genes [260]. Interaction with p65 has been shown for SOCS1, but no additional SOCS
family member. The N-terminal part of the SH2 domain contributes to p65 binding, whereas
the SOCS box is known to mediate E3 ubiquitin ligase activity. Therefore, a mutant lacking the
SOCS-box is ineffective in p65 ubiquitination [260]. It was also suggested that SOCS1 binds to
p65 depending on the ubiquitously expressed protein COMMD1. COMMD1 was found to inhibit
NFκB by stabilizing the interaction of SOCS1 with p65 [168]. In mice lacking nuclear SOCS1,
sustained NFκB signaling is expected. Indeed, Socs1-/-MGLtg mice showed sustained IL-12p40
protein levels in CD11c+ cells of the lung and spleen as well as higher NFκB p65 activity in
lung homogenate and pmTECs (Fig. 14). No differences were detected regarding TNFα protein
levels. Unlike TNFα that shows fast NFκB recruitment to constitutively and immediately
accessible promoters, IL-12p40 is a gene that needs a prolonged binding of NFκB to its promoter
[20], suggesting that the lack of nuclear SOCS1 leads to sustained activation of NFκB that is
affecting only a subset of NFκB dependent genes. Stimulation of DCs with different TLR
ligands has been shown to result in striking differences in the kinetics of NFκB activation [20].
Whereas LPS induced a rapid but short-lived activation of p65, CpG-DNA stimulation resulted
in prolonged p65 activity at the IL-12p40 promoter. In addition, a high number of differentially
expressed genes were discovered annotated to TLR and TNF signaling, and NFκB binding sites
were overrepresented among those differentially expressed genes (Table 2 and 3). Due to the lack
of a sufficiently specific antibody staining endogenous SOCS1, there is no prove for the absence
of SOCS1 in the nucleus of Socs1-/-MGLtg mice. Those mice might only have reduced nuclear
SOCS1 resulting in enhanced NFκB activity and altered cell cycle. Another possibility would
be altered cytoplasmic concentration of SOCS1 that accounts for the phenotype of Socs1-/-
MGLtg mice, which cannot be excluded. Nevertheless, data in Socs1-/-MGLtg mice is consistent
with previously described in vitro data using non-nuclear SOCS1∆NLS [260], suggesting that
Socs1-/-MGLtg mice lack functional SOCS1 in the cell nucleus.
6.3. SOCS1∆NLS is sufficient to regulate classical IFNγ signaling,
but fails to regulate a subset of non-canonical IFNγ dependent
genes
SOCS1∆NLS was sufficient to rescue Socs1-/-MGLtg mice from the early-lethal disease described
for Socs1-/- mice (Fig. 16), that otherwise die within 3 weeks due to excessive immune signaling
and multiorgan inflammation [173, 256, 193]. Besides neonatal death, Socs1-/- mice are charac-
terized by liver degeneration, hematopoietic infiltrations in various organs as well as accelerated
apoptosis and aberrant T cell activation [173, 256, 193]. This phenotype is highly dependent
on IFNγ hypersensitivity as it can be prevented in the neonatal period by the administration
of anti-IFNγ antibodies or using Socs1-/-IFNγ-/- mice that show reduced pathology [181, 6, 23].
Although treatment of Socs1-/- mice with nebulized anti-IFNγ antibodies rescued from lethal
liver disease, mice showed signs of a chronic disease including T-lymphocyte infiltrations in
skeletal muscle, skin, lung, pankreas, liver [23]. Also Socs1-/-IFNγ-/- mice developed chronic
granulomas in the gut and various other organs in addition to polycystic kidneys, pneumonia
and chronic skin ulcers [181]. Not only a elimination of the STAT1 gene, but also of STAT6 res-
cued SOCS1 deficient mice [195]. In both Socs1-/-STAT1-/- and Socs1-/-STAT6-/- mice, survival
was prolonged. 50% of the mice survived until day 85. In addition, hepatomegaly was prevented
and thymic atrophy was partly improved [195].
IFNγ signaling functions by binding to the IFNγ receptor complex, activating JAK1/2 and
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subsequently leading to tyrosine phosphorylation of STAT1 (pY-STAT1). pY-STAT1 dimers
in turn translocate into the nucleus and activate transcription of ‘canonical’ IFNγ-responsive
genes [255]. Socs1-/-MGLtg mice showed physiological regulation of canonical IFNγ signaling by
downregulating pY-STAT1 levels as well as IFNγ target gene expression upon IFNγ stimulation
(Fig. 16, 17). Whole genome expression analysis revealed only 86 genes to be differentially
regulated between BMMs of Socs1+/-MGLtg and Socs1-/-MGLtg mice with no canonical IFNγ
target genes or overrepresented STAT1 transcription factor binding sites (Fig. 18 and Table 2),
arguing that canonical IFNγ signaling was still efficiently regulated by Socs1∆NLS. In addition
to canonical signaling, a number of studies have shown that pY-STAT1-independent pathways
also exist [80, 226, 251]. It was reported that STATs translocate into the nucleus in a pY-
independent manner, where they activate expression of only a subset of ‘non-canonical’ IFNγ-
induced genes [30]. Although Socs1-/-MGLtg mice showed functional regulation of canonical
IFNγ signaling, a subset of non-canonical IFNγ dependent genes was differentially regulated
(Fig. 18). Minor, but non-significant differences were observed in Icam-1 expression upon
stimulation with IFNγ (Fig. 17D). Intercellular adhesion molecule 1 (Icam-1) is a ligand for
the leukocyte adhesion protein (LFA-1), involved in trafficking and activation of T cells [144].
Regulation of T cell activation requires two signals. First, the antigen is presented on MHC
molecules that interact with the T cell receptor complex. As a second signal, B7 interacts with
CD28 on the T cell. In addition, a second signal can also be delivered through Icam-1 interacting
with LFA-1 residing on the T cell. Not only T cell activation, but also T cell differentiation is
influenced by Icam-1. Numbers of regulatory T cells (Tregs) are significantly decreased in mice
lacking full-length Icam-1 [84]. Increased induction of Icam-1 in cells lacking nuclear SOCS1 is
in line with literature showing that upregulation of Icam-1 by IFNγ is inhibited by SOCS1 [212]
and that this inhibitory capacity depends on the functional NLS of SOCS1 [143].
In addition to Icam-1, Indoleamine 2,3-dioxygenase (Indo) was differentially regulated between
BMMs of Socs1-/-MGLtg and Socs1+/-MGLtg mice (see Fig. 18). This is in line with literature,
showing that SOCS1 deficient CD8+ DCs express increased mRNA levels of Indo [274]. Those
tolerogenic DCs have a significant role in the induction of peripheral tolerance through IL-
10 and the induction of Tregs. Furthermore, Indo induction inhibits clonal expansion of T
cells from TCR transgenic mice following adoptive transfer, arguing for an important role in
tolerance induction [180]. Indo is an enzyme that catalyzes the first and rate-limiting step
in tryptophan catabolism to N-formyl-kynurenine. Indo is involved in immune inhibition by
tryptophan depletion resulting in starvation and stress of immune cells and accumulation of
cytotoxic catabolites [90, 154]. In addition to immunosuppression, T cell apoptosis, proliferation
and differentiation are influenced by Indo [90, 65]. Upregulation of Indo in DCs by IFNγ
reduces Th1 cell responses [207, 208], whereas inhibition of Indo enhances the severity of Th1
cell-mediated diseases [150]. Odemuyiwa et al. showed that eosinophils constitutively express
functional Indo that is further enhanced by IFNγ treatment. When eosinophils expressing high
levels of Indo are co-cultured with either a Th1 or Th2 cells, they selectively inhibited anti-
CD3 induced proliferation of Th1 but not Th2 cells [203]. Th2 bias was verified by Platten et
al. showing that mice with experimental autoimmune encephalomyelitis treated with a peptide
promoting Th2 response display therapeutic effects, express 70 fold higher Indo mRNA and
produced increased Th2 cytokines [216]. This is in line with data from this work showing that
Socs1-/-MGLtg mice expressed increased Indo levels as well as Th2 cytokines.
6.4. SOCS1 in T cell development
CD4+ T cells are activated by foreign antigens presented on APC’s via MHC class II and induced
depending on the surrounding cytokine milieu into different Th cell subtypes. IL-12 and IFNγ
lead to activation of the transcription factor Tbet via STAT4 and differentiation of na¨ıve CD4+
T cell into Th1 cells [261]. In contrast, Th2 cells are characterized by the expression of Gata3
via STAT6 in an IL-4 and IL-10 dominant milieu [8] and Th17 cells are produced upon TGFβ
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and IL-6 stimulation. The latter express Rorc via STAT3 [288]. SOCS1 has been shown to be
important in helper T cell differentiation [51, 194, 257]. SOCS1 is rapidly induced in response to
many cytokines, including IFNγ and IL-4 and it is an important negative feedback inhibitor of
both signaling pathways. When Socs1-/- mice are crossed with either IFNγ-/- or STAT6-/- mice,
survival is prolonged [6, 195]. This indicates that SOCS1 regulates both IFNγ-driven Th1 and IL-
4-driven Th2 responses. Supporting this finding, CD4+ T cells from Socs1-/- mice spontaneously
differentiate into Th1 and Th2 cells thereby producing IFNγ and IL-4, respectively [72, 195].
Socs1-/-MGLtg mice showed enhanced percentage of Gata3+ CD4+ cells and increased expression
of IL-4, IL-5 and IL-13, suggesting that nuclear SOCS1 plays a role in T cell differentiation (Fig.
24). Even under neutral conditions, CD4+ T cells of Socs1-/-MGLtg mice tended to differentiate
into Gata3+ cells, suggesting a T cell intrinsic effect for nuclear SOCS1. It has previously been
shown in vitro that SOCS1 is a negative regulator of Th2-dependent pathways, achieved by
inhibition of pSTAT6 [73]. This inhibition, however, is known to be dependent on cytoplasmic
SOCS1 and no mechanism resulting Th2 skewing conditions has been found to be dependent on
nuclear SOCS1 so far.
CD11c+ cells from the lungs of Socs1-/-MGLtg mice showed increased NFκB p65 activity
and IL-12p40 protein levels even without stimulation (see Fig. 14). It remains unclear why
Socs1-/-MGLtg mice had a strong Th2 bias, although IL12p40 levels - favouring Th1 differen-
tiation - were elevated. Th2 skewing conditions in Socs1-/-MGLtg mice seem to prevent Th1
differentiation despite the presence of IL12p40. To analyze whether the Th2 bias observed in
Socs1-/-MGLtg mice is of physiological relevance, mice were challenged by IL-13. Upon IL-13
instillation, Socs1-/-MGLtg mice showed increased airway eosinophilia (Fig. 27). IL-13 induces
production of CCL26 which is a chemoattractant for eosinophils, explaining airway eosinophilia
upon IL-13 instillation. This IL-13 induced CCL26 production can be inhibited by SOCS1 [108].
In addition, IL-13 acts on B cells to produce IgE responsible for allergic inflammation in the
lungs [49]. Recently, SOCS1 has been shown to inhibit IL-13 induced CCL26 expression in
epithelial cells in vitro whereas reduced SOCS1 expression was correlated to enhanced airway
eosinophilia [57]. The exact mechanism of Th2 skewing due to the lack of nuclear SOCS1 re-
mains to be clarified. It might be that the increased Th2 response in the lung is due to lack
of p65 degradation. There is some indirect evidence that NFκB p65 is required for aspects of
Th2 responses [16]. It has been shown in vivo in men and mice that rhinovirus (RV) infec-
tion enhances bronchial epithelial cell NFκB p65 nuclear expression. RV-infected p65-deficient
mice exhibit reduced inflammation, yet interferon induction, antiviral responses and virus loads
were unaffected, indicating that NFκB p65 is required for pro-inflammatory, but not anti-viral
response. In addition, IL-4 treated macrophages make Th2 chemokines MDC and TARC that
seems to be partly NFκB dependent [199]. The exact mechanism of NFκB dependent Th2
skewing, however, remains elusive.
Further experiments could be performed evaluating Th2 bias in Socs1-/-MGLtg mice in more
detail using infection models dependent on Th1 or Th2 responses. For example Leishmania ma-
jor infection in mice results in a protective response in C57BL/6 mice - characterised by a Th1
cytokine pattern -, whereas BALB/c mice, that are characterised by a Th2 cytokine pattern,
are susceptible [112]. There are more infection models where a Th2 response leads to worsening
of the phenotype for example Plasmodium falciparum, Cyptococcus neoformans or recombinant
epitope-tagged Mycobacterium tuberculosis infection [269, 130, 282]. Upon infection with Plas-
modium falciparum, Th1 cytokines are upregulated and limit progression from uncomplicated
malaria to severe and life-threatening complications [269]. In addition, clearance of Cyptococcus
neoformans infection is highly dependent on the presence of Th1 cells [130]. The highly virulent
Cyptococcus neoformans strain H99 provokes a Th2 response that results in worsening of lung
function unlike the moderate virulent D55 strain that provokes a Th1 response [130]. Also infec-
tion with recombinant epitope-tagged Mycobacterium tuberculosis shows enhanced weight loss
and lung fibrosis in mice with adoptively transferred Th2 cells as compared to mice that received
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Th1 cells [282]. Therefore, it would be interesting to subject Socs1-/-MGLtg mice to the infection
models described above and see whether those mice with a Th2 skewing show a worsening of
the phenotype when compared to littermate controls with functional nuclear SOCS1.
Increased Th2 cytokine levels in lung homogenate of Socs1-/-MGLtg mice probably derive
not only from Th2 cells that are overrepresented in those mice (see Fig. 24), but also from
ILC2 cells. ILCs (innate lymphoid cells) are preferentially located at barrier surfaces and are
important for protection against pathogens and maintenance of organ homeostasis [254, 53].
They consist of cytotoxic natural killer (NK) cells, and the helper subsets of ILC1s, ILC2s and
ILC3s. Whereas ILC1s express the transcription factor T-bet and produce IFNγ [17], ILC3s
express Rorγt and secrete IL-22 and IL-17A [36] and ILC2s express Gata3 and secrete Th2
cytokines [119]. Stimulation of ILC2s with epithelial cell derived cytokines IL-25, IL-33 and
Tslp leads to the production of Th2 cytokines IL-4, IL-5 and IL-13. This has been observed also
in Rag2-/- mice, arguing against cytokine production by Th2 cells only [70]. Also in ovalbumin-
induced allergic asthma, the ILC2 population in lung and BAL fluid increases and is the major
source of IL-4, IL-5 or IL-13 [287]. Recently, various groups demonstrated the presence of
ILC2s in the respiratory system of mice and humans [26, 184, 185]. ILC2s play important
roles in the pathogenesis of allergic lung inflammation such as asthma or allergies [202, 98].
Furthermore, ILC2s were found in nasal polyps of patients with chronic rhinitis, a classical
Th2 disease [184, 183]. Interestingly, ILC3s have been shown to produce IL-22 that maintains
epithelial cell integrity [228, 252]. Since Socs1-/-MGLtg mice show reduced percentage of Th17
cells, they might also have a reduced number of ILC3s that would result in reduced IL-22 levels,
and explain disturbed epithelial cell integrity in Socs1-/-MGLtg mice. Therefore, presence of
ILC subpopulations as well as IL-22 levels should further be examined in Socs1-/-MGLtg and
control mice.
ILCs have been shown to differentially integrate signals from commensal microbes resulting in
altered transcriptional and epigenetic reprogramming [96, 268]. Depletion of ILCs resulted in a
changed microbiome and systemic inflammation, which could be prevented by administration of
IL-22, arguing for an important role of ILC3s [252]. Commensal microbes influence the activity
of the other ILC subsets as well. ILC2s for example are activated by IL-25, which is produced
in a microbiota-dependent manner [236]. Therefore, it might also be of interest to compare lung
microbiome between Socs1+/-MGLtg and Socs1-/-MGLtg mice.
6.5. Nuclear SOCS1 is a regulator of lung immunity
Socs1-/-MGLtg mice showed inflammation only in the lung and in no other analyzed organ.
This might be due to organ specific adapted and modulated innate immunity. Unlike in sterile
compartments of the body such as the blood, where every contact with a pathogen leads to
activation of cells belonging to the innate immune system, the respiratory tract is colonized
by commensal microbes similar to the skin or the gastrointestinal tract. Therefore, tolerance
mechanisms are important to prevent from constant activation. Some tolerance mechanisms
might be dependent on nuclear SOCS1 and the lack of it might lead to low-grade inflammation
in the lungs of Socs1-/-MGLtg mice. However, it remains unclear why Socs1-/-MGLtg mice
showed no inflammation in other organs with established tolerance mechanisms such as the
gastrointestinal tract. While the gut and lungs are both mucosa-associated organs with a shared
embryological origin, their anatomical features are different. This results in great variance in
numbers and composition of their microbiota. Migration of microbes in the digestive tract is
unidirectional and microbes must cope with extreme environments such as acidic pH of the
stomach and alkaline pH of the duodenum. In contrast, migration of microbes in the oxygen-
rich lung is bidirectional. Thus the microbiome of the lung is more dynamic and transient than
that of the gastrointestinal tract [52]. In contrast to the lung where commensal microbes are
found mainly in upper airways and only few in the lower respiratory tract [102], bacterial density
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in the intestine is orders of magnitude higher [116]. In addition, the gut and lung differ their
host–bacterial interactions. Whereas luminal IgA levels are higher in the gut, the lung exhibit
more interactions between bacteria and host immune cells [52]. Taken together, the respiratory
and the gastrointestinal tract show different environmental conditions resulting in divergent
microbiota that might explain why Socs1-/-MGLtg mice showed low-grade inflammation only in
the lung and not in the gut.
Socs1-/-MGLtg mice were analyzed for disease symptoms and spontaneous development of
low-grade inflammation in the lung was detected (Fig. 22). Expression of SOCS1 in the lung
has been reported for alveolar macrophages [56], bronchial epithelial cells [79] and eosinophils
[24]. Mice deficient for SOCS1 show extensive hematopoietic infiltration in the lung [256]. This
fits to the observation in Socs1-/-MGLtg mice and argues for an involvement of nuclear SOCS1
in immune regulation in the lung. NFκB p65 activation is associated with inflammation in
the airways of asthmatics [103], which might explain why Socs1-/-MGLtg mice with increased
NFκB p65 activity developed airway inflammation. Micro-CT analysis suggests that 5 out of
6 mice developed inflammatory aggregates in the lungs equally distributed in all lung lobes
(see Table 5), mainly occurring in close proximity to smaller bronchioles or blood vessels. It
remains to be analyzed of which immune cells such infiltrates consist. This could be done by
immunohistochemistry staining of different markers unique for a subset of immune cells. So
far, it is unclear why disease symptoms were not observed in all Socs1-/-MGLtg mice. Although
genotyping confirmed that disease-free mice were indeed Socs1-/-MGLtg mice, a small percentage
of analyzed mice (1 out of 6 mice according to micro-CT analysis) showed no disease symptoms
regarding lung inflammation. In addition, analysis of IgE levels, Th2 cytokines or epithelial cell
derived cytokines showed one population with increased expression of cytokines or IgE serum
levels and a smaller population with expression levels as compared to the controls. A gender
bias or age bias was ruled out. No difference in food pellets, bedding or location of the cages
was observable between mice showing symptoms and mice with no disease symptoms.
The role of nuclear SOCS1 in the pathogenesis of Th2 prone diseases such as asthma was
addressed upon ovalbumin (OVA) sensitization and challenge (see Fig. 25). Mouse models are
commonly used to study asthma pathogenesis and to identify underlying physiological and im-
munological processes by OVA challenge [201]. In addition to the classical OVA sensitization
and challenge model, house dust mite, cockroach extracts, or Aspergillus fumigatus are often
used [105, 299]. There are some disadvantages using asthma models in mice. First, unlike in
humans, mice exhibit only transient methacholine-induced AHR following allergen exposure. In
addition, there is a lack of chronicity of the response to allergen exposure in mice. Third, early-
and late-phase bronchoconstrictions are common in humans, though both are poorly defined in
mice. However, observations from mouse models of allergic asthma closely resembles clinical
disease symptoms of asthmatic patients such as eosinophilic lung inflammation, airway hyper-
responsiveness, increased IgE, mucus hypersecretion, and airway remodeling [63, 299]. Mice
challenged with ovalbumin develop a clinical syndrome that closely resembles allergic asthma.
Here, OVA i.p. sensitization and OVA aerosol challenge of Socs1-/-MGLtg mice was used as
a classical Th2 model, not necessarily reassembling all clinical features of asthma. Similar to
IL-13 instillation, upon OVA sensitization and challenge, Socs1-/-MGLtg mice showed enhanced
airway eosinophilia. Supporting this data, Socs1-/-IFNγ-/- mice showed considerably increased
serum IgE levels and infiltrating eosinophils in the lungs upon OVA-treatment as compared to
IFNγ-/- and C57BL/6 controls [153].
There have been several publications linking SOCS1 expression to allergic diseases such as
asthma [57, 73, 79, 101]. Socs1 gene expression is significantly lower in the airways of severe
asthmatics compared with mild/moderate asthmatics, and is inversely associated with airway
eosinophilia [57, 73], suggesting that the absence of SOCS1 leads to Th2 bias. A study assessing
functional variants of Socs1 within a population of adult Japanese asthma patients found a
significant association between the Socs1 promoter polymorphism (-1478CA >del) and adult
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asthma. It was suggested that this promoter polymorphism leads to increased SOCS1 and
inhibition of interferons, leading to higher susceptibility to virus-induced asthma exacerbations
[101]. In 2015, increased expression of nuclear SOCS1 in bronchial biopsies from atopic asthmatic
patients was confirmed [79]. Socs1-/-MGLtg mice are on a C57BL/6 background that is known to
show a Th1 bias when compared to BALB/c mice. Nevertheless, Socs1-/-MGLtg mice developed
a Th2 prone disease. As compared to BALB/c mice, C57BL/6 mice show elevated eosinophil
counts in BAL, but reduced airway reactivity to methacholine [93]. This might explain why
Socs1-/-MGLtg and control mice showed only a weak response to metacholine exposure. Using
Socs1-/-MGLtg mice, it was shown for the first time, that not only the presence of SOCS1, but
also the localization is crucial for effective regulation of Th2 responses. The question remains
about disease progression of Socs1-/-MGLtg mice in an asthma model for exacerbations. To
study asthma exacerbations, pI:C or rhinovirus (RV) infections could be additionally used. It
would be interesting to subject Socs1-/-MGLtg mice to RV-induced exacerbations upon OVA
sensitization and challenge. One could expect a worse disease in Socs1-/-MGLtg mice due to
Th2 skewing as observed for the OVA asthma model or IL-13 model. However, Socs1-/-MGLtg
mice might also be able to clear the infection better due to possibly increased IFN responses
[79, 101] as discussed in section 6.6.
6.6. Nuclear SOCS1 and IFN induction
Viral Infection with RNA viruses leads to activation of TLR3 and RIG I signaling. Both result
in activation of IRF3, thereby inducing IFNβ. In turn, IFNβ is secreted and can act in an
autocrine and paracrine manner to activate JAK/ STAT signaling. This broadens the set of
induced genes and amplifies the signal through a positive feedback mechanism. Since SOCS1 is
a negative regulator of JAK/ STAT signaling [62, 194, 257], it suppresses this feedback loop and
therefore reduces the production of cytokines upon stimulation with type I and type II IFNs [12].
In addition, IRF3 is targeted by SOCS1 for proteasomal degradation that impacts the early type
I IFN antiviral response [204]. In line with this, SOCS1 suppresses type I interferon induction by
influenza viruses by negative regulation of JAK/ STAT signaling and downregulation of innate
immune responses [219]. It would be interesting to study whether nuclear SOCS1 targets IRF3
as previously described [204]. This could be done by a pull-down assay between nuclear SOCS1
and IRF3. In Socs1-/-MGLtg mice, reduced IRF3 degradation and therefore increased interferon
signaling is suggested.
In addition to type I and type II interferon signaling, also type III interferon (IFNλ) signal-
ing leads to activation of JAK/ STAT signaling that can be inhibited by SOCS1 [283]. IFNλ
consists of 3 subtypes, IFNλ1 (IL-29), IFNλ2 (IL-28a), and IFNλ3 (IL-28b) [34]. Expression
of functional IFNλ receptor complexes in the lung and intestinal tract is mainly restricted to
epithelial cells [187]. Due to the importance of nuclear SOCS1 in epithelial cells, INFλ signaling
should be analyzed in epithelial cells of Socs1-/-MGLtg mice and compared to controls. Simi-
lar to type I interferons, IFNλ production results in antiviral, antiproliferative, and antitumor
activity. IFNλ plays an important role in the defense against several human pathogens that
infect the respiratory tract, such as influenza virus, respiratory syncytial virus or severe acute
respiratory syndrome (SARS) coronavirus [187]. In line with that, defects in IFNλ production
or signaling cause reduced innate immune responses to viral pathogens replicating in epithelia of
the lung [48]. Upon infection with rhinovirus, SOCS1 levels are increased in bronchial epithelial
cells which is associated with reduced levels of IFNλ. SOCS1 inhibits RV–induced IFNβ and
IFNλ promoter activation [79]. Whereas SOCS1 suppression of interferon receptor signaling has
been shown to be dependent on the SOCS box [215, 143], SOCS1 mediated suppression of RV-
induced interferon induction is independent of the SOCS box and does not require proteasomal
degradation [79]. However, it was dependent on nuclear localization because SOCS1 constructs
unable to localize to the nucleus were unable to suppress rhinovirus-induced interferon promoter
activation [79]. This argues for a different mechanism of nuclear SOCS1 mediated IFN suppres-
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sion that needs to be further investigated. In line with this, nuclear SOCS1 levels are also
increased in bronchial epithelial cells from atopic asthmatic patients suggested to be responsible
for impaired IFNλ secretion. Decreased IFNλ levels in asthmatic primary bronchial epithelial
cells and alveolar macrophages is highly correlated with severity of RV-induced asthma exac-
erbation and virus load [35]. Interestingly, recombinant IFNλ has been shown to upregulate
Indo expression, whereas silencing of IFNλ decreases Indo expression during influenza infec-
tion [71]. This might hint towards higher production of IFNλ in Socs1-/-MGLtg mice, since
these mice showed also increased Indo expression. It would be interesting to infect pmTECs
of Socs1-/-MGLtg mice with RV and see whether their immune response differs as compared to
wildtype mice. Therefore, inflammation markers OAS1 and MX1 as well as IL-6 and TNFα
could be measured. In addition, production of IFNβ and IFNλ protein and mRNA as well as
RV replication should be investigated. Three in vitro studies show that induction of IFNλ is
NFκB-dependent [205, 210, 247]. However, in vivo it has been shown, that IFNβ and IFNλ
are regulated independently of NFκB p65 [16], arguing against regulation of IFNλ by nuclear
SOCS1 via p65 degradation. The exact mechanism remains to be clarified.
6.7. Nuclear SOCS1 in lung epithelial cells
To study the question whether the lack of nuclear SOCS1 in hematopoietic cells is sufficient to
induce allergic lung inflammation observed in Socs1-/-MGLtg mice, bone marrow transplanta-
tion was performed. Lee et al. showed that serum IgE levels and infiltrating eosinophils were
considerably increased in the lungs of OVA-treated Socs1-/-IFNγ-/- mice [153]. They suggested
that regulation of SOCS1 mainly affects hematopoietic cells, but not epithelial cells. McCormick
et al. showed that reduced expression of SOCS1 prolonged IL-4-induced IRS-2 tyrosine phos-
phorylation and enhanced M2 differentiation [179], arguing for an important role of SOCS1 in
macrophages. Increased IRS-2 in turn promoted allergic lung inflammation and remodeling [44].
In line with this, CD11c+ cells from lung of Socs1-/-MGLtg mice showed increased NFκB signal-
ing and IL12p40 production even without stimulation. In addition, SOCS1 has been described
to be indispensable in T cell differentiation and activation [51, 194, 257]. Socs1-/-MGLtg mice
showed an increased percentage of Th2 cells and Th2 cytokines. Therefore, the relevance of nu-
clear SOCS1 in the hematopoietic compartment was examined by bone marrow transplantation.
Bone marrow from wildtype mice was transplanted in lethally irradiated Socs1-/-MGLtg mice
and vice versa and mice were analyzed with respect to the development of lung inflammation.
Interestingly, only lethally irradiated Socs1-/-MGLtg mice showed the allergic lung phenotype
(see Fig. 29). This data suggests structural cells such as epithelial cells or fibroblasts to be
responsible for the induction of airway inflammation in Socs1-/-MGLtg mice. In contrast, trans-
plantation of bone marrow from Socs1-/-MGLtg mice did not induce lung inflammation, arguing
against T cells, DCs or macrophages inducing airway inflammation in Socs1-/-MGLtg mice.
Multiple subpopulations of macrophages exist in the lung, residing in both the alveolar and in-
terstitial compartments [122]. Alveolar macrophages are a long-lived, self-renewing population
that is efficient in removing microorganisms and particles from the lung. In contrast, inter-
stitial macrophages function as antigen presenters and regulators of inflammation and fibrosis
and are thought to be replaced by infiltrating monocytes that migrate into the lung from the
circulation. Unlike interstitial macrophages, the current view is that alveolar macrophages do
not origin from monocytes, but are self-renewal, radiation-resistant [104, 266, 267]. Resistance
to radiation is only true, however, if lungs are shielded with lead (e.g. 2-inch lead screen [192])
instead of total body irradiation. Otherwise, loss of alveolar macrophages is observed due to
irreversible radiation-induced destruction of tissue macrophages or incomplete radiation-induced
suppression of tissue macrophage self-renewal [104, 192]. 3- 8 weeks after whole body irradiation,
alveolar macrophage populations are markedly reduced or non-existent [91, 229, 104, 192, 198].
Both Socs1-/-MGLtg mice transplanted with bone marrow cells from wildtype mice and wildtype
mice transplanted with bone marrow cells from Socs1-/-MGLtg mice were analyzed 8 weeks after
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radiation and therefore should have no remaining alveolar macrophages. After bone marrow
transplantation, 75 - 90% of blood cells were of donor origin (see Fig. 29). If the remaining 10 -
25% hematopoietic cells would account for the phenotype in lethally irradiated Socs1-/-MGLtg
mice, we would expected to see airway inflammation in lethally irradiated wildtype mice that
contain 75 - 90% of hematopoietic cells from Socs1-/-MGLtg mice as well. However, it might be
possible that mice need both structural cells lacking nuclear SOCS1 and a small percentage of
hematopoietic cells lacking nuclear SOCS1 to develop airway inflammation. In summary, data
suggests a more important role for nuclear SOCS1 in structural, radiation-resistant cells. There-
fore, epithelial cells were analyzed in more detail. In addition to epithelial cells, also endothelial
cells or fibroblasts could be responsible for the observed phenotype in Socs1-/-MGLtg mice.
Epithelial cells form of a physical barrier between the outside environment and immune cells
through cell-cell contacts, remove pathogens by ciliary clearance and secrete antimicrobials.
To prevent from constant activation by commensal microbes, epithelial cells produce NO and
prostaglandin E2 that is acting on both T cells, alveolar macrophages and DCs [133]. In addi-
tion, epithelial cells condition DCs to produce less MHC class II, CD80 and CD86 and secrete
more IL-10 and TGFβ [178]. This might explain why nuclear SOCS1 deficiency only in struc-
tural radiation-resistant cells had a consecutive impact on lung immunity, leading to airway
inflammation. pmTECs of Socs1-/-MGLtg mice showed increased expression of epithelial cell
derived cytokines IL-25, IL-33 and Tslp. Epithelial cell derived cytokines, including IL-25, IL-
33 and thymic stromal lymphopoietin (TSLP), are known to promote Th2 cell responses and
allergic inflammation [128]. IL-25 is a member of the IL-17 cytokine family. It can be induced in
response to allergens, particles, and helminth infection [99, 121, 70]. Main IL-25 producers are
epithelial cells, eosinophils, mast cells, and basophils [55]. Administration of IL-25 was shown
to induce IL-4, IL-5, IL-13 and eotaxin production, even in Rag2 deficient mice, arguing for an
important role of IL-25 acting on ILC2 cells [70, 121]. In addition, IL-25-deficient mice are more
susceptibile to infection with the parasitic helminthes Nippostrongylus brasiliensis and Trichuris
muris due to an impaired Th2 response [211, 66]. Mice treated with IL-25 also developed ep-
ithelial cell hyperplasia, increased mucus secretion, and airway hyperreactivity [121]. Besides
amplification of Th2 responses, IL-25 causes increased eosinophilic infiltration in mice [263].
This is in line with findings in Socs1-/-MGLtg mice that showed increased IL-25 levels and air-
way eosinophilia. Blocking IL-25 can prevent airway hyperresponsiveness in allergic asthma [13].
IL-33 belongs to the IL-1 family and binds a receptor complex consisting of the IL-1R accessory
protein and ST2 that is expressed on mast cells and Th2 cells [158, 38, 238]. IL-33 functions as
an alarmin that is stored within the cell and rapidly released upon cellular damage or cellular
stress [25, 188]. Release of IL-33 by epithelial cells results in activation of DCs [99, 145, 214].
IL-33-activated DCs prime na¨ıve CD4+ T cells to produce the Th2 cytokines Il4, IL-5 and
IL-13 [270, 18]. In vivo, IL-33 exposure induces DC recruitment and activation in the lung,
resulting in allergic lung inflammation [18] similar to Th2 prone lung disease in Socs1-/-MGLtg
mice. Epithelial expression of IL-33 is also increased in asthmatic patients [222]. Upon fun-
gal infection with Cryptococcus neoformans, mice develop pulmonary cryptococcosis associated
with IL-33-dependent type 2 immunity. This infection results in E-Cadherin downregulation
that is dependent on IL-33 [114]. TSLP is an IL-7–like cytokine [250]. Besides promoting Th2
development, TSLP exerts a direct inhibitory effect on the development of iTregs [289]. Also
Tslp is produced by epithelial cells, endothelial cells, neutrophils, macrophages, and mast cells
and promotes the production of Th2 cytokines [292, 142]. In addition, it induces secretion of
Th2-attracting chemokines CCL17 and CCL22 [253]. TSLP expression is increased in the lungs
of mice with antigen-induced asthma, whereas TSLP receptor–deficient mice have considerably
attenuated disease [297]. In addition, mice that express a lung-specific TSLP transgene develop
a spontaneous and progressive asthma-like disease [107]. Taken together, published data pro-
vides a link between epithelial cell derived cytokines IL-25, IL-33 and Tslp and the development
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of allergic lung diseases similar to what is observed in Socs1-/-MGLtg mice.
pmTEC cultures were used to study the involvement of epithelial cells in allergic lung disease
of Socs1-/-MGLtg mice. These cultures have been described to differentiate into epithelial cells,
expressing E-Cadherin, Pan-Cytokeratin and ZO-1 [177]. In addition, it has been shown that
pmTECs consist of polarized ciliated and secretory epithelial cells with a high transepithelial
resistance [47, 280]. However, it is uncertain of which epithelial cell types pmTECs consist and
whether composition is altered in pmTECs of Socs1-/-MGLtg mice. pmTECs of Socs1-/-MGLtg
showed decreased transepithelial resistance and increased FITC-Dextran flux. Confirming this
observation, albumin levels in BAL of Socs1-/-MGLtg mice were increased arguing for a leaky
epithelial cell barrier in the lung of Socs1-/-MGLtg mice (see Fig. 32). A disrupted epithelial
cell barrier might explain low-grade inflammation in the lungs of Socs1-/-MGLtg mice. Loss of
barrier function in Claudin18-/- mice was shown to lead to increased susceptibility of mice to
infection and injury by pathogens and proteases [151]. In general, disruption of tight junctional
complexes increases epithelial permeability and inflammation in both conducting airways and
alveoli. This has been shown to contribute to the pathogenesis of asthma, acute respiratory
distress syndrome and lung injury [151, 75, 85, 19]. Due to disrupted epithelial cell barrier
in Socs1-/-MGLtg mice, pathogens might be easier accessible for the immune cells such as DCs
leading to activation and inflammation. Activation of epithelial cells by pathogens or commensal
microbes leads to sustained NFκB signaling due to the lack of nuclear SOCS1. This might lead
to secretion of epithelial cell derived cytokines IL-25, IL-33 and Tslp that in turn promote
Th2 differentiation. Epithelial cell derived cytokines additionally activate ILC2s and stimulate
further production of Th2 cytokines and differentiation of na¨ıve CD4+ T cells into Th2 cells.
Th2 cells in turn secrete classical Th2 cytokines IL-4, IL-5 and IL-13. IL-5 together with CCl26
produced by epithelial cells attracts eosinophils, leading to airway eosinophilia. IL-4 and IL-13
acts on B cells to stimulate the production of IgE antibodies. IL-13 itself acts on the epithelial
cells leading to increased expression of IL-25, IL-33 and Tslp and amplification of the signal
(Fig. 35).
Further experiments proving the role of nuclear SOCS1 in epithelial cells could be done using
conditional knock-out mice lacking nuclear SOCS1 only in epithelial cells. Therefore, a Sonic
hedgehog promoter line can be used, which has been used to study trachea and lung development
[273]. However, it is not possible to distinguish between alveolar type I or type II cells. Further
optional epithelium-specific transgenic strains are the surfactant protein C promoter strains,
specific for alveolar type II cells [284], or Aquaporin 5 promoter strains specific for alveolar type
I cells [69]. In addition, type I and type II alveolar epithelial cells should be isolated by FACS
[77] from Socs1-/-MGLtg and control mice and cultured to test for transepithelial resistance. An
interesting in vitro approach to test the influence of nuclear SOCS1 in human cells would be
using CrispR/Cas to genetically modify human bronchial epithelial cell cultures. This would
allow to generate human bronchial epithelial cells lacking nuclear SOCS1 and re-performing
experiments to analyze epithelial cell barrier integrity in a human system.
6.8. Possible mechanism for disrupted epithelial cell barrier in the
lungs of Socs1-/-MGLtg mice
So far, it remains unclear which factor is responsible for disrupted barrier integrity. One ex-
planation for disrupted epithelial cell barrier would be apoptosis. TNFα for example induces
apoptosis of intestinal epithelial cells and causes a large gap between adjacent intestinal epithe-
lial cells [82]. However, this hypothesis is unlikely, because healthy adjacent cells rapidly stretch
out and maintain epithelial barrier function [166, 186]. In addition, no cell death was observed
in pmTEC cultures. Nevertheless, an apoptosis assay should be performed since SOCS1 has
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Figure 35.: Schematic view summarizing the important nuclear functions of SOCS1 in lung immunity
In mice lacking nuclear SOCS1, epithelial cell integrity is disturbed that might facilitate pathogens (green)
to cross epithelial barrier. Pathogens might be easier detected by cells of the innate immune system such
as DCs (orange). Activation of epithelial cells by pathogens might lead to sustained NFκB signaling due
to the lack of nuclear SOCS1. This leads to increased production of IL-25, IL-33 and Tslp that favours
differentiation of na¨ıve CD4+ T cells into Th2 cells (blue) producing classical Th2 cytokines IL-4, IL-5
and IL-13. IL-5 together with CCl26 produced by epithelial cells attracts eosinophils (red), explaining
airway eosinophilia. IL-4 and IL-13 act on B cells (green) and stimulate the production of IgE antibodies.
IL-13 itself can act on the epithelial cells leading to increased expression of IL-25, IL-33 and Tslp and
amplification of the signal.
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been shown to promote apoptosis of intestinal epithelial cells by activating p53 [39].
Increased expression of the epithelial cell derived cytokine IL-33 was observed in pmTEC
cultures of Socs1-/-MGLtg mice (Fig. 32). Since it has been shown previously [114], that IL-33
has an impact on epithelial integrity, higher IL-33 levels in Socs1-/-MGLtg mice might result in
epithelial barrier disruption. Recently, it was shown that IL-33 is constitutively expressed in the
cell nucleus in epithelial cells [188] where direct interaction between SOCS1 and IL-33 might be
possible. Although IL-33 mRNA levels were elevated in Socs1-/-MGLtg mice, no difference was
observed on protein level (preliminary data not shown).
Moreover, Th2 cytokines shown to result in reduced transepithelial resistance. Since elevated
Th2 cytokine mRNA and protein levels have been observed in Socs1-/-MGLtg mice, this might
explain disrupted epithelial cell barrier integrity in those mice. IL-4 caused an increase in epithe-
lial permeability in various cell types [286]. IL-4 treatment of intestinal T84 monolayers for 24 h
led to a 60% decrease in transepithelial resistance. Also in animal models, intraperitoneal IL-4
caused a decrease in mouse intestinal tissue transepithelial resistance [146], whereas STAT6-/-
mice were protected from this effect [167]. In addition to IL-4, IL-13 was shown to downregulate
junctional components including E-Cadherin in bronchial epithelial cells leading to disruptive
effects on airway epithelial barrier function [231]. IL-13 also caused a decrease in transepithe-
lial resistance in HT-29 cells [113, 235]. However, no difference in E-Cadherin expression or
localization could be found in Socs1-/-MGLtg mice. Since decreased transepithelial resistance
was also observed in pmTEC cultures without the presence of IL-4 or IL-13 producing cells,
there seem to be an additional mechanism for disrupted epithelial cell barrier in Socs1-/-MGLtg
mice. Increased Th2 cytokines might, however, have an additional effect on epithelial cell barrier
integrity in vivo.
Not only Th2 cytokines, but also Th1 cytokines were found to alter transepithelial resistance.
IFN-γ induced an uptake of Occludin from junctional complexes into early endosomes through
macropinocytosis leading to a leaky barrier [22, 166, 286]. Besides, TNFα was shown to cause a
decrease in transepithelial resistance in renal epithelial cell line [191], retina [10] and intestinal
epithelial cells [172, 164] by downregulation of ZO-1 and Claudin-5 mRNA and altering their
subcellular localization to the cytoplasm. This effect was mediated via myosin light-chain kinase
(MLCK) and by activation of nuclear transcription factor NFκB [163, 291]. Activated NFκB
translocates to the nucleus and activates the MLCK gene transcription. The increase in MLCK
protein results in MLCK-triggered opening of the TJ barrier. Other groups reported that
epithelial NFκB protein leads to internalization of tight junction proteins Occludin, Claudin-1
and ZO-1 [265, 164]. In esophagus cells, NFκB was suggested to bind to Claudin-4 promotor
[28]. Although there are different cell adhesion proteins reported to be regulated by NFκB
in different celltypes, published data is convincing that increased NFκB signaling leads to a
decrease in transepithelial resistance. Since pmTECs and lung homogenate of Socs1-/-MGLtg
mice showed increased NFκB p65 activity (Fig. 14) due to limited degradation of p65 by
nuclear SOCS1, this is likely to be responsible for decreased epithelial cell barrier function in
Socs1-/-MGLtg mice. This hypothesis could be further investigated by adding NFκB inhibitors
such as curcumin or triptolide to pmTEC culture of Socs1-/-MGLtg mice and see if transepithelial
resistance increases. In addition, siRNA knockdown of p65 and an IκB or the pharmacological
IKKβ inhibitors could be used im pmTEC cultures of wildtype mice.
The exact mechanism how increased NFκB leads to increased epithelial cell permeability,
however, remains to be solved. Therefore, cell junction proteins should be investigated in more
detail. In particular, adherens junctions (built from Cadherins and Catenins), tight junctions
(built from Claudins), gap junctions (built from Connexins) and desmosomes (built from Cad-
herins) should be analyzed. First, E-Cadherin was picked as a protein important to built ad-
herens junctions and analyzed regarding its protein expression by Western Blot and localization
by immunofluorescence and immunohistochemistry (see Fig. 33). Cadherins are the major
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cell adhesion molecules responsible for Ca2+-dependent cell-cell adhesion in vertebrate tissues
with E-Cadherin mainly expressed in epithelial cells. However, no difference in protein levels
or localization of E-Cadherin was observable in epithelial cells of Socs1-/-MGLtg mice (see Fig.
33). Next, tight junctions should be investigated regarding the expression and localization of
Occludin, ZO-1, Claudin-1 and Claudin-4, since those tight junction proteins have been shown
to be downregulated upon enhanced NFκB signaling [28, 265, 164]. In addition, MLCK protein
should be analyzed.
6.9. Summary
Taken together, cytoplasmic localization of murine SOCS1∆NLS was shown as well as func-
tional regulation of cytoplasmic IFNγ signaling by SOCS1∆NLS. Therefore, a BAC transgenic
mouse model was established including a mutated Socs1 (Socs1∆NLS) that fails to translocate
in the cell nucleus, eGFP and Luciferase, termed MGL. Three MGL transgenic founders were
compared with respect to their SOCS1 expression and regulation. Since no differences were
observed between the individual founders and both expression and regulation of SOCS1∆NLS
was comparable with SOCS1, stable integration of the BAC was assumed. Socs1-/-MGLtg mice,
expressing non-nuclear SOCS1∆NLS on an otherwise SOCS1 deficient background, showed sus-
tained NFκB signaling and an altered cell cycle, arguing for a lack of functional SOCS1 in the
cell nucleus. Unlike Socs1-/- mice that die due to excessive IFNγ upon 2-3 weeks after birth,
SOCS1∆NLS was able to rescue this lethal phenotype of Socs1-/-MGLtg mice. Functional IFNγ
signaling in Socs1-/-MGLtg mice was confirmed by unaltered regulation of pY-STAT1 levels,
classical IFNγ target genes and whole genome-expression analysis. However, Socs1-/-MGLtg
mice showed a slightly reduced weight and differential regulation of a subset of non-canonical
IFNγ target genes including Indo. Socs1-/-MGLtg mice spontaneously developed low-grade in-
flammation in the lung with a Th2 bias. Airway eosinophilia and Th2 type cytokines were even
more pronounced in an experimental asthma model using ovalbumin and upon IL-13 treatment.
Bone marrow transplantation revealed a critical role for radiation-resistant cells in development
of this phenotype. Interestingly, it was found that airway epithelial cells of Socs1-/-MGLtg mice
showed disrupted epithelial cell integrity as well as sustained NFκB activation. However, E-
Cadherin protein levels and subcellular localization remained unaltered. Therefore, the exact
mechanism of epithelial cell barrier disruption needs to be further examined. Taken together,
the findings allow the conclusion that Socs1-/-MGLtg mice can be used as reporter mice and to
study the function of nuclear SOCS1 in vivo. The lack of functional SOCS1 in the cell nucleus
was suggested to be involved in development of low-grade airway inflammation and Th2 skewing
conditions. Moreover, data suggests that nuclear SOCS1 plays an important role in epithelial
cells that is so far underestimated.
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